AUTHOR INDEX

Abbasi, F., 151, 544
Abe, T., 1215, 1506
Abiko, A., 567
Ablondi, F., 548
Abrams, S., 1326
Abu-Basha, E.A., 1370
Ackermans, T., 839
Adachi, T., 990
Adamonis, W., 594
Afandi, B., 270, 753
Agarwal, S., 67, 537, 1496
Ahn, Y.-H., 92
Ahrén, B., 1518
Aizawa, H., 1118
Akerstrom, V., 1444
Akinci, A., 626
Akiyama, T., 1167
Alderson, N.L., 395
Aleksandrowicz, Z., 594
Aljada, A., 147, 799
Alvarez, E., 709
Amato, B., 1164
Amemiya, S., 186
Amery, C.M., 450
Amusquivar, E., 1180
An, P., 298, 1014
Andersen, R.N., 1485
Anderson, P.J., 1523
Andersson, S., 259
Ando, N., 479
Annabi, B., 1200
Ansari, B.M., 819
Antonacci, E., 424
Aoki, T., 588
Apperson-Hansen, C., 1124
Arafeh, A.-H., 270
Arakawa, H., 1001
Araki, E., 920
Araki, N., 567
Arango, A., 790
Arciero, P.J., 101
Ardehali, H., 814
Ardigo, D., 959
Ardilouze, J.-L., 1055
Argentieri, G., 1301
Arias, A.M.P., 839
Armellini, F., 6
Arnelo, U., 486
Arnett, D.K., 293
Asano, T., 308
Ascaso, J.F., 1627
Ashcroft, F.M., S2:3
Ashidate, K., 479
Assami, T., 1176
Assmann, G., 770
Astrup, A., 731, 969, 1335
Atkinson, E.J., 1278
Attali, J.R., 600
Aubó, C., 557
Aubry, V., 1243
Augustin, L.S.A., 1496
Avila, E., 873
Awata, S., 1025
Awata, T., 1145
Azhar, S., 1106
Azzam, A., 232

Babaya, N., 651
Badimón, L., 942
Bae, J.H., 92
Bahouth, S.W., 239, 804, 1485
Bailey, L.B., 1440
Bairati, C., 1352
Bakker-Arkema, R., 167
Ball, R.O., 444
Banchini, A., 548
Bank, I., 215
Bannister, P.A., 563
Barakat, H.A., 285, 858, 1473
Barilli, A.I., 499
Barilli, L.A., 959
Barnard, R.J., 736
Barré, P.E., 215
Barrett, P.H.R., 1204
Bartoli, W.P., 395
Basabe, J.C., 1346
Basso, L.E., 1092
Battistini, B., 373
Battula, S.B., 1049
Bays, H., 1234
Bechstein, W.O., 367
Behar, A., 880
Belch, J.J.F., S1:23
Bendtsen, F., 47
Benowitz, N.L., 101
Bercovitch, D.D., 215
Bergeron, J., 432, 513
Bermudo, F., 672
Bessesen, D.H., 379
Betteridge, D.J., S1:3
Bianchi, A., 155
Bianchi, G., 1434
Bibby, B.M., 969
Biol, M.-C., 526
Biolo, G., 689
Birgel, M., 666
Biro, F.M., 1124
Bissoli, L., 6
Bistrian, B.R., 611
Björkling, F., 178
Björntorp, P., 1197
Black, D., 167
Blackard, W.G., 232
Blázquez, E., 709
Boddie, A., 1440
Boden, G.H., 1491
Boel, E., 996
Boemi, M., 1529
Boers, G.H.J., 1071
Bogovich, K., 314
Boitard, C., 1243
Boivin, A., 134
Bolognino, M., 1424
Bonnet-Eymard, M., 1156
Boozer, C.N., 503
Borecki, I.B., 203
Borgiani, P., 424
Børglum, J.D., 906
Borkenstein, M.H., 890
Born, J., 794, 950
Børsheim, E., 579
Bosello, O., 6
Bossoni, S., 634
Bosutti, A., 689
Botero, D., 790
Bottini, E., 424
Bouchard, C., 203, 298, 432, 513, 1014, 1063, 1197
Bougnères, P.F., 1243
Bougopoulos, C.L., 101
Boulahdour, H., 880
Boutros, A., 270
Branca, F., 1467
Brand-Miller, J.C., 1
Braun, B., 1036
Bretzel, R.G., 1134
Briaud, I., 532
Brizi, M., 1434
Brogan, R., 778
Brown, W.V., 167, 1271
Browne, R., 799
Brownlee, M., S1:9
Brunengraber, H., 1211
Buemann, B., 969, 1335
Buffington, C., 804, 1485
Burattin, A., 634
Burattini, R., 1529
Burge, M.R., 195
Burguera, B., 1278
Burkey, B.F., 1301
Burlina, A., 1352
Butler, P.C., 896
Butterfield, G.E., 1036
Byrne, C.D., 81

Cacho, J., 1180
Cadeau, P., 1239
Cagampang, G.B., 1496
Caixàs, A., 640
Cameron, D., 845
Campanini, C., 499
Cantin, B., 53
Cañete, R., 672
Capdevila, A., 1542
Capotorto, J.V., 755
Capristo, E., 220, 704
Carantoni, M., 499, 544
Carel, J.C., 1243
Carmena, R., 1627
Carter, L., 962
Casals, E., 1511
Casamitjana, R., 305
Causey, A., 698

AUTHOR INDEX

Abbasi, F., 151, 544
Abe, T., 1215, 1506
Abiko, A., 567
Ablondi, F., 548
Abrams, S., 1326
Abu-Basha, E.A., 1370
Ackermans, T., 839
Adachi, T., 990
Adamonis, W., 594
Afandi, B., 270, 753
Agarwal, S., 67, 537, 1496
Ahn, Y.-H., 92
Ahrén, B., 1518
Aizawa, H., 1118
Akerstrom, V., 1444
Akinci, A., 626
Akiyama, T., 1167
Alderson, N.L., 395
Aleksandrowicz, Z., 594
Aljada, A., 147, 799
Alvarez, E., 709
Amato, B., 1164
Amemiya, S., 186
Amery, C.M., 450
Amusquivar, E., 1180
An, P., 298, 1014
Andersen, R.N., 1485
Anderson, P.J., 1523
Andersson, S., 259
Ando, N., 479
Annabi, B., 1200
Ansari, B.M., 819
Antonacci, E., 424
Aoki, T., 588
Apperson-Hansen, C., 1124
Arafeh, A.-H., 270
Arakawa, H., 1001
Araki, E., 920
Araki, N., 567
Arango, A., 790
Arciero, P.J., 101
Ardehali, H., 814
Ardigo, D., 959
Ardilouze, J.-L., 1055
Argentieri, G., 1301
Arias, A.M.P., 839
Armellini, F., 6
Arnelo, U., 486
Arnett, D.K., 293
Asano, T., 308
Ascaso, J.F., 1627
Ashcroft, F.M., S2:3
Ashidate, K., 479
Assami, T., 1176
Assmann, G., 770
Astrup, A., 731, 969, 1335
Atkinson, E.J., 1278
Attali, J.R., 600
Aubó, C., 557
Aubry, V., 1243
Augustin, L.S.A., 1496
Avila, E., 873
Awata, S., 1025
Awata, T., 1145
Azhar, S., 1106
Azzam, A., 232

Babaya, N., 651
Badimón, L., 942
Bae, J.H., 92
Bahouth, S.W., 239, 804, 1485
Bailey, L.B., 1440
Bairati, C., 1352
Bakker-Arkema, R., 167
Ball, R.O., 444
Banchini, A., 548
Bank, I., 215
Bannister, P.A., 563
Barakat, H.A., 285, 858, 1473
Barilli, A.I., 499
Barilli, L.A., 959
Barnard, R.J., 736
Barré, P.E., 215
Barrett, P.H.R., 1204
Bartoli, W.P., 395
Basabe, J.C., 1346
Basso, L.E., 1092
Battistini, B., 373
Battula, S.B., 1049
Bays, H., 1234
Bechstein, W.O., 367
Behar, A., 880
Belch, J.J.F., S1:23
Bendtsen, F., 47
Benowitz, N.L., 101
Bercovitch, D.D., 215
Bergeron, J., 432, 513
Bermudo, F., 672
Bessesen, D.H., 379
Betteridge, D.J., S1:3
Bianchi, A., 155
Bianchi, G., 1434
Bibby, B.M., 969
Biol, M.-C., 526
Biolo, G., 689
Birgel, M., 666
Biro, F.M., 1124
Bissoli, L., 6
Bistrian, B.R., 611
Björkling, F., 178
Björntorp, P., 1197
Black, D., 167
Blackard, W.G., 232
Blázquez, E., 709
Boddie, A., 1440
Boden, G.H., 1491
Boel, E., 996
Boemi, M., 1529
Boers, G.H.J., 1071
Bogovich, K., 314
Boitard, C., 1243
Boivin, A., 134
Bolognino, M., 1424
Bonnet-Eymard, M., 1156
Boozer, C.N., 503
Borecki, I.B., 203
Borgiani, P., 424
Børglum, J.D., 906
Borkenstein, M.H., 890
Born, J., 794, 950
Børsheim, E., 579
Bosello, O., 6
Bossoni, S., 634
Bosutti, A., 689
Botero, D., 790
Bottini, E., 424
Bouchard, C., 203, 298, 432, 513, 1014, 1063, 1197
Bougnères, P.F., 1243
Bougopoulos, C.L., 101
Boulahdour, H., 880
Boutros, A., 270
Branca, F., 1467
Brand-Miller, J.C., 1
Braun, B., 1036
Bretzel, R.G., 1134
Briaud, I., 532
Brizi, M., 1434
Brogan, R., 778
Brown, W.V., 167, 1271
Browne, R., 799
Brownlee, M., S1:9
Brunengraber, H., 1211
Buemann, B., 969, 1335
Buffington, C., 804, 1485
Burattin, A., 634
Burattini, R., 1529
Burge, M.R., 195
Burguera, B., 1278
Burkey, B.F., 1301
Burlina, A., 1352
Butler, P.C., 896
Butterfield, G.E., 1036
Byrne, C.D., 81

Cacho, J., 1180
Cadeau, P., 1239
Cagampang, G.B., 1496
Caixàs, A., 640
Cameron, D., 845
Campanini, C., 499
Cantin, B., 53
Cañete, R., 672
Capdevila, A., 1542
Capotorto, J.V., 755
Capristo, E., 220, 704
Carantoni, M., 499, 544
Carel, J.C., 1243
Carmena, R., 1627
Carter, L., 962
Casals, E., 1511
Casamitjana, R., 305
Causey, A., 698

Cawthorne, M.A., 1610
Ceda, G.P., 548
Celi, M., 760
Cerasi, E., S2:1
Cerci, S., 760
Cerda, J.J., 1440
Ceresini, G., 548
Ceriello, A., S1:27
Cersosimo, E., 676
Cha, M.C., 503, 977
Chagnon, C., 1197
Chagnon, M., 203, 1197
Chagnon, Y.C., 203, 432, 1063
Chakrabarti, R., 1417
Chan, J.C.N., 1021, 1523
Chan, L., 22
Chan, O., 862
Chandramouli, V., 1211
Charlton, E., 1239
Charron, M.J., 340
Chaturvedi, N., 245
Chen, M.C., 1267
Chen, M.H., 1267
Chen, W., 1301
Cherrington, A.D., 1619
Chhibber, V.L., 39
Chiba, M., 1145
Chicco, A., 1346
Chien, E.J., 253
Child, A., 1036
Chirtel, S.J., 508
Chiu, K.C., 1501
Chiu, M.C., 1267
Chou, C.J., 503
Chowen, J.A., 709
Chrisoulidou, A., 563
Christensen, M., 996
Christiansen, E., 32
Christiansen, J.S., 906
Chu, C.A., 1619
Chuang, L.-M., 1267, 1501
Chugh, S.N., 160
Cianfarani, S., 1467
Ciaraldi, T.P., 962
Cipriano, P., 1164
Claypool, M.D., 1390
Clemmons, D.R., 626
Clifton, P., 1453
Clore, J.N., 232
Cobelli, C., 367
Cockram, C.S., 1021
Coggan, A.R., 122
Cohen-Boulakia, F., 880
Colagiuri, S., 1
Collins, P., 1049
Conley, L., 778
Connelly, P.W., 67
Considine, R., 724
Conti, M., 748
Cooper, A.J., 742
Copeland, K.C., 626
Cordain, L., 1473
Cornell-Kennon, S., 755
Cornier, M.-A., 379, 1473
Corsetti, J.P., 1424
Corssmit, E.P.M., 839
Cortese, C., 718
Cossins, E., S1:14
Costa, S., 73
Coste, T., 868
Coudray, C., 1326
Coutant, R., 1243
Cowan, G.S.M., Jr, 804, 1485
Cox, J.H., 858
Creech, R.H., 1491
Crepaldi, G., S2:21
Critchley, J.A.J.H., 1021, 1523
Crombleholme, W.R., 1043
Crook, D., 245
Cunnane, S.C., 67

Dagenais, G.R., 53
Dagnelie, P.C., 931
Dailey, G.E., 1491
Damario, M.A., 314
Dandona, P., 147, 799
Danon, M., 790
Dantz, D., 794
Darcy-Vrillon, B., 141
Davidman, M., 215
Davidson, M.H., 1234
Davis, W.P., 826
Dawson, R., Jr., 1479
Deckelbaum, L.I., 1365
Deepa, R., 455
DeFronzo, R., 814
De Gaetano, A., 220, 704
De Leeuw, I., 724
De Leiva, A., 640
D'Elia, J.A., 88, 1491
Delport, R., 1092
Delsignore, R., 499, 959
De Marinis, L., 155
DeMoss, D., 1130
D'Erasmo, E., 760
DeSantiago, S., 873
Desfaits, A.-C., S1:17
Deshaies, Y., 134
De Souza, C.J., 755, 1301
De Souza, J.B., 937
Després, J.-P., 53, 432, 513, 1063
De Toma, G., 760
Devroede, G., 1224
Diamandis, E.P., 537
Dicker-Brown, A., 736
Didlake, R.H., 698
Di Iorio, R., 760
Di Marino, L., 1164
Di Palma, R., 1164
DiPaola, L.M., 1124
Discher, T., 1134
Djemli-Shipkolye, A., 868
Dobs, A.S., 115, 1234
Doga, M., 634
Doi, K., 1001
Doi, Y., 308
Dong, M., 1301
Dragonas, N., 1301
Dralyuk, F., 1579
Dubbeldam, S., 833
Ducros, V., 1326
Duée, P.-H., 141
Dufour-Lamartinie, J.-F., 880
Durstine, J.L., 395

Earm, Y.E., 92
Eckfeldt, J., 293
Eckhardt, M., 1301
Eddings, K., 280
Efendic, S., 1211
Elased, K.M., 937
El-Bahrani, B., 984, 1411
Elbein, S.C., 280
ElZalabany, M.M., 819
Emilsson, V., 1610
Endert, E., 839
Eng, J., 709
Entes, L.J., 1390
Erkelens, D.W., 833
Erlandsen, M., 32
Essig, D.A., 395
Etgen, G.J., 684
Eto, M., 567

Fain, J.N., 239, 804, 1485
Faulkner, D., 67, 537
Federici, G., 718
Federlin, K., 1134
Fehm, H.L., 794, 950
Feillet-Coudray, C., 1326
Ferguson, M.A., 395
Fernández-Real, J.M., 305
Ferrari, E., 548
Ferraris, N., 1346
Ferretti, J., 676
Feussner, G., 770
Field, P.A., 492
Fink, L., 736
Finkelstein, A., 270
Fioretto, P., S2:21
Fisher, S.J., 386
Fitzsimons, O., 1049
Floras, J.S., 373
Fonseca, V., 736
Fontaine, R.N., 845
Forte, T.M., 22
Fortino, A., 1346
Foxall, T.L., 826
Fragasso, G., 748
Franco-Colin, M., 1287
Freddi, M., 548
Frederich, R.C., 611
Fried, S.K., 421
Friese, G., 1134
Fritsche, A., 335
Fruehwald-Schultes, B., 794, 950
Fujioka, T., 552
Fujisawa, T., 651
Fujishima, M., 308
Fujitsuka, N., 954
Fujiwara, K., 1361
Fujiwara, K., 427

Fukatsu, A., 588
Fukuda, M., 331
Fukumitsu, K.-I., 1167
Fukushima, M., 1001
Fulgoni, V., III, 1496
Fumelli, D., 1529
Fumelli, P., 1529

Gadbois, T.M., 1106, 1390
Gagen, K., 1301
Gagnon, J., 298, 432, 513, 1014
Gallagher, J.J., 563
Galli, L., 748
Gallice, P., 868
Gallistl, S., 890
Gan, S.T., 1
Gannon, M.C., 1565
Garenc, C., 432
Garlick, P., 676
Garmong, A., 626
Garsetti, M., 67, 537, 1496
Gasbarrini, G., 220
Gascón, F., 672
Gasparini, P., 499, 959
Gastaldelli, A., 122
Gentilella, R., 155
Gepp, H., 458
Gerich, J.E., 1318, S2:12
Gernone, F., 748
Gesmar, H., 1335
Ghanim, H., 799
Ghosh, A., 1417
Giacca, A., 862, 984, 1411
Giancaterini, A., 704
Gibbons, G.F., 492
Gill, R., 232
Giustina, A., 155, 634, 778
Gleason, R.E., 88, 1491
Gloria-Bottini, F., 424
Glueck, C.J., 845
Gnasso, A., 718
Gniuli, D., 220, 704
Godi, D., 778
Godsland, I.F., 245, 742
Goh, T., 1411
Goi, G., 1352
Going, S.B., 1379
Goldfine, A.B., 400
Goldstein, B.J., 400
Golling, M., 367
Gómez, R., 709
Gomis, R., 1511
Goodpaster, B.H., 467
Gooren, L.J.G., 648
Goto, T., 1395
Gottschling-Zeller, H., 666
Gowri, M., 1106
Goyke, E., 594
Granner, D., 814
Gravholt, C.H., 32, 896
Gray, R., 563
Greaves, K.A., 1188
Greco, A.V., 220, 704
Gréco, S., 526
Gregersen, S., 208, 264
Grewerus, D., 367
Gribble, F.M., S2:3
Griffin, L.C., 67
Grill, V., 657
Grøfte, T., 1598
Grosenstein, P., 1301
Grösser, P., 607
Grossi, G., 1434
Grue-Sørenson, G., 178
Guarnieri, G., 689
Guedes, D.P., 1379
Guerre-Millo, M., 764
Gueux, E., 1326
Gullo, A., 689
Gupta, N., 1411
Gustafson, W.C., 1604
Gylling, H., 473

Haas, M.J., 1572
Hackler, L., 1444
Hada, T., 97, 886
Haderslev, K.V., 360
Haffner, S.M., S1:1, S1:30
Halabe, A., 192
Hales, C.N., 81
Halter, J.B., 386
Hamamoto, A.E., 1473
Hamouda, W., 799
Hanehira, T., 1356
Hara, T., 588
Harada, E., 1228
Hardman, A.E., 1150
Hargrove, D., 280
Häring, H., 335
Harrower, A., S2:7
Harris, P.A., 232
Hashimoto, K., 1400
Hatton, M.W.C., 1449
Hauner, H., 666
Hayakawa, T., 1215, 1506
Hayashi, H., 1285
Hayashi, K., 1361
Hayashi, M., 1561
Hayashi, R., 427
He, Y.-J., 1479
Heaney, R.P., 1083
Hellmich, B., 353
Hennig, B., 1006
Henriksen, J.H., 47
Henry, R.R., 962
Hermansen, K., 208, 264
Herrera, E., 1180
Herrington, M., 486
Herrlinger-Garcia, K., 1440
Heyman, R., 1610
Higashida, K., 186
Higashino, K., 97
Higashiyama, M., 1285
Hill, J.O., 1473
Hinokio, Y., 1145
Hirai, M., 1145
Hiramatsu, S., 657
Hiramatsu, Y., 853
Hirashima, T., 108
Hirayama, R., 411
Hirose, H., 1616
Ho, L.T., 1386
Ho, W.-K., 92
Ho-Kim, M.A., 203
Hoffer, L.J., 215
Hoffmann, M., 770
Holck, P., 32
Holeček, M., 1330
Holst, J.J., 969, 1598
Hong, Y., 293, 298, 1014
Hong, Y.-S., 92
Hongo, M., 1145, 1255
Hongsprabhas, P., 215
Höög, A., 657
Hori, M., 11
Horiuchi, S., 567
Hort-Legrand, C., 880
Hosoda, K., 326
Hosoda, T., 1295
Houmard, J.A., 285, 858
Hsu, W.H., 1370
Hunt, S.C., 293
Hurt-Camejo, E., 942
Hutson, A.D., 1440
Hwu, C.-M., 1386

Ide, T., 521
Iida, M., 11
Ikeda, H., 347, 1261
Ikeda, M., 11
Ikeda, Y., 1400
Ikegami, H., 651
Ikuma, K., 1395
Illingworth, R.D., 1234
Imai, T., 1255
Innis-Whitehouse, W., 167
Inoguchi, T., 1030
Inoue, G., 326
Inoue, M., 1400
Inoue, S., 574
Iozzo, P., 814
Isaksson, B., 486
Iscra, F., 689
Ishida, B.Y., 22
Ishihara, G., 853
Ishihara, T., 186
Ishii, T., 1616
Ishikawa, S.-e., 1285
Ishikawa, T., 912, 1588
Isoda, F., 1261
Israel, R.G., 1473
Itakura, Y., 129
Ito, S., 331
Ito, T., 1228
Ito, T., 552
Itoh, H., 1118
Itoh, M., 427
Iwakura, T., 990
Izumino, K., 1219

Jackman, M.R., 379
Jackson, C.-J., 537, 1496

Jacob, R., 1365
Jacqueminet, S., 532
Jannot, M.F., 868
Jansen, S., 692
Jansson, P.-A., 579
Jeejeebhoy, K.N., 1309
Jenden, D.J., 1542
Jenkins, D.J.A., 67, 537, 1496
Jennings, P.E., S1:23, S2:17
Jenssen, T., 1318
Jeppesen, P.B., 208
Jia, D.M., 1167
Jiang, Z.Y., 400
Jiménez Perepérez, J.A., 692
Johnson, A., 1049
Johnson, D.G., 1491
Johnston, D.G., 563
Jones, P.J.H., 977
Jorba, O., 640
Jørgensen, J.O.L., 906
Josse, R., 67
Jovin, I.S., 1431
Juhl, C.B., 896

Kaaja, R., 259
Kabir, M., 764
Kahara, T., 1215
Kahn, C.R., 400
Kaiser, F.E., 1239
Kajimoto, Y., 11
Kakkar, R., 160
Kakumu, S., 588
Kallies, B., 1340
Kamin, J.R., 195
Kaneko, K., 479
Kano, H., 560, 1356
Karabatas, L., 1346
Karonen, S.-L., 259
Kastin, A.J., 1444
Kataoka, K., 1001
Kato, C., 1295
Kato, K., 662
Katz, E.B., 340
Kauwell, G.P.A., 1440
Kawaguchi, Y., 651
Kawamori, R., 862
Kawamura, I., 1395
Kawamura, M., 479
Kawano, K., 108, 1030
Kawazu, S., 1118
Keith, M., 1309
Kekäläinen, P., 1247
Kelley, D.E., 467
Kendall, C.W.C., 67, 537, 1496
Kennedy, F.P., 1491
Keough, J.A., 88
Kern, P.A., 736
Kern, W., 794, 950
Khan, M.A., 1565
Kharb, S., 160
Khosla, S., 1278
Kikuchi, N., 186
Kim, C.-H., 17
Kim, G.S., 17
Kim, S.W., 17
Kishikawa, H., 920
Kissler, H.J., 458
Kitamura, K., 990
Kiuchi, Y., 1261
Klar, E., 367
Klaus, S., 1340
Klein, I., 275
Klöting, I., 1140
Knardahl, S., 579
Knauf, M., 1619
Kobayashi, K., 186
Kobayashi, K., 186
Kobayashi, K., 22
Kobayashi, K-i., 163, 1215, 1506
Kobayashi, T., 427
Kochan, Z., 594
Kodama, H., 1025
Kodama, I., 784
Kohno, M., 560, 1356
Koistinen, H., 259
Koivisto, V., 259
Komiya, I., 440
Konrad, T., 367
Korytkowski, M., 1318
Kousta, E., 563
Koutsari, C., 1150
Kovács, P., 1140
Koval, J., 814
Koyama, M., 347
Kris-Etherton, P., 1101
Kristensen, K., 906
Krokowski, M., 1243
Kubota, M., 11
Kudo, T., 853
Kugiyama, K., 1228
Kumar, S.K.B., 1417
Kumon, Y., 1400
Kunz, I., 1340
Kurabayashi, M., 1118
Kuro-o, M., 1118
Kuroda, A., 11
Kurosaki, E., 411
Kusaka, I., 1285
Kush, D., 1234
Kusunoki, M., 588
Kwok, C.F., 1386
Kyung, S., 1271

Laakso, M., 1247
Lacaille, M., 203
Ladrière, L., 178
Lahlou, N., 1243
Laivuori, H., 259
Lakshman, M.R., 508, 1406
Lam, L., 984
Lamarche, B., 53
Lamendola, C., 151
Landaker, E.J., 400
Landau, B.R., 1211
Lange, U., 1134
Laromiguiere, M., 764
Lawrence, N., 563
Le, N.-A., 167, 1271
LeBlanc, R., 400
Lee, A.T., 88
Lee, B., 1496
Lee, N.P., 1501
Lee, R., 331
Lee, S.C., 1021
Lee, Z.S.K., 1021, 1523
Lehan, P.H., 698
Lehmann, R., 335
Lei, H.H., 1267
Leiter, L.A., 67
Lemieux, I., 53
Lenoir, D., 526
Leon, A.S., 298, 432, 513, 1014
Leppert, M.F., 293
Leroux, G., 53
Lestrade, R., 880
Letizia, C., 760
Levy, H.L., 1071, 1542
Li, J., 232, 804
Li, X., 167, 1271
Li, Z., 954
Lifshitz, F., 790
Lin, J., 293
Lindenthal, B., 62
Ling, P.R., 611
Lipinska, I., 88
Liu, H.-C., 314
Liu, Q.-H., 508, 1406
Liu, Y.-L., 1610
Liverani, E., 704
Löfgren, A., 724
Lohman, T.G., 1379
Lohmeyer, J., 1134
Lombardo, A., 1352
Lombardo, Y.B., 1346
Lönnroth, P., 579
López-Miranda, J., 692
López Segura, F., 692
Lormeau, B., 600
Louisot, P., 526
Lu, C.-C., 253
Lucarelli, P., 424
Lucas, A., 1449
Lucky, A.W., 1124
Lukkarinen, M., 621
Lundkvist, I., 486
Lupien, P.J., 53
Lydon, E., 611

McCready, D., 1239
MacDonald, K.G., 285
McGullam, J.L., 1501
McKeigue, P.M., 245
McLaughlin, T., 151, 544
MacLean, P.S., 285, 858
McNulty, P.H., 1365
Maeda, K., 560, 1356
Maestre, O., 709
Maezono, K., 814
Maffettone, A., 1164
Magsino, C.H., Jr., 799
Maheux, P., 1055, 1224
Mahon, A., 367

Maison, P., 81
Makino, I., 567
Makowski, J.P., 1370
Malaisse, W.J., 178, 1111
Malkova, D., 1150
Man, Z.-W., 108
Mancini, A., 155
Manco, M., 220
Mandarino, L., 814
Mandel, S., 513
Manelli, F., 634, 778
Mano, T., 427
Manzanares, J.M., 1511
Manzon, A., 386
Marchesini, G., 1434
Marckmann, P., 731
Marinoni, E., 760
Markov, A.K., 698
Marliss, E.B., 386
Marmillot, P., 508, 1406
Marra, G., 718
Mårtensson, H., 1518
Martin, R.L., 1479
Martos, R., 672
Maruyama, H., 1616
März, W., 770
Masana, L., 942
Mascardi, C., 155
Mason, T.M., 1411
Massaccesi, L., 1352
Massironi, P., 499, 959
Masuyama, H., 853
Masuzaki, H., 326
Mathoo, J.M.R., 862
Matsuhisa, M., 11, 984
Matsumoto, K., 1219
Matsumura, Y., 1118
Mattila, K., 621
Mayer, O., Jr., 418
Mazur, A., 1326
Mazza, A., 718
Mazzeo, R.S., 1036
Méchin, M.-C., 1200
Meerarani, P., 1006
Mehling, C.C., 67
Melby, C.L., 1473
Melton, L.J., III, 1278
Meneilly, G.S., 373
Merchante, A., 1627
Meszaros, K., 1390
Meyerovitch, J., 321
Micciolo, R., 6
Midorikawa, S., 662
Miettinen, T.A., 473
Milardi, D., 155
Millard, W.J., 1479
Miller, D.K., 1085
Miller, S., 115
Minami, A., 588
Minami, M., 560, 1356
Mingrone, G., 220, 704
Mino, A., 6
Minoura, H., 616
Misra, P., 1417
Mitchel, Y., 1234
Mito, N., 1295
Mitrakou, A., 1318
Mittal, A.A., 1579
Mittleman, K.D., 421
Miyake, S., 1219
Miyamoto, S., 1228
Miyata, T., 588
Miyazaki, S., 479
Mizukami, H., 347
Mizuno, Y., 1228
Mobbs, C.V., 1261
Mochizuki, M., 186
Mochizuki, T., 521
Mohan, V., 455
Möller, C., 657
Møller, J., 1598
Møller, N., 1598
Møller, S., 47
Monciotti, C., 1352
Monti, L.D., 73, 748, 959
Mooradian, A.D., 1572
Moore, L.G., 1036
Moore, S.K., 845
Morais, J.A., 386
Moreno, S., 1049
Morganti, S., 548
Mori, A., S1:14
Mori, S., 108
Moriwaki, Y., 97, 886
Morley, J.E., 1085, 1239
Moroz, P., 1204
Morrison, J.A., 1124
Mortensen, S.B., 996
Mosseri, R., 321
Motoshima, H., 920
Motti, C., 718
Mudaliar, S., 962
Mudd, S.H., 1071, 1542
Mulder, H., 1518
Müller-Gerghaus, G., 1431
Muntean, W., 890
Muñoz, R.M., 709
Murakami, K., 521
Murakami, T., 574, 954
Muscato, N., 1619
Musliner, T.A., 115
Mutoh, S., 1395
Myers, R.H., 293

Nabeshima, Y., 1118
Nagai, R., 1118
Nagai, Y., 163, 1215, 1506
Nagasaka, A., 427
Nagasaka, S., 1001, 1285
Nagasaki, M., 954
Nagata, C., 1561
Nagata, I., 1001
Nakagawa, H., 427, 784
Nakagawa, T., 129
Nakahara, I., 11
Nakai, A., 427
Nakai, N., 954
Nakai, Y., 1001
Nakamura, A., 1361
Nakamura, H., 1167
Nakamura, S., 1228
Nakamura, S., 308
Nakamura, T., 1285
Nakamura, T., 1400
Nakamura, T., 588
Nakano, I., 427
Nakano, R., 411
Nakao, K., 326, 1228
Nakaya, Y., 588
Nakayama, C., 129
Nakayama, K., 1025
Nakayama, K., 588
Nakayama, M., 1228
Nakazawa, S., 186
Nakazawa, T., 521
Näntö-Salonen, K., 621
Nardi, A., 607
Natalucci, S., 1529
Nattrass, M., 450
Navarro, M., 709
Nawata, H., 1030
Neal, D.W., 1619
Neely, W.A., 698
Neri, G., 115
Ness, R.B., 1043
Nestel, P., 1453
Neuhaus, P., 367
Nijpels, G., 839
Nikoulina, S.E., 962
Nindl, B.C., 101
Ning, C., 1460
Nishikai, K., 1616
Nishimura, H., 326
Nishiyama, T., 920
Niwa, M., 862
Noakes, M., 1453
Nobukata, H., 912
Nobukata, N., 1588
Noda, K., 616
Noda, Y., S1:14
Noguchi, H., 129
Nohara, E., 163
Nojima, K., 651
Nomura, G., 1215, 1506
Nonomura, T., 129
Nørrelund, H., 906
Norwich, K.H., 1309
Nowotny, P., 229
Nulli, A., 718
Nuttall, F.Q., 1565
Nyholm, B., 32, 896

Obata, M., 912, 1588
Obayashi, M., 954
Ochi, H., 1030
Odaka, H., 347
O'Dowd, J., 1610
O'Fallon, W.M., 1278
Ogawa, H., 1228
Ogawa, S., 331
Ogawa, Y., 326
Ogihara, T., 651

Ohama, K., 784
Ohnaka, M., 588
Ohno, T., 1118
Ohta, M.Y., 163
Ohyama, Y., 1118
Ojamaa, K., 275
Oka, K., 22
Oka, Y., 1118
Okada, K., 588
Okamoto, Y., 990
Okamura, F., 1255
Oku, A., 990
Oldham, B.A., 684
Olivares, E., 1111
O'Neill, D.S., 1473
Ono, M., 129
Ordóñez-Llanos, J., 640
Ørskov, L., 1598
Osaka, T., 574
Oshida, Y., 954
Östenson, C.-G., 486
Otsuki, M., 1167
Otto, C., 810
Oturai, P.S., 996
Owens, D., 1049
Ozawa, Y., 1361

Packer, L., S1:14
Palmarino, R., 424
Panarotto, D., 1055, 1224
Paniagua, J.A., 692
Panini, R., 225
Pankiewicz, A., 594
Pappa, V., 1537
Pariès, J., 600
Park, K.S., 962
Park, W.K., 92
Parker, T., 67, 537
Pastore, A., 718
Patrick, P., 1085, 1239
Patti, M.-E., 400
Pearson, T.A., 1101
Pedersen, K.E., 996
Pedersen, S.B., 906
Pedreño, J., 942
Pegorier, J.-P., 1200
Pencharz, P.B., 444
Pendergrass, M., 814
Pérez, A., 640
Perez, E., 1479
Pérez-Heras, A., 1511
Pérez-Jiménez, F., 692
Perez-Lamboy, G.I., 1592
Permert, J., 486
Perry, H.M., III, 1085, 1239
Pérusse, L., 203, 432, 1063, 1197
Pesek, J.F., 1424
Peters, A., 794, 950
Pfeiffer, A., 353
Phan, C.V., 73
Phillips, H., 845
Piatti, P.M., 73, 748
Piercy, V., 1548
Pimenta, W., 1318
Pincus, S., 896
Pinkett, J.G., 1390
Platti, P.M., 959
Playfair, J.H.L., 937
Poisson, J., 1224
Poitout, V., 532
Polderman, K.H., 648
Polonsky, K.S., 1579
Pommer, D., 340
Pontiroli, A.E., 73, 748
Poretsky, L., 314
Pories, W.J., 285
Pørksen, N., 896
Poulsen, C.R., 208
Poulson, P.L., 1598
Pouncey, L., 804, 1485
Pozza, G., 73
Prat, T., 640
Premkumar, M., 1417
Printz, R., 814
Province, M.A., 203, 293, 432
Pu, Y.B., 1021
Pugh, W.L., 1579
Pulkki, K., 621
Pun, K., 1572

Qu, Z., 611
Qualls, C.R., 195
Quarto, G., 1164
Quevedo-Corona, L., 1287
Quistorff, B., 1335

Raben, A., 731
Raccah, D., 868
Racotta, R., 1287
Raguso, C.A., 122
Rajagopalan, R., 1417
Ramadass, P., 1006
Rampersaud, G.C., 1440
Ranganathan, S., 736
Rankinen, T., 1063
Rao, A.V., 67, 537, 1496
Rao, C.S., 1417
Rao, D.C., 203, 298, 432, 513, 1014
Rao, M.N., 508, 1406
Raptis, S.A., 1537
Rashid, S., 862
Rayssiguier, Y., 1326
Reach, G., 532
Real, J.T., 1627
Reaven, G.M., 151, 418, 499, 544, 959, 1106, 1390
Rebecchi, I., 548
Reddy, K.N., 1417
Reed, M.J., 1390
Reed, R.G., 1101
Rehfeld, J.F., 969
Reinacher, D., 1572
Relas, H., 473
Rema, M., 455
Renier, G., S1:17
Renn, W., 335
Ricart, W., 305
Riccardi, G., 1164
Ricci, M.R., 421
Rice, T., 203, 298, 513, 1014
Rich, S.S., 293
Richelsen, B., 906
Richter, W.O., 810
Riggs, B.L., 1278
Rigla, M., 640
Ríos, R., 672
Rivellese, A.A., 1164
Rizkalla, S.W., 764
Rizzo, W.B., 232
Roberts, J.M., 1043
Roberts, S.A., 444
Roch, M., 1542
Rock, P.B., 1036
Rodgers, C., 984
Rodrigo, A., 1627
Rodriquez de Fonseca, F., 709
Rodríguez-Villar, C., 1511
Roe, M.W., 1579
Röhrig, K., 666
Rolin, B., 996
Romanelli, G., 634
Romijn, J.A., 839
Roncero, I., 709
Ronchi, M., 1434
Ros, E., 1511
Rosenberg-Zand, R.S., 537
Rosenwaks, Z., 314
Roshan, B., 88
Rosmond, R., 1197
Rosolová, H., 418
Ross, B., 1449
Ross, D., 742
Rossi, B., 1434
Rossi, L., 1467
Rouault, C., 532
Round, R.A., 450
Roy, S., 203
Ruz, F.J., 672
Ryan, M.A., 67
Ryu, J.M., 1501

Saad, M.F., 1501
Sabet, A., 275
Saboohi, F., 215
Sacco, M., 1164
Saito, A., 990
Saito, I., 1616
Saito, T., 1285
Saito, T., 1285
Saito, Y., 1118, 1228
Sakai, K., 920
Sakai, M., 1001
Sakamaki, H., 1219
Sakamoto, S., 588
Sakasita, T., 784
Sakuraba, H., 347
Salama, M., 819
Salvioli, G., 225
Sanada, M., 784
Sánchez-Quesada, J.L., 640
Sandoli, E.P., 73
Sardinha, L.B., 1379

Sarlund, H., 1247
Saruta, T., 1361, 1616
Sato, K., 1295
Sato, T., 331
Sato, W., 662
Sato, Y., 1255
Sato, Y., 954
Satoh, Y., 1145
Sauerwein, H.P., 839
Sawanobori, E., 186
Scarpetta, G., 225
Schade, D.S., 195
Schalkwijk, C.G., 648
Schatz, H., 353
Schellner, M., 353
Schichiri, M., 920
Schifter, S., 47
Schmitz, O., 32, 896, 1598
Schocken, D.D., 1592
Schorr, U., 1340
Schrott, H., 1234
Schuler-Lüttmann, S., 770
Schüller, A., 367
Schumann, W.C., 1211
Schussler, G.C., 270, 753
Schwandt, P., 810
Schwenke, D.C., 1188
Schwille, P.O., 458
Scott, F.W., 1111
Scribner, K.A., 1106
Scroggin, E., 280
Seeff, L.B., 1406
Segal, S., 1460
Segalini, G., 1352
Seino, Y., 990
Seki, J., 1395
Sener, A., 1111
Sennitt, M., 1610
Sentí, M., 557
Serra, J.R., 640
Serri, O., S1:17
Seyler, H., 67
Shadoan, M.K., 1188
Shafrir, E., 321
Shapiro, D.R., 115
Sharma, A., 160
Sharma, A.M., 1340
Shaw, W.N., 1424
Shefi, M., 321
Shi, Z.Q., 984
Shiba, Y., 11
Shibasaki, M., 411
Shibata, M., 651
Shibutani, Y., 912, 1588
Shige, H., 1453
Shih, K.-C., 1386
Shihara, N., 990
Shikama, H., 411
Shimasaki, Y., 1228
Shimaya, A., 411
Shimizu, H., 1561
Shimoike, T., 1030
Shimomura, Y., 954
Shimoshige, Y., 1395
Shinohara, R., 427
Shintani, M., 326
Shiomi, M., 552
Shirakami, A., 920
Shirotani, T., 920
Shohat, B., 192
Shrier, I., 215
Shum, K., 862
Sidossis, L.S., 122
Sieve-Smith, L., 845
Sigal, R.J., 386
Simell, O., 621
Singh, G.P., 160
Skinner, J.S., 298, 432, 513, 1014
Slama, G., 764
Sledzinski, Z., 594
Smagghue, O., 600
Smith, J.M., 450
Soejima, H., 1228
Solerte, S.B., 548, 634
Soliman, A.T., 819
Song, D.-K., 92
Song, W., 736
Soriano, C., 39
Southward, S.M.R., 1449
Sparks, C.E., 1424
Sparks, J.D., 1424
Spencer, C.P., 742
Spies, J., 1092
Sprecher, D.L., 1124
Šprongl, L., 1330
Sreenan, S.K., 1579
Staun, M., 360
Stehouwer, C.D.A., 648
Stehr, A., 1431
Steil, G.M., 755
Stein, E.A., 1234
Steinberg, S.F., 275
Steinmüller, T., 367
Stephan, E., 1134
Stevenson, J.C., 245, 742
Stewart, P.W., 1101
Stracke, H., 1134
Strader, D.B., 1406
Strömmer, L., 486
Stuart, C.A., 1604
Stumvoll, M., 335
Subioli, S., 760
Suchi, T., 1255
Sudi, K.M., 890
Suehiro, T., 1400
Suga, T., 1118
Sugahara, K., 1025
Sugimura, K., 331
Sun, G., 1063
Sundler, F., 1518
Suzuki, S., 1145, 1255
Sviridov, D., 1453
Swart, G.R., 931
Swierczynski, J., 594

Tabaru, A., 1167
Taborski, U., 1431
Taguchi, T., 920
Tai, T.Y., 1267
Taiji, M., 129
Taira, M., 440
Taira, T., 440
Takahashi, S., 97, 886
Takakura, S., 1395
Takami, R., 1561
Takamura, T., 163, 1215, 1506
Takasu, N., 440
Takazoe, K., 1228
Takeda, N., 1561
Takeuchi, K., 331
Tamura, D., 1255
Tanaka, H., 440
Tanaka, S.-i., 1261
Tangerman, A., 1071
Taniguchi, A., 1001
Taniguchi, M., 1506
Taniguchi, S., 22
Tannapfel, A., 458
Tashiro, A., 1145, 1255
Tate, A.C., 115
Tayek, J.A., 39
Tchipashvili, V., 862
Teichmann, J., 1134
Teixeira, P.J., 1379
Tellez-Lopez, A.M., 1287
Teng, K., 280
Teppa, R.J., 1043
Teramoto, T., 479
Terpstra, A.H.M., 826
Terry, J., III, 698
Tessier, D., 1055
Testa, I., 1529
Testa, R., 1352
Theriaque, D.W., 1440
Theriault, R., 467
Thoda, H., 479
Thomas, G.N., 1021, 1523
Thomas, T., 1278
Thompson, E.A., 1604
Thomsen, J.L., 264
Thorpe, J.M., 444
Tichý, M., 1330
Timm, C.T., 195
Toborek, M., 1006
Toffolo, G., 367
Tofler, G.H., 88
Toigo, G., 689
Tokuyama, H., 1361
Tokuyama, K., 186, 1001
Tomás, M., 557
Tominaga, Y., 1219
Tomita, T., 11
Tomkin, G.H., 1049
Tomlinson, B., 1021, 1523
Tomono, S., 1118
Torres, N., 873
Toseland, C.D.N., 1548
Toubro, S., 969
Tovar, A.R., 873
Toyoda, N., 616
Toyonaga, T., 920

Toyota, T., 1145
Tracy, T., 845
Trivedi, N., 755
Tsai, C.-L., 253
Tsai, G.P., 1501
Tsai, S.-C., 253
Tsao, T.-S., 340
Tschritter, O., 335
Tsigos, C., 1537
Tsimaratos, M., 868
Tsiotra, P.C., 1537
Tsuda, K., 990
Tsugawa, T., 427
Tsujita, Y., 552
Tsutsumi, K., 588
Tsutsumi, Z., 97, 886
Turner, N.C., 1548

Ubbink, J.B., 1092
Uchimura, K., 427
Uchiyama, M., 1176
Uchiyama, T., 1118
Ueda, H., 651
Ueki, Y., 1219
Ueta, K., 990
Ukkola, O., 1063
Uma, C., 1417
Umeda, F., 1030
Usadel, K.H., 367
Utsugi, T., 1118
Utsumi, A., 1145
Utumi, A., 1255

Vadlamudi, S., 285
Vague, P., 868
Valayoudon, P., 600
Valensi, P.E., 600, 880
Valenti, G., 548
Valle, D., 155
Valle, M., 672
Valsecchi, G., 73, 748, 959
Van Broeckhoven, C., 724
Van de Werve, G., 1200, 1411
Van den Berg, J.W.O., 931
Van den Brandt, J., 1140
Van der Auwera, J.-C., 724
Van der Gaast, A., 931
Van Gaal, L., 724
Van Haeften, T.W., 833, 1318
Van Kamp, G.J., 648
Veldhuis, J.D., 896
Venkatesan, S., 563
Ventura, P., 225
Vera, R., 753
Verbruggen, I., 178
Verlato, C., 225
Vermaak, W.J.H., 1092
Vesely, D.L., 1592
Vicini, P., 367
Vidgen, E., 67, 537, 1496
Vierhapper, H., 229, 607
Vikramadithyan, R., 1417
Vogt, C., 814
Von Bergmann, K., 62
Von Duvillard, S.P., 826
Von Eckardstein, A., 770
Vranic, M., 386, 862
Vuksan, V., 67, 537, 1496

Wach, L., 594
Wada, M., 1176
Wada, R., 347
Wagner, C., 1542
Wagner, J.D., 1188
Wahl, H.G., 335
Wajngot, A., 1211
Wakisaka, M., 308
Waldhäusl, W., 229
Wan, C.K.N., 984
Waner, T., 321
Wang, P., 845
Wang, P.S., 253
Wang, S., 1610
Wareham, N.J., 81
Watanabe, F., 427
Watanabe, T., 662
Watford, M., 141
Watkins, B.A., 1006
Watkins, S.C., 467
Wattimena, J.L.D., 931
Watts, G.F., 1204
Wauters, M., 724
Webster, N.J.G., 962
Weeke, J., 896
Wehrenberg, W.B., 778
Weinhandl, G., 890
Weinrauch, L.A., 88, 1491
Weir, G.C., 755
Weir, M., 1491
Weisnagel, S.J., 1063
Weiss, S., 115
Wen, G., 1604
Whitehead, M.I., 742
Wickbom, M., 486
Wieland, H., 770
Wiernsperger, N., 1619
Wiklund, O., 942
Wilcken, B., 1071
Willem, R., 178
Williams, R.R., 293
Willsky, G.R., 400
Wilmore, J.H., 298, 432, 513, 1014
Wilsky, C.E., 1440
Wilson, J.H.P., 931
Witt, T.L., 1555
Wittmann, W., 367
Wolfel, E.E., 1036
Wong, N.C.W., 1572
Wong, W., 1309
Wright, G.L., 1130
Wu, M., 1234
Wu, Y.-J., 755

Xu, M., 954

Yagihashi, S., 347
Yamada, D., 662
Yamada, K., 651
Yamada, Y., 990
Yamakawa, T., 1261
Yamakita, J.-i., 97
Yamamoto, T., 1395
Yamamoto, T., 97, 886
Yamasaki, Y., 11
Yamashita, H., 1215, 1506
Yamato, E., 651
Yamazaki, Y., 574
Yang, W.S., 1267
Yano, H., 990
Yano, M., 1219
Yap, M.G., 270, 753
Yarasheski, K.E., 1555
Yasuda, K., 1561
Yasuda, K., 990
Yasue, H., 1228
Yasunari, K., 560, 1356
Yeckel, C.W., 122
Yibchok-anun, S., 1370
Yki-Jarvinen, H., 1318
Yki-Järvinen, H., 814
Ylikorkala, O., 259
Yonemitsu, S., 326
Yoshikawa, J., 560, 1356
Yoshimasa, Y., 326
Yoshimura, A., 954
Yoshimura, M., 1228
Yoshinari, M., 308
Yoshizato, K., 920
Young, L.H., 1365
Yu, S., 1025

Zachwieja, J.J., 1555
Zambón, D., 1511
Zamboni, M., 6
Zambrana, J.L., 692
Zamudio, S., 1036
Zannis, J., 1411
Zavaroni, I., 499, 959
Zawalich, K.C., 1156
Zawalich, W.S., 1156
Zhang, L., 1188
Zhu, Y., 770
Zittermann, A., 1078
Zonderland, M.L., 833
Zoratti, R., 245
Zuberi, L., 400
Zuelzer, W., 232
Zuijdgeest-van Leeuwen, S.D., 931

SUBJECT INDEX

A, *see* Androstenedione
AAs, *see* Amino acids
Abdominal adipose tissue (AT)
  and LPL gene, 434
  steady-state level of LPL mRNA in omental AT versus, 1224-1227
  see also Intraabdominal adipose tissue in NIDDM
Absorptiometry, *see* Dual-energy x-ray absorptiometry
AC (adenylyl cyclase) isoforms, changes in cardiac, and T_3 and T_4 modulation of cardiac β-adrenergic receptor responsiveness, 275-279
ACAT (acyl coenzyme A:cholesterol acyltransferase), aging and activity of, in HHL, 553-554
ACE (angiotensin-converting enzyme) inhibitors, effects of, on LVH and circulating BNPs in hypertensive elderly subjects, 1356-1360
Acetate
  cyclical norethindrone, effects of oral or transdermal 17β-estradiol with oral, on insulin sensitivity, secretion, and elimination in postmenopausal women, 742-747
  effects of elevated plasma FFAs on acetoacetate, in men, 452, 453
  effects of 4α-phorbol-12-myristate-13-, on MeAIB uptake, 876
  phenylacetate effects on glucose production and gluconeogenesis, 1211-1214
  TPA effects on pancreatic islets, 266
Acetoacetate, effects of elevated plasma FFAs on, in men, 452, 453
Acetyl-L-carnitine (ALC), and glucose disposal in NIDDM, 704-708
Acetyl-coenzyme A (CoA) carboxylase in SAT, 596, 597
N-Acetyl-β-D-glucosaminidase, plasma, at onset of IDDM with obesity and during IVGTT of healthy subjects, 1352-1355
Acipimox (ACX), lipolysis inhibition by, and isoproterenol- but not FFA-induced acute leptin suppression, 335-339
Acromegaly, exercise-induced microalbuminuria in active, acute slow lanreotide effects on, 634-639
ACTH, *see* Adrenocorticotropic hormone; Adrenocorticotropic hormone syndrome
β (beta)-Actin mRNA (messenger ribonucleic acid), triacsin C effects on, 327
Active acromegaly, exercise-induced microalbuminuria in, acute slow lanreotide effects on, 634-639
Acute alcohol intake, urinary excretion and concentration of serum mevalonic acid during, 62-66
Acute cold exposure, effects of, on plasma leptin in women, 421-423
Acute galanin (GAL) administration, effects of, on hypothalamic galanin synthesis in male and female subjects, long-loop GAL autofeedback and, 778-783
Acute leptin suppression, isoproterenol- but not FFA-induced, despite lipolysis inhibition by ACX, 335-339
Acute slow lanreotide effects on exercise-induced microalbuminuria in active acromegaly, 634-639
ACX (acipimox), lipolysis inhibition by, and isoproterenol- but not FFA-induced acute leptin suppression, 335-339
Acyl coenzyme A:cholesterol acyltransferase (ACAT), aging and activity of, in HHL, 553-554
Acyltransferase
  acyl coenzyme A:cholesterol, aging and activity of, in HHL, 553-554
  plasma lecithin:cholesterol, in TD, 771
ADAM (Androgen Deficiency in Aging Males) questionnaire, 1239-1242
Adenoma
  adrenal, in Cushing's syndrome, testosterone production and, 230
  parathyroid, in primary hyperparathyroidism, effects of excision of, on levels of IL-2 receptors and IL-6, 192-194
  pituitary, *see* Pituitary adenoma, and Cushing's syndrome
Adenosine, plasma concentration and urinary excretion of, furosemide effects on, 886-889
Adenosine monophosphate, cyclic, *see* cAMP
Adenosine triphosphatase (ATPase), RBC Na/K, in IDDM, insulin and C-peptide effects on, 868-872
Adenosine triphosphate, *see* K^+ channels, ATP-sensitive
Adenylyl cyclase (AC) isoforms, changes in cardiac, and T_3 and T_4 modulation of cardiac β-adrenergic receptor responsiveness, 275-279
Adipocytes
  leptin in, FFAs, triacsin C, palmitate, and 2-bromopalmitate downregulating, 326-330
  PAI-1 secretion of subcutaneous and omental, effects of TNF-α and TGF-β_1 on, 666-671
  of pregnant and nonpregnant subjects, effects of dietary FA composition on lipolytic β_3-adrenergic agonist response to hyperinsulinemia in, 1180-1187
Adipose tissue (AT; body fat)
  dexamethasone and, *see* Dexamethasone, and AT
  exercise and, *see* Adipose tissue, exercise and
  GH and, *see* Adipose tissue, GH and
  insulin resistance and, *see* Adipose tissue, insulin resistance and
  and kinetics of TEF, 1342, 1344
  leptin and, *see* Leptin in AT
  lipogenic potential of, 594-599
  LPL gene and, *see* Adipose tissue, LPL gene and
  in metabolic syndrome subjects, 1023
  weight of, *see* Organ weight, AT
  see also Adipose tissue distribution; Adipose tissue in lean and obese subjects; Adipose tissue in NIDDM; Obesity
Adipose tissue (AT; body fat), exercise and
  AT metabolism during endurance and/or high-intensity exercise in men, 122-128
  blood lipid response to cycle-ergometer exercise, 515
  lipolytic response to β-adrenergic receptor stimulation and delayed increase in AT blood flow of, in lean and obese men after exercise, 579-587
Adipose tissue (AT; body fat), GH and
  GH regulation of lipolysis in AT, 239-244
  GH therapy effects on HSL and LPL gene in, during weight loss, 906-911
Adipose tissue (AT; body fat), insulin resistance and
  in Afro-Caribbean, European, and South Asian men, variation in NIDDM and CHD risk and, 245-252
  in lean and obese nondiabetic subjects, effects of, on Lp subpopulation and, 287
Adipose tissue (AT; body fat), LPL gene and
  GH therapy effects on AT and muscle LPL and HSL genes during weight loss, 906-911
  LPL gene association with postheparin lipase activity, plasma lipid and Lp concentrations in, 432-439
  steady-state LPL gene mRNA level in omental tissue versus AT, 1224-1227

Adipose tissue (AT; body fat) distribution
in NIDDM, leptin, metabolic parameters and, and apo E polymorphism, 724-730
relationship of PP RMR and TEF to body composition and, in lean and obese subjects, 6-10
see also Abdominal adipose tissue; Intercapsular brown adipose tissue; Subcutaneous adipose tissue; Visceral adipose tissue; White adipose tissue
Adipose tissue (AT; body fat) in lean and obese subjects
lipolytic response to β-adrenoceptor stimulation and delayed BF increase in men, 579-587
relationship of PP RMR and TEF to body composition and distribution of, 6-10
see also Adipose tissue in nondiabetic lean and obese subjects
Adipose tissue (AT; body fat) in NIDDM
in Afro-Caribbean, European, and South Asian men, variation in CHD and NIDDM risk in, 245-252
CS-045 effects on weight of, 1171, 1172
intraabdominal, restricted diet effects on TG content of, 110
leptin, metabolic parameters and, and apo E polymorphism, 724-730
with PPARγ2 Pro12Ala gene, 1268, 1269
see also Adipose tissue in obese NIDDM subjects
Adipose tissue (AT; body fat) in nondiabetic lean and obese subjects
insulin resistance effects on Lp subpopulation in, 287
and weight loss effects on intramuscular lipids in women, 469
Adipose tissue (AT; body fat) in obese NIDDM subjects
weight loss effects on intramuscular lipids in women, 469
YM440 effects on hyperglycemia of NIDDM without AT weight change, pioglitazone and troglitazone effects compared with, 411-417
Adolescents, obese
NIDDM Japanese, glucose intolerance in, 186-191
relationship between PAI-1-Ag and tPA-Ag, fat mass, and leptin in, 890-895
Adrenal adenoma in Cushing's syndrome, testosterone production and, 230
Adrenal carcinoma in Cushing's syndrome, testosterone production and, 230
Adrenal hyperplasia, congenital, lipids in, 790-793
Adrenal steroidogenesis, high-dose simvastatin effects on gonadal and, in hypercholesterolemic men, 1234-1238
Adrenaline, *see* Epinephrine
α (alpha)-Adrenergic antagonists, effects of, on glucose regulation during and after high-intensity exercise, 386-394
α_2 ($alpha_2$)-Adrenergic receptor(s) (AR) gene, interaction between obesity phenotype, β_3-AR gene, and β_2-AR gene, 1063-1070
β (beta)-Adrenergic receptor(s) (AR)
changes in cardiac adenylyl cyclase isoforms and T_3 and T_4 modulation of responsiveness of, 275-279
lipolytic response to stimulation of, and post-exercise AT blood flow increase in lean and obese men, compared, 579-587
β_2 ($beta_2$)-Adrenergic receptor (AR) gene
interaction between obesity phenotype, α_2-AR gene, β_3-AR gene and, 1063-1070
see also Gln27Glu polymorphism of β_2-AR gene
β_3 ($beta_3$)-Adrenergic agonists
lipolytic response of, to hyperinsulinemia in adipocytes of pregnant and nonpregnant subjects, effects of dietary FA composition on, 1180-1187
see also Epinephrine; Isoproterenol
β_3 ($beta_3$)-Adrenergic receptor (AR) agonist, CL 316,243 as, effects of, on AT lipolysis, 240
β_3 ($beta_3$)-Adrenergic receptor (AR) gene, interaction between obesity phenotype, α_2-AR gene, β_2-AR gene and, 1063-1070
Adrenocortical function in hypercholesterolemic men, simvastatin effects on, 1235-1236
Adrenocorticotropic hormone (ACTH; corticotropin)
aging effects on, 1119, 1121
circulating adrenomedullin in ACTH-dependent Cushing's syndrome due to pituitary adenoma, 760-763
Adrenocorticotropic hormone (ACTH; corticotropin) syndrome, ectopic, in Cushing's syndrome, testosterone production and, 230
Adrenomedullin, circulating, in ACTH-dependent Cushing's syndrome due to pituitary adenoma, 760-763
Adriamycin, NO-1886 effects on nephrotic syndrome induced by, 588-593
Advanced glycation end (AGE) product(s)
serum, in diabetic nephropathy, 1030-1035
see also Advanced glycation end product(s) in DM; Advanced glycation end product receptors
Advanced glycation end (AGE) product(s), and oxidative stress in NIDDM
glycation-oxidative stress relationship and, S1:32
increase in oxidative stress and, S1:9-13
see also Gliclazide scavenging activity in NIDDM
Advanced glycation end (AGE) product(s) in DM
effects of inhibition of, and cross-link breakage on, 996-100
levels of, in kidney and liver in, immunochemical assays of, 567-573
see also Advanced glycation end product(s), and oxidative stress in NIDDM
Advanced glycation end (AGE) product receptors, effects of, on gene expression in NIDDM, oxidative stress and, S1:10
Aerobic capacity, *see* $\dot{V}O_2$
Aerobic fitness, and thermic response to caffeine in older and young women, 101-107
African Americans, *see* Race and ethnicity
Afro-Caribbean men, plasma lipid relationship to FFAs, AT, and insulin resistance in European, South Asian and, variation in NIDDM and CHD risk and, 245-252
Ag(s) [antigen(s)], PAI-1 and tPA-, relationship between leptin, fat mass and, in obese children and adolescents, 890-895
Age
of acromegalic subjects, 635
of alcoholics, 1408
of atherosclerotic subjects, 1272
of cachexic cancer subjects, 932, 933
of cirrhotic subjects, *see* Age of cirrhotic subjects
of Cushing's syndrome, *see* Age of Cushing's syndrome subjects
of depressed subjects, 1146
of diabetic nephropathy subjects, *see* Age of diabetic nephropathy patients
estradiol and estrogen effects on lipids in 10-to-15-year-old boys, race and, 1124-1129
and exercise, *see* Age of exercising subjects
of FHTG subjects, 944, 945
of HIV subjects, bone metabolism and, 1135
and HKII expression in SM, 815
of homocystinuric subjects, 1072, 1073
of hypercholesterolemic men, and simvastatin and pravastatin effects on gonadal function, 117
and hyperhomocysteinemia, *see* Age of hyperhomocysteinemic subjects
of hyperinsulinemic women, plasma leptin and, 1056
of hyperlipidemic subjects, 1628, 1629
of hypermethioninemic subjects, 1544
of hypertensive subjects, *see* Age of HTN subjects
of hyperthyroidic subjects, 1286, 1287
and hypopituitarism, 564
of IDDM subjects, *see* Age of IDDM subjects

Age (*Continued*)
of IGT subjects, 1319, 1323
and IMGU with relatively low Mg, 419
insulin resistance and, *see* Age, and insulin resistance
insulin sensitivity and, *see* Age, and insulin sensitivity
of IUGR infants, 1468
and kinetics of TEF, 1342-1344
leptin and, *see* Age, leptin and
of liver transplantation recipients, 368
of LPI subjects, 622
and LPL mRNA level, 1225
and metabolic effects of diet, 1112
of metabolic syndrome subjects, 749, 750, 1023
morning cortisol levels, S_G and, 306, 307
of NIDDM subjects' relatives, beta cells in, 834, 897
of normolipidemic subjects, 1208
of obese subjects, *see* Age of obese subjects
of PEM subjects, 820, 821
of perimenopausal and postmenopausal women, psychological well-being and, 1562
of postmenopausal women, *see* Age of postmenopausal women
of pregnant subjects, and 4G/G PAI-1 polymorphism, 846
and RBC FA composition, 1165
and SM insulin responsiveness to NA-induced changes in PC and PE FAs, 233
and SNP effects on insulin-mediated SM blood flow and glucose uptake, 374
soy protein effects on arteries and, 1191
subcutaneous central AT, risk of CV disease and, in men, 1380
of TD patients, 771
TEF and, *see* Age, TEF and
and TG effects on HDL- and LDL-C relationship to apo B and apo A-I, 55
and tyrosine effects on Phe hydroxylation, 445
of untrained men, AT metabolism and, 123
see also Aging, effects of; Children; Older subjects; Young subjects *and specific conditions*
Age, and insulin resistance
CV risk factors and, 1248, 1251
depression and, 1256
and insulin resistance correlation with increased SFAs in SM TGs, 221
lack of linkage between VLDL receptor gene and HOMA insulin resistance index, 294
of nondiabetic lean and obese women, 287
plasma NO and, 960
TNF-α *Nco*I gene polymorphism and, 1507, 1508
Age, and insulin sensitivity
iPTH and, 1502, 1503
in NIDDM subjects' children, 1220
Age, leptin and
apo E polymorphism and, in NIDDM, 725, 726
body composition, serum leptin, and age, 1279-1280
fasting plasma leptin, plasma insulin and, 500
and leptin relationship to serum insulin and insulin sensitivity in healthy and/or preeclamptic pregnancy, 260
Age, TEF and
and relationship of PP RMR and TEF to body composition and AT distribution in lean and obese subjects, 7, 8
thermic response of young and older women to caffeine and, 103
Age of cirrhotic subjects
circulating CT and, 48
GSH synthesis and, 1435
Age of Cushing's syndrome subjects
with ACTH-dependent Cushing's syndrome, 761
Age of Cushing's syndrome subjects (*Continued*)
testosterone production and, 230
Age of diabetic nephropathy patients
and pulsatile IV insulin effects on progression of diabetic nephropathy, 1493
serum AGE products and, 1031
Age of exercising men
AT metabolism and, 123
and DHEAS response to long-term endurance exercise, 299
lean and obese, and postexercise lipolytic response to β-adrenergic receptor stimulation, 580
young men, α-adrenergic antagonist effects on glucose regulation and, 387
Age of exercising subjects
and BK effects on exercise-induced glucose uptake and GLUT4 translocation in SM, 923
and blood lipid response to cycle-ergometer exercise, 515
and exercise effects on leptin and insulin, 859
see also Age of exercising men
Age of HTN subjects
and antihypertensive therapy effects on fasting FFAs, 82
obese, 1525
of older hypertensive subjects with LVH, 1357
Age of hyperhomocysteinemic subjects
ESRD subjects on HD, 217
methionine-induced hyperhomocysteinemia subjects, 225
Age of IDDM subjects
and IGFBP-2 protease activity, 627, 629
and insulin and C-peptide effects on RBC Na/K ATPase, 869
on intensive insulin therapy, 441
Age of NIDDM subjects
and ALC effects, 705
apo E polymorphism, leptin and, 725, 726
bezafibrate therapy effects and, 332
and BK effects on exercise-induced glucose uptake and GT4 translocation in SM, 923
carotid IMT and, 719, 721
with fibrinolysis, 663
and low-dose epinephrine effects on plasma glucose, 196
and metabolic effects of $VOSO_4$, 400-410
nephropathic, TGF-β_1 activation and, 355
obese, *see* Age of obese NIDDM subjects
with PPARγ2 Pro12Ala gene, 1268
TGs, BMI and, 1002
TNF-α G308A gene polymorphism and, 1617
Age of obese men
and impaired skin vasoconstrictive response to sympathetic activation, 601
and lipolytic response to β-adrenergic receptor stimulation after exercise, 580
Age of obese NIDDM subjects
glucose intolerance and, 187
see also Age of obese NIDDM subjects, weight loss effects and
Age of obese NIDDM subjects, weight loss effects and
effects on HDL and apo A-I subfraction, 1454
effects on intramuscular lipids, 469
Age of obese subjects
GH therapy, weight loss and, 907
HTN and, 1525
Japanese, β_2-AR gene polymorphism and, 1215
and relationship between PAI-1 antigen, leptin, and FM, 891, 892
of women, prevalence of paradoxically normal serum C and, 608, 610
see also Adolescents, obese; Age of obese men; Age of obese NIDDM subjects

Age of postmenopausal women
on 17β-estradiol with cyclical oral NETA, 743
on estrogen alone or estrogen with progestin, 785
AGE products, *see entries beginning with terms*: Advanced glycation end product
Aging, effects of
on calcitonin secretion, 253-258
on insulin secretion and insulin sensitivity, 1118-1123
on plasma C and C metabolism in HHL, 552-556
SM IRS-1 and PI 3K decrease as, exercise effects on, 954-958
see also Older subjects; Testosterone, decrease and/or deficiency of, in older men
Agouti-related protein(83-132) [AgRP(83-132)], blood-brain barrier crossing by, 1444-1448
Alanine (Ala)
effects of, on system A transport of MeAIB in mammary gland, 875, 876
fructose effects on, 1568
in glutamine-containing diet, 142
hyperammonemia effects on metabolism of, 1332, 1333
IV glutamine effects on synthesis of muscle, 1556, 1557
metformin effects on, 1621
in NIDDM, *see* Alanine in NIDDM
plasma, *see* Plasma alanine
Alanine (Ala) in NIDDM
MTHFR gene and, 721
and PPARγ2 Pro12Ala gene, BMI and, 1267-1270
[2-^{13}C]Alanine (Ala), hepatocyte, effects of glycerol-1,2,3-tris(methyl-[2,3^{13}C]succinate) on, 179
[3-^{13}C]Alanine (Ala), hepatocyte, effects of glycerol-1,2,3-tris(methyl-[2,3^{13}C]succinate) on, 179
Alanine aminotransferase (ALT) in NIDDM with fibrinolysis, troglitazone effects on, 665
Albumin
anthocyanoside effects on capillary filtration of, in SM of STZ-DM subjects, 880-885
and bone metabolism in HIV infection, 1136, 1137
in cachexic cancer subjects, 934
in cirrhosis, 1435
and hyperhomocysteinemia, *see* Albumin, hyperhomocysteinemia and
in nephrotic syndrome, NO-1886 effects on, 589
in PEM children, 819-825
in sepsis, 754
serum, in cirrhosis, circulating CT and, 48
see also Albuminuria; Lactalbumin
Albumin, hyperhomocysteinemia and
in methionine-induced hyperhomocysteinemia, 225
and vitamin B_{12} effects on plasma HcY in ESRD subjects on HD, 217
Albuminuria
in IDDM, IGFBP-2 protease activity and, 627
in NIDDM nephropathy, TGF-β_1 activation and, 355
see also Microalbuminuria; Proteinuria
ALC (acetyl-L-carnitine), and glucose disposal in NIDDM, 704-708
Alcohol intake
acute, urinary excretion and concentration of serum mevalonic acid during, 62-66
and influence of TG concentration on HDL- and LDL-C relationship to apo B and apo A-I, 55
insulin resistance, CV risk factors and, 1248, 1249, 1251
by postmenopausal and perimenopausal women, 1562
by postmenopausal women, effects of 17β-estradiol with cyclical oral NETA and, 743
sex and nutritional status effects on ethanol metabolism, 379-385
in soy protein diet, 538
Alcohol intake (*Continued*)
and variation in NIDDM and CHD risk in men, 247
see also Chronic alcohol intake; Reverse cholesterol transport, and alcohol consumption
Alkaline phosphatase (ALP)
cellular, HCTZ and furosemide effects on production of, 18
serum, in cirrhosis, circulating CT and, 48
Allele frequency
of LPL S447X polymorphism, 435
TH gene microsatellite polymorphism and, in depressive disorder, 1146, 1147
of VLDL receptor gene, 294
ALP, *see* Alkaline phosphatase
Alpha (α)-adrenergic blockers, effects of, on glucose regulation during and after high-intensity exercise, 386-394
Alpha (α) cells in NIDDM, voglibose effects and, 349
Alpha (α)-glucosidase inhibitors, beta cell mass in NIDDM reduced by, 347-352
Alpha-ketoisocaproate, *see* α-Ketoisocaproate
Alpha$_2$ (β_2)-adrenergic receptor (AR) gene, interaction between obesity phenotype and, 1063-1070
7 Alpha (α)-hydroxylase, C, aging and activity of, in HHL, 553, 554
Alpha-lipoprotein, *see* High-density lipoprotein
Alpha-tocopherol, *see* α-Tocopherol
Alphacel in soy protein diet, 1189
ALT (alanine aminotransferase) in NIDDM with fibrinolysis, troglitazone effects on, 665
Altitude, sympathoadrenal response to exercise by women at high, 1036-1042
Amenorrhea
in HIV infection, 1136
secondary, in Cushing's syndrome, testosterone production and, 230
AMGN (aminoguanidine), as inhibitor of AGE product formation, S1:10-11
Amino acids (AAs)
in LPI, lysine effects on, 622-624
see also Branched-chain amino acids *and specific amino acids*
Aminoguanidine (AMGN), as inhibitor of AGE product formation, S1:10-11
Aminotransferase
alanine, in NIDDM with fibrinolysis, troglitazone effects on, 665
aspartate, *see* Aspartate aminotransferase
Ammonia, *see* NH_3
Amyloid polypeptide, islet, effects of HF diet-induced insulin resistance on insulin mRNA and, 1518-1522
Amylopectin in starch diet, 765
Amylose in starch diet, 765
AN (anorexia nervosa), galanin effects on GH and PRL secretion in, 155-159
Androgen(s)
deficiency of, in aging men, 1239-1242
soy protein effects on, 540
see also Testosterone, decrease and/or deficiency of, in older men *and specific androgens*
Androgen Deficiency in Aging Males (ADAM) questionnaire, 1239-1242
Androstenedione (A; Δ_4-DIONE)
in CAH, 791
serum, rIGF-I and hCG effects on concentrations of, in ovaries, 316
Angiotensin II (Ang II), EPA suppression of migration in VSMCs induced by, 560-562
Angiotensin-converting enzyme (ACE) inhibitors, effects of, on LVH and circulating BNPs in hypertensive elderly subjects, 1356-1360

Anorexia nervosa (AN), galanin effects on GH and PRL secretion in, 155-159
ANPs, *see* Atrial natriuretic peptides
Antecedent hypoglycemia, hypothermic response to hypoglycemia after, 794-798
Anthocyanosides, effects of, on capillary SM CFA in STZ-DM, 880-885
Antidiabetic effects of nicotinamide in lean subjects, 1548-1554
Antigen(s) [Ag(s)], PAI-1- and tPA-, relationship between leptin, fat mass and, in obese children and adolescents, 890-895
Antihypertensive therapy
  effects of HTN and, on fasting NEFAs, SNS role in, 81-87
  in elderly subjects, kinetics of TEF and, 1342, 1344
  see also specific antihypertensive agents
Antioxidant(s)
  against free radical-mediated tissue damage, S1:5; *see also* Scavenging activity
  M1 as, effects of, on LDL oxidation and oxidized LDL-induced cytotoxicity, 479-485
  peroxidation indices and total plasma antioxidant capacity in methionine-induced hyperhomocysteinemia, 225-228
  T_3 effects on leukocyte generation of ROS, oxidative damage indices, and reserve of, 799-803
  see also specific antioxidants
Antisense oligonucleotides (ODNs), GS, effects of, on GS protein expression, 962-968
Aortic endothelial cell nitric oxide synthase (EC NOS), insulin effects on, 147-150
Aortic smooth muscle cells, OA and LA effects on ET-1 binding and action in, 1386-1389
Apheresis of LDLs, lipid reduction with, 1431-1433
Apo(s), *see specific apolipoproteins*
Apolipoprotein(s) (apo)
  atorvastatin effects on distribution and composition of, in hypertriglyceridemia, 167-177
  see also specific apolipoproteins
Apolipoprotein(a) [(apo(a)], fasting serum, and variation in NIDDM and CHD risk, 248
Apolipoprotein A-I (apo A-I)
  in alcoholics, 1408
  in FHTG, 944-946
  in hyperlipidemia, 1628
  and LPL gene, 434, 435
  in NIDDM, *see* Apolipoprotein A-I in NIDDM
  in premenopausal women, 1103
  and risk of CV disease, *see* Apolipoprotein A-I, risk of CV disease and
  soy protein effects on, 1498
  in TD, 771, 774, 776
  TGs and, *see* Apolipoprotein A-I, TGs and
  see also Apolipoprotein A-I gene mRNA
Apolipoprotein A-I (apo A-I), risk of CV disease and
  and insulin resistance, 1248, 1249, 1251
  subcutaneous central AT and, 1380, 1383
Apolipoprotein A-I (apo A-I), TGs and
  in HTG, atorvastatin effects on, 170-171
  TG concentration and HDL- and LDL-C relationship to level of apo B and, 53-61
Apolipoprotein A-I (apo A-I) gene mRNA (messenger ribonucleic acid)
  fasting inducing expression, 1572-1578
  in NIDDM with dyslipidemia, 25
Apolipoprotein A-I (apo A-I) in NIDDM
  with dyslipidemia, 23, 25-27
  effects of weight loss by obese NIDDM subjects on distribution of subfractions of, 1453-1459
  fasting serum, and variation in risk of NIDDM and CHD, 248
Apolipoprotein A-I (apo A-I) in NIDDM (*Continued*)
  HDL_3 binding to leukocytes and, 691
  plasma, response of, to cycle-ergometer exercise, 516
Apolipoprotein A-II (apo A-II)
  fasting serum, and variation in NIDDM and CHD risk, 248
  in HTG, atorvastatin effects on, 170-171
Apolipoprotein B (apo B)
  apheresis of, 1432
  fasting serum, and variation in NIDDM and CHD risk, 248
  in hyperlipidemia, 1628
  kinetics of, in normolipidemia, 1204-1210
  and LPL gene, 434, 435
  in NIDDM, *see* Apolipoprotein B in NIDDM
  plasma, response of, to cycle-ergometer exercise, 516
  in premenopausal women, 1103
  risk of CV disease and, *see* Apolipoprotein B, risk of CV disease and
  soy protein effects on, 1498
  in 10-to-15-year-old boys, race and variation in, 1126, 1127
  TGs and, *see* Apolipoprotein B, TGs and
  VLDL-, kinetics of, in normolipidemia, 1204-1210
  see also Apolipoprotein B mRNA
Apolipoprotein B (apo B), risk of CV disease and
  and insulin resistance, 1248, 1249, 1251
  subcutaneous central AT and, 1380, 1383
Apolipoprotein B (apo B), TGs and
  in HTG, atorvastatin effects on, 170-172
  TG concentration and HDL- and LDL-C relationship to level of apo A-I and apo B, 53-61
Apolipoprotein B (apo B) mRNA (messenger ribonucleic acid) in NIDDM with dyslipidemia, 25
Apolipoprotein B in NIDDM
  with dyslipidemia, 23, 25, 26
  HDL_3 binding to leukocytes and, 691
Apolipoprotein B-48 (apo B-48)-containing lipoproteins (Lps), PP, in NIDDM, cerivastatin effects on TGs and, 1049-1054
Apolipoprotein B-48 (apo B-48) mRNA (messenger ribonucleic acid) in NIDDM with dyslipidemia, 25
Apolipoprotein B-100 (apo B-100)
  depletion of, and plasma viscosity in HCL or HTG, 810-813
  in FHTG, 944-946
  in NIDDM with dyslipidemia, 25, 26
  in premenopausal women, 1103
  VLDL-, GH therapy effects on turnover of, in hypopituitarism, 563-566
Apolipoprotein B-100 (apo B-100)-containing lipoproteins (Lps), PP, in NIDDM, cerivastatin effects on TGs and, 1049-1054
Apolipoprotein C-II (apo C-II) in HTG, atorvastatin effects on, 170-172
Apolipoprotein C-III (apo C-III) in HTG, atorvastatin effects on, 170-172
Apolipoprotein E (apo E)
  in alcoholics, 1408
  C efflux from TD and normal fibroblasts into plasma deficient in, 770-777
  in NIDDM, *see* Apolipoprotein E in NIDDM
  in normolipidemia, 1208
  VLDL-, and platelet function in FHTG, 942-949
  see also Apolipoprotein E mRNA; Apolipoprotein E phenotype
Apolipoprotein E (apo E) mRNA (messenger ribonucleic acid)
  in HTG, atorvastatin effects on, 170-173
  in NIDDM with dyslipidemia, 25
Apolipoprotein E (apo E) in NIDDM
  dyslipidemic NIDDM, 25, 26
  polymorphism of, AT distribution, leptin, metabolic parameters and, 724-730
Apolipoprotein E (apo E) phenotype in TD, 771

Applesauce in soy protein diet, 1189
AR(s) (ADRs), *see entries beginning with terms*: Adrenergic receptor
Arachidonic acid, RBC and SM membrane, 1165
Arg16Gly polymorphism, β_2-AR gene, lack of association between obesity and, in Japanese men, 1215-1218
Arginine (Arg)
  effects of, on system A transport of MeAIB in mammary gland, 875, 876
  in glutamine-containing diet, 142
  hyperammonemia effects on metabolism of, 1332
  IV glutamine effects on synthesis of muscle, 1556, 1557
  see also Arg16Gly polymorphism; Gln/Arg 192 polymorphism
Arterial glucose in NIDDM, JTT-501 effects on, 864
Arterial low-density lipoprotein (LDL), soy protein effects on, and on LDL-C delivery to arteries of diabetic and nondiabetic male subjects, 1188-1196
Arterial O_2 (oxygen), saturation of, in cirrhosis, circulating CT and, 48
Arterial plasma free fatty acids (FFAs) in lean and obese exercising men, 582
Arterial plasma glucose, vagotomy effects on, 13
Arterial plasma glycerol in lean and obese exercising men, 581-582
Arterial plasma hormones in lean and obese exercising men, 581-582
Arterial pressure, *see* Blood pressure
Arteries
  of diabetic and nondiabetic male subjects, soy protein effects on arterial LDL and LDL-C delivery to, 1188-1196
  see also entries beginning with terms: Aortic, Arterial
Arylesterase, activity of serum, in NIDDM, PON1 gene polymorphisms and, 1400-1405
Asn, *see* Asparagine
Asp, *see* Aspartate
Asparagine (Asn)
  effects of, on system A transport of MeAIB in mammary gland, 875, 876
  in glutamine-containing diet, 142
  hyperammonemia effects on metabolism of, 1332
Aspartate (Asp)
  effects of, on system A transport of MeAIB in mammary gland, 875, 876
  in glutamine-containing diet, 142
  hyperammonemia effects on metabolism of, 1332
Aspartate aminotransferase (AST)
  in NIDDM with fibrinolysis, troglitazone effects on, 665
  serum, in cirrhosis, circulating CT and, 48
Aspartate (Asp)-malate shuttle in beta cells in NIDDM, 92-96
AST, *see* Aspartate aminotransferase
AT, *see* Adipose tissue
Atherosclerosis
  LDL oxidation in, 1271-1277
  systemic and/or portal venous drainage site effects on insulin action after pancreas transplantation and risk of, 458-466
Atherothrombosis, infantile obesity and risk of, 672-675
Athletes, *see* Exercise
Atorvastatin, effects of, on lipid and apo distribution and composition in hypertriglyceridemia, 167-177
ATP (adenosine triphosphate), *see* K^+ channels, ATP-sensitive
ATPase (adenosine triphosphatase), RBC Na/K, in IDDM, insulin and C-peptide effects on, 868-872
Atrial natriuretic peptides (ANPs)
  effects of long-acting vessel dilator, kaliuretic peptides and, on urinary excretion of β_2-microglobulin, 1592-1597
  interaction between metabolic clearance of BNPs and, in heart failure, 1228-1233
Autoantibodies, PP lipemia, to oxidatively modified LDLs in atherosclerosis, 1271-1277
Autofeedback, long-loop GAL effects of acute and chronic GAL administration on hypothalamic galanin synthesis in male and female subjects, 778-783
2,2-Azobis(4-methoxy-2,4-dimethylvaleronitrile) (MeOAMVN)-mediated low-density lipoprotein (LDL; β-lipoprotein) oxidation, M1 effects on oxidized LDL-induced cytotoxicity and, 479-485

Basal cortisol secretion in men, polymorphism of 5'-flanking region of glucocorticoid receptor gene locus associated with, 1197-1199
Basal insulin secretion, effects of Intralipid-induced plasma FFA elevation on GIIS and, in men, 450-454
BAT (brown adipose tissue), intercapsular, in obese STZ-DM subjects, 135
BBB (blood-brain barrier), agouti-related prqtein(83-132) crossing of, 1444-1448
BCAAs, *see* Branched-chain amino acids
BDNF (brain-derived neurotrophic factor), effects of metformin and intermittent, on glucose metabolism in obese NIDDM subjects, compared, 129-133
Behenic acid, RBC and SM membrane, 1165
Beta (β)-actin mRNA (messenger ribonucleic acid), triacsin C effects on, 327
Beta-adrenergic receptor(s), *see* β-Adrenergic receptor(s)
$Beta_2$-adrenergic receptor gene, *see* β_2-Adrenergic receptor gene
$Beta_3$ (β_3)-adrenergic agonists, *see* β_3-Adrenergic agonists
$Beta_3$ (β_3)-adrenergic receptor (AR) agonist, CL 316,243 as, effects of, on lipolysis in AT, 240
$Beta_3$ (β_3)-adrenergic receptor (AR) gene, interaction between obesity phenotype and, 1063-1070
Beta-carotene, *see* β-Carotene
Beta (β) cells
  contribution of tissue insulin sensitivity and, to IGT, 1318-1325
  GIIS loss in dysfunctional, elevated plasma lipid or beta cell TGs and, 755-759
  glucose concentration and effects of long-term exposure of, to palmitate on insulin gene expression, 532-536
  in NIDDM, *see* Beta cells in NIDDM
  postbreakfast and fasting, Ultralente insulin effects on, in healthy subjects, 1243-1246
  stevioside effects on insulin secretion by, independent of activity of cAMP and ATP-sensitive K^+ channels, 208-214; *see also* Insulin release and secretion
  transplantation of, in STZ-DM, diazoxide effects on function of, 657-661
Beta (β) cells in NIDDM
  aspartate-malate shuttle in, 92-96
  impaired, S2:12-16
  stimulation of, S2:12
  voglibose reducing mass of, 347-352
  see also Relatives of NIDDM subjects, beta cells in healthy; Sulfonylureas
17Beta (β)-estradiol, effects of, cyclical oral or NETA transdermal, on insulin sensitivity secretion, and elimination in postmenopausal women, 742-749
Beta (β)-hydroxy-5-androsten-17-one (dehydroepiandrosterone sulfate), measurement of, before and after long-term endurance exercise program, 298-304
Beta (β)-hydroxybutyrate, serum, correlation between apo A-I mRNA and, 1574-1575
$Beta_2$ (β_2)-microglobulin, effects of long-acting vessel dilators, natriuretic peptides, and kaliuretic peptides on, 1592-1597
Betaine, effects of, on methionine transamination in homocystinuria, 1075
Beta-lipoprotein, *see* Low-density lipoprotein
Bezafibrate, blood glucose reduced by, in NIDDM, 331-334

BF, *see* Blood flow
BIA (bioelectrical impedance analysis), determination of body composition of underweight chronic gastrointestinal disease subjects with DXA, SF, TBW-^3H_2O and, compared, 360-366
Bilirubin
serum, in cirrhosis, circulating CT and, 48
total, in cirrhosis, 1435
Binding protein
mRNA of fatty acid-, in NIDDM, YM440, troglitazone, and pioglitazone effects on, compared, 413
thyroxine-, in sepsis, 753-754
see also entries beginning with terms: Insulin-like growth factor-binding protein
Bioelectrical impedance analysis (BIA), determination of body composition of underweight chronic gastrointestinal disease subjects with DXA, SF, TBW-^3H_2O and, compared, 360-366
Birth weight in healthy and/or preeclamptic pregnancy, 260
BK, *see* Bradykinin
BK_2 (bradykinin$_2$) receptors, and BK effects on glucagon secretion, 1370-1373
Black Americans, *see* Race and ethnicity
Blood-brain barrier (BBB), agouti-related protein(83-132) crossing, 1444-1448
Blood flow (BF)
AT, lipolytic response to β-adrenergic receptor stimulation and delayed increase in, in lean and obese men after exercise, compared, 579-587
cutaneous, and effects of rheological disorders on skin vasoconstrictive response to sympathetic activation, 600-606
hepatic, *see* Hepatic blood flow
insulin-mediated glucose disposal and SM, in the elderly, SNP effects on, 373-378
Blood glucose
effects of dietary FA composition in pregnant and nonpregnant subjects on, 1183
effects of elevated plasma FFAs on, in men, 451, 452
fasting, *see* Fasting blood glucose
hyperinsulinemia effects on, 1366
in IDDM, *see* Blood glucose in IDDM
IRS-1 and PI 3K effects on, 956
in NIDDM, *see* Blood glucose in NIDDM
in obesity, rheological disorders and skin vasoconstrictive response to sympathetic activation, 601
in STZ-DM, diazoxide effects on, 658
Blood glucose in IDDM
before and after glycemia control and after vitamin E supplementation, oxidative stress and, 161, 162
vanadate effects on, in lean subjects, 322
Blood glucose in NIDDM
bezafibrate reducing, 331-334
with dyslipidemia, 23-25
following vitamin E supplementation and before and after glycemia control, oxidative stress and, 161, 162
gliclazide and glibenclamide effects on, S1:24, S1:33
YM440, troglitazone, and pioglitazone effects on, compared, 412
Blood glycerol, effects of elevated plasma FFAs on, in men, 451
Blood insulin in hyperinsulinemia, 1366
Blood ketones, effects of elevated plasma FFAs on, in men, 451-453
Blood lactate
effects of elevated plasma FFAs on, in men, 451
effects of exercise at high altitude on, 1039
Blood lipids
effects of LF diet with starchy foods or sucrose on, 731-735
response of, to cycle-ergometer exercise, race and, 513-520
see also Blood lipids, soy protein effects on
Blood lipids, soy protein effects on
in hyperlipidemia, 539-540
soy-based breakfast cereal effects on, 1496-1500
Blood pressure (BP)
in acute acromegaly, lanreotide effects on, 636
CS-045 effects on, 1362
in Cushing's syndrome, 761
in diabetic nephropathy, 1493, 1494
in FHTG, 944, 945
and free leptin increase in pregnancy, 1044
of healthy insulin-resistant subjects, 960
in healthy and/or preeclamptic pregnancy, 260
in hyperinsulinemia, plasma leptin and, 1056
in hyperlipidemia, 1628
in IDDM, and exercise effects on Lp(a) and LDL modifications, 643
in insulin resistance, 1507, 1508
in insulin sensitivity, 1502
in metabolic syndrome, 749, 750, 1023
in NIDDM, *see* Blood pressure in NIDDM
in obesity, *see* Blood pressure in obesity
in postmenopausal women, effects of 17β-estradiol with cyclical oral NETA on, 743
rheological disorders and skin vasoconstrictive response to sympathetic activation and, 601
and risk of atherosclerosis after pancreas transplantation, 463
and seasonal variation in S_I and S_G, 34
SNP effects on, 374
soy-based breakfast cereal effects on, 1498
subcutaneous central AT, risk of CV disease and, 1380, 1382
see also Hypertension
Blood pressure (BP) in NIDDM
exercise effects on, and Lp(a) and LDL modifications in NIDDM, 643
HDL_3 binding to leukocytes and, 691
JTT-501 effects on, 864-865
and MTHFR gene, 719, 721
TNF-α G308A gene polymorphism and, 1617
variation in risk of NIDDM and CHD and, 247
$VOSO_4$ effects on, 404-405
Blood pressure (BP)
effects of regular moderate wine consumption on BP in moderately obese women, 1475
independent of insulin resistance in normoglycemic Hong Kong Chinese, as determinant of BP, 1523-1528
Blood urea nitrogen, *see* BUN
Blood uric acid, D-tagatose effects on, 969-976
BMI, *see* Body mass and body mass index
BMSCs (bone marrow stromal osteoprogenitor cells), human, effects of hydrochlorothiazide and furosemide on, compared, 17-21
BNPs, *see* Brain natriuretic peptides
Body composition
DXA of, *see* Dual-energy x-ray absorptiometry
relationship between serum leptin, sex steroid levels, insulin levels and, in HRT, 1278-1284
TEF and, *see* Thermic effect of food, body composition and
see also Adipose tissue; Fat-free mass; Fat mass; Postmenopausal women, body composition of; Premenopausal women, body composition of
Body fat, *see* Adipose tissue
Body mass and body mass index (BMI)
of acromegalic subjects, 635
of cachexic cancer subjects, 933
of depressed subjects, 1146
and exercise, *see* Body mass and body mass index, exercise and
FFAs and, *see* Body mass and body mass index, FFAs and

Body mass and body mass index (BMI) (*Continued*)
of healthy and/or preeclamptic pregnant women, 260
of HIV subjects, bone metabolism and, 1135
and HKII expression in SM, 815
of HTN subjects, *see* Body mass and body mass index of HTN subjects
of hyperinsulinemic women, plasma leptin and, 1056, 1059
of hyperlipidemic subjects, 1628, 1629
of hyperthyroidic subjects, 1286, 1287
and hypopituitarism, 564
of IDDM subjects, *see* Body mass and body mass index of IDDM subjects
of IGT subjects, 1319, 1323
and IMGU with relatively low Mg, 419
and insulin resistance, *see* Body mass and body mass index, insulin resistance and
and insulin sensitivity, *see* Body mass and body mass index, insulin sensitivity and
and kinetics of TEF, 1342
of lean subjects, *see* Body mass and body mass index of lean and obese subjects
leptin and, *see* Body mass and body mass index, leptin and
of liver transplantation recipients, S_G and, 368
and LPL gene, 434, 1224
of metabolic syndrome subjects, 749, 750, 1023
of methionine-induced hyperhomocysteinemia subjects, 225
morning cortisol levels, S_G and, 306, 307
of NIDDM subjects, *see* Body mass and body mass index of NIDDM subjects
of NIDDM subjects' relatives, 834, 897
of normolipidemic subjects, 1208
of obese subjects, *see* Body mass and body mass index of lean and obese subjects; Body mass and body mass index in obesity with NIDDM; Obesity
of PEM subjects, 820, 821
of postmenopausal and perimenopausal women, 1562
and RBC FA composition, 1165
and skin vasoconstrictive response to sympathetic activation, 601
subcutaneous central AT, risk of CV disease and, in men, 1380-1382
of 10-to-15-year-old boys, race and estradiol and estrogen effects on lipids in, race and, 1125-1127
TGs and, *see* Body mass and body mass index, TGs and
Body mass and body mass index (BMI), exercise and
blood lipid response to cycle-ergometer exercise, 515
DHEAS response to long-term exercise and, 299
and exercise effects on leptin and insulin, 859
Lp(a) and LDL modifications in IDDM and NIDDM and, 643
in young men, α-adrenergic antagonist effects on glucose regulation and, 387
Body mass and body mass index (BMI), FFAs and
antihypertensive therapy effects on fasting FFAs and, 82
variation in NIDDM and CHD risk and, 247
Body mass and body mass index (BMI), insulin resistance and
CV risk factors and, 1248, 1251
depression and, 1256
and lack of linkage between VLDL receptor gene and HOMA insulin resistance index or fasting serum insulin, 294
role of TGs and BMI in insulin-sensitive and insulin-resistant Japanese NIDDM subjects, 1001-1005
TNF-α *Nco*I gene polymorphism and, 1507, 1508
Body mass and body mass index (BMI), insulin sensitivity and
in children of NIDDM subjects, 1220
TGs and BMI in insulin-sensitive Japanese NIDDM subjects, 1001-1005
Body mass and body mass index (BMI), leptin and
serum leptin, body composition and, 1279-1280
see also Body mass and body mass index, plasma leptin and
Body mass and body mass index (BMI), plasma leptin and
fasting plasma leptin, plasma insulin and, 500
plasma insulin-plasma leptin link compared with plasma insulin-BMI link in healthy subjects, 544-547
Body mass and body mass index (BMI), TGs and
TGs and BMI effects on HDL- and LDL-C relationship to apo B and apo A-I, 55
TGs and BMI in insulin-sensitive and insulin-resistant Japanese NIDDM subjects, 1001-1005
Body mass and body mass index (BMI) of HTN subjects
and antihypertensive drug effects on fasting FFAs, 82
glucose metabolism and, 1531
obese, 1525
of older subjects with LVH, 1357
Body mass and body mass index (BMI) of IDDM subjects
exercise effects on, 643
following vitamin E supplementation and before and after glycemia control, oxidative stress and, 161
on intensive insulin therapy, voglibose effects associated nocturnal hypoglycemia and, 441
Body mass and body mass index (BMI) of lean and obese subjects
of insulin-resistant nondiabetic subjects, 287
and lipolytic response to β-adrenergic receptor stimulation after exercise by men, 580
and relationship of PP RMR and TEF to body composition and AT distribution, 7
seasonal variation of S_I and S_G and, in men, 33
Body mass and body mass index (BMI) of NIDDM subjects
apo E polymorphism, leptin and, 725, 726
bezafibrate therapy effects and, 332
and BK effects on exercise-induced glucose uptake and GT4 translocation in SM, 923
effects of high-monounsaturated fat diet and olive oil diet on, 1513
exercise effects on, 643
with fibrinolysis, 663
following vitamin E supplementation and before and after glycemia control, oxidative stress and, 161
HDL_3 binding to leukocytes and, 691
and indomethacin effects on insulin secretion, 840
and low-dose epinephrine effects on plasma glucose, 196
and metabolic effects of $VOSO_4$, 400-410
and MTHFR gene, 719, 721
with nephropathy, TGF-β_1 activation and, 355
obese, *see* Body mass and body mass index in obesity with NIDDM
with PPARγ2 Pro12Ala gene, 1267-1270
role of TGs and BMI in insulin-resistant healthy Japanese subjects, 1001-1005
TNF-α G308A gene polymorphism and, 1617
variation in NIDDM and CHD risk and, 247
Body mass and body mass index (BMI) in obesity
B_2-AR gene polymorphism and, 1215
effects of regular moderate wine consumption by moderately obese women on, 1475
GH therapy, weight loss and, 907
HTN and, 1525, 1527
interaction between α_2-, β_2-, and β_3-AR genes and obesity phenotype, 1067
and prevalence of paradoxically normal serum C in obese women, 608-610
and relationship between PAI-1 antigen, leptin, and FM, 891, 892, 894
see also Body mass and body mass index of lean and obese subjects; Body mass and body mass index in obesity with NIDDM

Body mass and body mass index (BMI) in obesity with NIDDM
and ALC effects on glucose disposal, 705
glucose intolerance and, 187
Body mass and body mass index (BMI) of postmenopausal women
on 17β-estradiol with cyclical oral NETA, 743
on estrogen alone or estrogen with progestin, 785
Body water, total, determination of, in underweight chronic gastrointestinal disease subjects with DXA, BIA, SF, and TBW-^3H_2O, compared, 360-366
Body weight (BW)
at birth in healthy and/or preeclamptic pregnancy, 260
cerivastatin effects on, 1050
diet effects on, *see* Body weight, diet effects on
in DM, *see* Body weight of DM subjects
of ESRD subjects on HD, vitamin B_{12} effects on plasma HcY and, 217
of exercising subjects, *see* Body weight of exercising subjects
fetal, in relation to expression of insulin genes I and II, 616-620
of HIV subjects, bone metabolism and, 1135
in HTG, JTT-501 effects on, 575
of hyperthyroidic subjects, 1286, 1287
of IGT subjects, 1319, 1323
insulin, hCG, and rIGF-I effects on, 315
IRS-1 and PI 3K effects on, 956
of IUGR infants, 1468, 1469
and kinetics of TEF, 1342-1344
leptin and, Body weight, leptin and
of metabolic syndrome subjects, 749, 750
of nephrotic syndrome subjects, NO-1886 effects on, 589
of NIDDM subjects' children, insulin sensitivity and, 1220
of normolipidemic subjects, 1208
of PEM subjects, 820
of postmenopausal women on estrogen alone or estrogen with progestin, 785
post-pancreas transplantation, 461
of pregnant subjects, and 4G/G PAI-1 polymorphism, 846
of rheological disorder subjects, 601
and seasonal variation of S_I and glucose effectiveness in men, 33
and SM insulin responsiveness to NA-induced changes in PC and PE FAs, 233
of 10-to-15-year-old boys, estradiol and estrogen effects on lipids in, race and, 1125, 1126
TGs and, *see* Body weight, TGs and
and tyrosine effects on Phe hydroxylation, 445
of underweight chronic gastrointestinal disease subjects, DXA, BIA, and TBW-^3H_2O methods in determination of body composition and, 360-366
see also Lean subjects; Obesity; Underweight subjects; Weight gain; Weight loss
Body weight (BW), diet effects on
dietary fat and energy intake effects, 979
HF diet effects, 505, 1519
metabolic effects, 1112
obesity-inducing diet effects, 1297
restricted diet effects, 109, 110
S-rich diet effects, 1348
starch diet effects, 766
see also Body weight, soy protein and
Body weight (BW), leptin and
plasma leptin in hyperinsulinemic women, 1056
serum leptin, body composition and, 1279
Body weight (BW), soy protein and
and arterial LDL delivery, 1191
and LDL oxidation, 540
Body weight (BW), TGs and
and insulin resistance correlation with increased SFAs in SM TGs, 221
and masoprocol effects on F-induced HTG, 1107
and restricted diet effects on TGs, 109, 110
Body weight (BW) of DM subjects
and AGE product levels in liver and kidney, 568
CS-045 effects on, 1362
in IDDM subjects, exercise effects on, 643
see also Body weight of NIDDM subjects; Body weight of STZ-DM subjects
Body weight (BW) of exercising men
α-adrenergic antagonist effects on, 387
AT metabolism and, 123
Body weight (BW) of exercising subjects
effects of exercise on plasma HDL CE, 828
and exercise effects on leptin and insulin, 859
on Lp(a) and LDLs, in NIDDM, 643
see also Body weight of exercising men
Body weight (BW) of NIDDM subjects
and ALC effects, 705
apo E polymorphism, leptin and, 725, 726
and BK effects on exercise-induced glucose uptake and GLUT4 translocation in SM, 923, 925
CS-045 effects on, 1168, 1172
with dyslipidemia, 23-25
effects of high-monounsaturated fat diet and olive oil diet on, 1513
exercise effects on, 643
metabolic effects of $VOSO_4$ and, 400-410
paternal-maternal effects on phenotypes of, 654
and voglibose effects on beta cell mass, 348
YM440, troglitazone, and pioglitazone effects on, compared, 412
see also Body weight of NIDDM subjects, thiazolidinedione effects on; Weight loss in NIDDM
Body weight (BW) of NIDDM subjects, thiazolidinedione effects on
and restricted diet effects on TGs and NIDDM, 109, 110
and thiazolidinedione effects on FA oxidation, 522
Body weight (BW) of STZ-DM subjects
diazoxide effects on, 658
hyperinsulinemia and LPL activity in, 135
nicorandil effects on, 428
T-1095 effects on, 991-992
Bone marrow stromal osteoprogenitor cells (BMSCs), effects of hydrochlorothiazide and furosemide on, compared, 17-21
Bone metabolism
in HIV infection, calciotropic hormones and, 1134-1139
see also Bone turnover
Bone turnover
in hypertension, 1130-1133
in young women on OCs, urinary Ca excretion and, 1078-1084
Boys
estradiol and estrogen effects on lipids in, race and, 1124-1129
see also specific conditions
BP, *see* Blood pressure
BQ123 (ET_A receptor antagonist), effects of, on GIIS, 265, 266
BQ3020 (ET_A receptor antagonist), effects of, on GIIS, 265, 266
Bradykinin (BK)
effects of, on exercise-induced glucose uptake and GLUT4 translocation in SM of healthy and NIDDM subjects, 920-930
effects of, on glucagon secretion, BK_2 receptors and, 1370-1373
Bradykinin$_2$ (BK_2) receptors, BK effects on glucagon secretion and, 1370-1373
Brain
accumulation of cystathionine, CK, and PHTZDC acid in, D,L-propargylglycine effects on, 1025-1029

Brain (*Continued*)
SERP-1 distribution to, 1452
see also Brain-blood barrier; Brain-derived neurotrophic factor; Brain natriuretic peptides *and entries beginning with term*: Hypothalamic
Brain-blood barrier, agouti-related protein(83-132) crossing, 1444-1448
Brain-derived neurotrophic factor (BDNF), effects of metformin and intermittent, on glucose metabolism in obese NIDDM subjects, compared, 129-133
Brain natriuretic peptides (BNPs)
circulating, temocapril effects on LVH and, in hypertensive elderly subjects, 1356-1360
interaction between metabolic clearance of ANPs and, in heart failure, 1228-1233
Branched-chain amino acids (BCAAs)
effects of, on plasma uridine not mediated by glucagon or insulin, 97-100
myocardial, hyperinsulinemia effects on uptake of, in CHD, 1365-1369
see also specific amino acids
BrdU (5-bromodeoxyuridine), vascular smooth muscle cell uptake of, 1589-1590
Breakfast, Ultralente insulin effects in healthy subjects after, 1243-1246
Breakfast cereal, effects of soy-based, on LDL oxidation and blood lipids, 1496-1500
BRL-37344, effects of, on lipolytic β_3-adrenergic agonist response to hyperinsulinemia in adipocytes of pregnant and nonpregnant subjects, 1180-1187
5-Bromodeoxyuridine (BrdU), vascular smooth muscle cell uptake of, 1589-1590
2-Bromopalmitate, effects of triacsin C, palmitate, FFAs and, on adipocyte leptin, 326-330
Brown adipose tissue, *see* Intercapsular brown adipose tissue
BUN (blood urea nitrogen)
CS-045 effects on, in DM with obesity, 1362
in nephrotic syndrome, NO-1886 effects on, 589
Butter in soy protein diet, 1189
tert-Butylhydroquinone in HF diet, 504
BW, *see* Body weight
Bypass graft, coronary artery, thyroxine-binding globulin consumption during, 270-274

C, *see* Cholesterol
Ca and Ca^{2+} (calcium)
bone turnover and urinary excretion of, in young women on OCs, 1078-1084
insulin secretion stimulated by GLP-1 via mechanisms independent of, in DM, 1579-1587
plasma, and aging effects on, 254-256
in primary hyperparathyroidism, 193
serum, *see* Serum Ca and Ca^{2+}
and stevioside effects of beta cell insulin secretion, 209
see also $CaCl_2$; $^{45}CaCl_2$
CABG (coronary artery bypass graft), thyroxine-binding globulin consumption during, 270-274
Cachexia syndrome in cancer, lipolysis and lipid oxidation in, 931-936
$CaCl_2$ (calcium chloride), and aging effects on CT secretion, 254-255
$^{45}CaCl_2$ (calcium chloride), effects of Mg supplementation on intestinal absorption of, in women with low erythrocyte Mg, 1092-1098
Caffeine, thermic effect of, in young and older women, compared, 101-107
CAH (congenital adrenal hyperplasia), lipids in, 790-793
Calciotropic hormones, and bone metabolism in HIV infection, 1134-1139
Calcitonin (CT)
aging effects on secretion of, 253-258
circulating, in cirrhosis, relationship of, to disease severity and CGRP, 47-52
Calcitonin gene-related peptide (CGRP) in cirrhosis, circulating CT relationship to severity of cirrhosis and, 47-52
Calcium, *see* Ca and Ca^{2+}; $CaCl_2$; $^{45}CaCl_2$
Calories
in LF diet with soluble fiber and soy and vegetable protein, 68
see also Thermic effect of food *and entries beginning with term*: Energy
Calphostin C, effects of, on ET-1-stimulated insulin secretion, 266
cAMP (cyclic adenosine monophosphate)
BCAA effects on, not mediated by glucagon or insulin, 98, 99
dibutyril, effects of, on MeAIB uptake, 876
stevioside effects on beta cell insulin secretion independent of activity of ATP-sensitive K^+ channels and, 208-214
Campesterol
serum, stanol ester effects on, 474
in soy protein diet, 539
Cancer cachexia syndrome, lipolysis and lipid oxidation in, 931-936
Capillary electrophoresis of agouti-related protein(83-132) crossing of BBB, 1444-1448
Capillary filtration of albumin (CFA) of SM in STZ-DM, anthocyanoside effects on, 880-885
Carbachol, PLC isozymes in pancreatic islets stimulated by, 1159
Carbohydrate (CHO) intake
by cachexic cancer subjects, 933
and CHO oxidation, 233
and delayed effects of exercise on plasma leptin concentrations, 396
effects of high-CHO diet on metabolic profile in NIDDM, high-monounsaturated fat diet and olive oil diet effects compared with, 1511-1517
in high-S diet with dexamethasone, 1290
in LF diet, 68, 732
in obesity-inducing diet, 1296
short-term variation in dietary fat and, PP lipemia after, 1150-1155
in soy protein diet, *see* Carbohydrate intake with soy protein diet
by young women on OCs, 1079
Carbohydrate (CHO) intake with soy protein diet
glucocorticoid receptor gene locus polymorphism and, 1189
LDL oxidation and, 58, 538, 1497
and sex hormone receptor activity in hyperlipidemia, 538
Carbon dioxide (CO_2), FDP effects on consumption of, 700
Carbonylated proteins, T_3 effects on reserve of, 801
Carboxykinase, hepatic phosphoenolpyruvate, vanadate effects on hepatic G6Pase and G6PDH and, in lean IDDM subjects, gluconeogenesis and, 321-325
Carboxylase, acetyl-coenzyme A, in SAT, 596, 597
Cardiac β (beta)-adrenergic receptors (β-ARs), T_3 and T_4 modulations of responsiveness of, and changes in cardiac adenylyl cyclase isoforms, 275-279
Cardiac muscle, *see* Myocardium
Cardiac output in cirrhosis, circulating CT and, 48
Cardiovascular (CV) fitness, subcutaneous central AT associated with risk of CV disease independently of total AT and, 1379-1385
Cardiovascular system, *see* Cardiovascular fitness; Coronary heart disease; Myocardium; Risk of CV disease *entries beginning with terms*: Aortic, Arterial, Cardiac, Coronary, Heart, Vascular, Venous, Ventricular *and specific blood vessels*
β (beta)-Carotene
in soy protein diet, 539
T_3 effects on reserve of, 801

Carotid artery, intima-media thickness of, in NIDDM, lack of association between MTHFR gene polymorphism or serum HcY and, 718-723
Casein
in diet of hyperinsulinemic pregnant and nonpregnant subjects, 1181
in HF diet, 504
in obesity-inducing diet, 1296
in restricted FA and energy diet, 978
in soy protein diet, 1189
Catalytic subunit p36 of microsomal hepatic G6Pase system, ontogeny of G6Pase transporter proteins and, 1200-1203
Catecholamines, *see* Epinephrine; Plasma norepinephrine
CBG (cortisol-binding globulin), morning cortisol levels, S_G and, 306, 307
CD4 cells in HIV infection, bone metabolism and, 1134-1139
CE, *see* Cholesteryl ester
Cell-cell interaction, effects of AGE products on, and oxidative stress in NIDDM, S1:9-10
Cell-matrix interaction, effects of AGE products on, and oxidative stress in NIDDM, S1:9-10
Cellular alkaline phosphatase (ALP), HCTZ and furosemide effects on production of, 18
Cellular osteocalcin, HCTZ and furosemide effects on production of, 18
Cellular redox potential in mesangial cells, troglitazone effects on, 310-311
Cellulose
in diet of hyperinsulinemic pregnant and nonpregnant subjects, 1181
in HF diet, 504
in obesity-inducing diet, 1296
in restricted FA and energy diet, 978
in starch diet, 765
Central adipose tissue (AT), subcutaneous, associated with risk of CV disease in men independently of total AT and CV fitness, 1379-1385
Central effects of GLP-1 receptor agonist on satiety and weight loss in NIDDM, peripheral effects versus, 709-717
Cereal, effects of soy-based breakfast, on LDL oxidation and blood lipids, 1496-1500
Cerivastatin, effects of, on TGs in NIDDM, 1049-1054
CETP, *see* Cholesteryl ester transfer protein
CFA (capillary filtration of albumin) in SM of STZ-DM subjects, anthocyanoside effects on, 880-885
CGP-12177, effects of, on lipolytic β_3-adrenergic agonist response to hyperinsulinemia in adipocytes of pregnant and nonpregnant subjects, 1180-1187
CGRP (calcitonin gene-related peptide) in cirrhosis, circulating CT relationship to severity of disease and, 47-52
C7H (cholesterol 7α-hydroxylase), aging and activity of, in HHL, 553-554
CHD, *see* Coronary heart disease
Chemoattractant protein-1 mRNA (messenger ribonucleic acid), monocyte, TNF-α-induced expression of, in mesangial cells, troglitazone effects on, 162-166
Children
of NIDDM subjects, insulin sensitivity and insulin secretion in, 1219-1223
see also Boys; Children, leptin in; Infant(s)
Children, leptin in
obese children, relationship between PAI-1-Ag and tPA-Ag, fat mass, and leptin in, 890-895
serum leptin in children with PEM, 819-825
Chloride (Cl), *see* $CaCl_2$; $^{45}CaCl_2$
CHO, *see* Carbohydrate intake
Cholera toxin, effects of, on GLP-1-induced insulin secretion in DM, 1581-1583
Cholestanol, serum, stanol ester effects on, 474
Δ8 (delta8)-Cholestenol, serum, stanol ester effects on, 474
Δ8 (delta8)-Cholestenol/sitosterol, serum, stanol ester effects on, 474
Cholesterol (C)
in atherosclerosis, 1272
diet effects on, *see* Cholesterol, diet effects on
dietary, *see* Dietary cholesterol
effects of HF diet-induced insulin resistance on, 1519
efflux of, from normal and TD fibroblasts into normal, HDL-deficient, and apo E-deficient plasmas, 770-777
in HHL, aging-associated changes in metabolism of, 552-556
in HTN, 1531
in HTG, atorvastatin effects on, 170-172
in IDDM, *see* Cholesterol in IDDM
in insulin-resistant lean and obese nondiabetic women, 287
in metabolic syndrome, 749
in NIDDM, *see* Cholesterol in NIDDM
in normolipidemia, 1208
plasma, *see* Plasma cholesterol
in premenopausal women, 1103
risk of atherosclerosis after pancreas transplantation and, 463
serum, *see* Serum cholesterol
total, *see* Total cholesterol
transport of, *see* Transport, cholesterol
in young women on OCs, 1079
see also Cholesterol acyltransferase; Cholesterol 7α-hydroxylase; High-density lipoprotein-cholesterol; Hypercholesterolemia; Intermediate-density lipoprotein-cholesterol; Lecithin:cholesterol acyltransferase; Low-density lipoprotein-cholesterol
Cholesterol (C), diet effects on
of LF diet with sucrose and starchy foods on, 733
of ω3-PUFAs and chronic ethanol consumption on reverse C transport, 508-512
of soy protein diet, 1189
Cholesterol acyltransferase, acyl coenzyme A:, aging and activity of, in HHL, 553-554
Cholesterol 7α-hydroxylase (C7H), aging and activity of, in HHL, 553-554
Cholesterol (C) in IDDM
exercise effects on, 643
following vitamin E supplementation and before and after glycemia control, oxidative stress and, 161
Cholesterol (C) in NIDDM
exercise effects on, 643
following vitamin E supplementation and before and after glycemia control, oxidative stress and, 161
see also Cholesterol in NIDDM, weight loss effects on; Serum cholesterol in NIDDM; Total cholesterol in NIDDM
Cholesterol (C) in NIDDM, weight loss effects on
in obese subjects, 1454
transport of, 1457-1458
Cholesteryl ester (CE)
plasma HDL, exercise effects on, 826-832
see also Cholesteryl ester transfer protein
Cholesteryl ester transfer protein (CETP)
in HTG, atorvastatin effects on, 173
plasma, *see* Plasma cholesteryl ester transfer protein
Choline
in diet of hyperinsulinemic pregnant and nonpregnant subjects, 1181
EPA effects on oxidized LDLs and lysophosphatidylcholine-induced migration in VSMCs, 560-562
measurement of *S*-adenosylmethionine and, in hypermethioninemia, 1542-1547
in restricted FA and energy diet, 978
Choline bitartrate in HF diet, 504

Cholinesterase in cirrhosis, 1435
Chorionic gonadotropin, human, synergistic effects of rIGF-I and, in ovaries, 314-320
Chromatography
  GC/MS of plasma galactose and galactitol in galactosemia due to GALT deficiency, 1460-1466
  liquid, *see* Liquid chromatography
  size-exclusion, of agouti-related protein(83-132) BBB crossing, 1444-1449
Chronic alcohol intake
  effects of ω3-PUFAs and, on RCT, 508-512
  moderate, of wine, effects of, on insulin sensitivity in moderately obese women, 1473-1478
Chronic galanin (GAL) administration, effects of, on hypothalamic GAL synthesis in male and female subjects, long-loop GAL autofeedback and, 778-783
Chronic gastrointestinal disease in underweight subjects, DXA, BIA, SF, and TBW-^3H_2O methods in measurement of body composition in, compared, 360-366
Chronic high-glycemic index starch diet, leptin regulation by, 764-769
Chronic intraperitoneal (IP) insulin, effects of, on hepatic glucose metabolism in STZ-DM, 1411-1416
Chylomicrons
  cerivastatin effects on, 1050
  delayed clearance of, from circulation, and hepatic expression of LDL receptor and LDL receptor-related protein in older and young subjects, 492-498
  effects of regular moderate wine consumption by moderately obese women on, 1475
  stanol ester effects on, 473-478
Cigarette smoking, *see* Smoking
Circadian rhythms of serum DHEA, cortisol, and cortisol/DHEA molar ratio after single DHEA administration in young and older subjects, compared, 548-551
Circulating adrenomedullin in ACTH-dependent Cushing's syndrome due to pituitary adenoma, 760-763
Circulating brain natriuretic peptides (BNPs), temocapril effects on LVH and, in hypertensive elderly subjects, 1356-1360
Circulating calcitonin (CT) in cirrhosis, relationship of increased, to disease severity and CGRP, 47-52
Circulating insulin, developmental changes in, 527
Circulation
  chylomicron clearance from, and hepatic expression of LDL receptor and LDL receptor-related protein in older and young subjects, compared, 548-551
  see also Blood flow *and entries beginning with term*: Circulating
Cirrhosis
  GSH synthesis in response to methionine in, 1434-1439
  liver transplantation for, S_G following, 367-372
  relationship of circulating CT to CGRP and severity of, 47-52
Citrate lyase, ATP-, in SAT, 596, 597
CK (cystathionine ketamine), accumulation of cystathionine, PHTZDC acid and, in brain, D,L-propargylglycine effects on, 1025-1029
Cl (chloride), *see* $CaCl_2$; $^{45}CaCl_2$
CL 316,243, effects of, on lipolysis in AT, 240
CO_2 (carbon dioxide), FDP effects on consumption of, 700
CoA (coenzyme A), *see* Acetyl-coenzyme A carboxylase; Acyl coenzyme A:cholesterol acyltransferase; 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase
Coagulation abnormalities, long-term EPA-E preventing DM and DM-related, 912-919
Coenzyme A, *see* Acetyl-coenzyme A carboxylase; Acyl coenzyme A:cholesterol acyltransferase; 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase
Cold exposure, effects of acute, on plasma leptin in women, 421-423
Collagen cross-links, early postnatal growth of IUGR infants and, 1467-1472
Combination therapy for oxidative stress reduction, S1:33
Combined hyperlipidemia, familial, Lp phenotype and insulin resistance in, 1627-1631
Congenital adrenal hyperplasia (CAH), lipids in, 790-793
Connecting peptides, *see* C-peptides
Contraceptives, oral, urinary Ca excretion and bone turnover in young women on, 1078-1082
Copper (Cu^{2+})-mediated low-density lipoprotein (LDL; β-lipoprotein) oxidation, M1 effects on, 479-485
Cornstarch
  in diet of hyperinsulinemic pregnant and nonpregnant subjects, 1181
  in HF diet, 504
  in obesity-inducing diet, 1296
  in restricted FA and energy diet, 978
Coronary artery bypass graft (CABG), thyroxine-binding globulin consumption during, 270-274
Coronary heart disease (CHD)
  hyperinsulinemia effects on myocardial BCAA uptake in, 1365-1369
  see also Coronary heart disease, NIDDM and
Coronary heart disease (CHD), NIDDM and
  in Afro-Caribbean, European, and South Asian men, plasma lipid relationship to insulin resistance, FFAs, and AT, variation in risk of, 245-252
  oxidative stress and, S1:30-34
Corticosterone, plasma, in obesity, exendin-4 effects on, in NIDDM, 711, 712
Corticotropin, *see* Adrenocorticotropic hormone; Adrenocorticotropic hormone syndrome
Cortisol (hydrocortisone)
  basal secretion of, in men, polymorphism of 5'-flanking region of glucocorticoid receptor gene locus associated with, 1197-1199
  circadian rhythms of serum DHEA, cortisol/DHEA molar ratio and, after single DHEA administration in young and older subjects, compared, 548-551
  glucagon effects on concentrations of, dosage and, 41, 43
  plasma, *see* Plasma cortisol
  see also Cortisol, S_G and; Cortisol-binding globulin; Cortisol/dehydroepiandrosterone molar ratio
Cortisol (hydrocortisone), S_G and
  fasting, in liver transplantation recipients, 368
  morning levels of, 305-307
  in PEM children, 819-825
Cortisol-binding globulin (CBG), morning cortisol levels, S_G and, 306, 307
Cortisol/dehydroepiandrosterone (hydrocortisone/DHEA) molar ratio, circadian rhythms of serum DHEA, cortisol and, after single DHEA administration in young and older subjects, compared, 548-551
C-peptides (connecting peptides; CPs)
  fasting, *see* Fasting C-peptides
  glucagon dosage effects on concentrations of, 41
  and glycemia after protein ingestion, 2
  in IDDM, effects of insulin and, on RBC Na/K ATPase in, 868-872
  in NIDDM, *see* C-peptides in NIDDM
  plasma, *see* Plasma C-peptides
  and relationship between PAI-1 Ag, leptin, and FM, 891, 892
C-peptides (connecting peptides; CPs) in NIDDM
  apo E polymorphism, leptin and, 725, 726
  fasting, *see* Fasting C-peptides in NIDDM
  in Japanese obese NIDDM obese adolescents, 187
  low-dose epinephrine effects on, 197
  plasma, and variation in risk of NIDDM, 248

Creatinine (Cr) and creatinine clearance
in acute acromegaly, lanreotide effects on, 636
BCAA effects on, not mediated by glucagon or insulin, 98-100
and bone metabolism in HIV infection, 1136, 1137
in diabetic nephropathy, 1493
hyperhomocysteinemia and, *see* Creatinine and creatinine clearance in hyperhomocysteinemia
and IMGU with relatively low Mg, 419
in metabolic syndrome, 749, 750
in nephrotic syndrome, NO-1886 effects on, 589
in NIDDM, *see* Creatinine and creatinine clearance in NIDDM
in obesity, HTN and, 1525
serum, *see* Serum creatinine
soy protein effects on, 540
in weight-losing cancer subjects, 934
Creatinine (Cr) and creatinine clearance in hyperhomocysteinemia
in methionine-induced hyperhomocysteinemia, 225
and vitamin B_{12} effects on plasma HcY in ESRD subjects on HD, 217
Creatinine (Cr) and creatinine clearance in NIDDM
and MTHFR gene, 719, 721
with nephropathy, TGF-β_1 activation and, 355
Creatininemia in obesity with rheological disorders, skin vasoconstrictive response to sympathetic activation and, 601
Cross-links
AGE product, effects of breakage of, on STZ-DM, 996-1000
collagen, early postnatal growth in IUGR infants and, 1467-1472
CβS, *see* Cystathionine-β-synthase
CS-045, *see* Troglitazone
CT, *see* Calcitonin
Cu^{2+} (copper)-mediated low-density lipoprotein (LDL; β-lipoprotein) oxidation, M1 effects on, 479-485
Cushing's syndrome
ectopic ACTH syndrome in, testosterone production and, 230
see also Pituitary adenoma, and Cushing's syndrome
Cutaneous blood flow (BF), and impaired skin vasoconstrictive response to sympathetic activation due to rheological disorders, 600-606
CV (cardiovascular) system, *see* Cardiovascular fitness; Coronary heart disease; Myocardium; Risk of CV disease *entries beginning with terms*: Cardiac, Heart
Cyclase, isoforms of cardiac adenylyl, and T_3 and T_4 modulation of cardiac β-adrenergic receptor responsiveness, 175-179
Cycle-ergometer exercise, blood lipid response to, race and, 513-520
Cyclic adenosine monophosphate, *see* cAMP
Cyclical norethindrone acetate (NETA), effects of oral or transdermal 17β-estradiol with oral, on insulin sensitivity, secretion, and elimination in postmenopausal women, 742-747
Cystathionine, brain accumulation of CK, PHTZDC acid and, D,L-propargylglycine effects on, 1025-1029
Cystathionine ketamine (CK), brain accumulation of cystathionine, PHTZDC acid and, D,L-propargylglycine effects on, 1025-1029
Cystathionine-β-synthase (CβS)
effects of HF diet with sucrose on MTHFR and, on HcY metabolism, 736-741
methionine transamination in homocystinuria due to deficiency in, 1071-1077
Cysteine (Cys)
in glutamine-containing diet, 142
plasma, in ESRD patients on HD, vitamin B_{12} effects on, 217
Cystine, effects of, on system A transport of MeAIB in mammary gland, 875, 876
L-Cystine
in HF diet, 504
in obesity-inducing diet, 1296
in restricted FA and energy diet, 978
Cytokines
in obesity, 1295-1300
see also specific cytokines
Cytotoxicity, M1 effects on LDL oxidation and oxidized LDL-induced, 479-485

Daidzein in soy protein diet, 538
Daidzin in soy protein diet, 538
Damage, *see* Trauma and injury
Dehydroepiandrosterone (DHEA; β-hydroxy-5-androsten-17-one)
serum, effects of single administration of, on circadian rhythms of cortisol, cortisol/DHEA molar ratio and, in young and older subjects, compared, 548-551
serum leptin, body composition and, 1279
Dehydroepiandrosterone sulfate (DHEAS)
genetic measurement of, before and after long-term endurance exercise, 298-304
serum, and soy protein intake in relation to psychological well-being in perimenopausal and postmenopausal women, 1561-1564
Dehydrogenase
glucose-6-phosphate, *see* Glucose-6-phosphate dehydrogenase
mRNA of glyceraldehyde-3-phosphate, in AT, GH effects on, 240
6-phosphogluconate, lactate, and malate, in SAT, 596, 597
Delta8 (Δ8)-cholestenol, serum, stanol ester effects on, 474
$Delta_4$ DIONE, *see* Androstenedione
Delta7 (Δ7)-lathosterol, serum, stanol ester effects on, 474
Delta7 (Δ7)-lathosterol/sitosterol, serum, stanol ester effects on, 474
Depression and depressive disorders, insulin resistance in
minimal model analysis of, 1255-1260
TH gene microsatellite polymorphism associated with insulin resistance, 1145-1149
Desmosterol, serum, stanol ester effects on, 474
Desmosterol/sitosterol, serum, stanol ester effects on, 474
Development
of DM, nicotinamide accelerating, in obese subjects, 1548-1554
see also Ontogeny; Postnatal growth and development
Dexamethasone (DEX)
effects of, on apo A-I mRNA, 1576
see also Dexamethasone, and AT
Dexamethasone (DEX), and AT
effects of long-term high-S diet with dexamethasone on AT depots, liver steatosis, and lipid fluxes through retroperitoneal and splanchnic areas, 1289-1291
see also Leptin in AT, dexamethasone and
Dextrin in soy protein diet, 1189
DHA (dihydroxyacetone), effects of, on beta cell insulin secretion in NIDDM, 93
DHEA, *see* Dehydroepiandrosterone
DHEAS, *see* Dehydroepiandrosterone sulfate
Diabetes mellitus (DM)
insulin secretion stimulated by GLP-1 via Ca^{2+}-independent mechanisms in, 1579-1587
long-term EPA-E effects on DM-related coagulation abnormalities and on, 912-919
soy protein effects on arterial LDL and LDL-C delivery to arteries in, 1188-1196
see also Advanced glycation end product(s) in DM; Hb in DM; Insulin-dependent diabetes mellitus; Liver in DM; Long-term eicosapentaenoic acid ethyl ester in DM ; Non-insulin-dependent diabetes mellitus; Obesity with DM; Streptozotocin-induced diabetes mellitus *and entries beginning with term*: Diabetic
Diabetic nephropathy
in NIDDM, TGF-β_1 activation in, 353-359
pulsatile IV insulin effects on progression of, 1491-1495

Diabetic nephropathy (*Continued*)
serum AGE products in, 1030-1035
Diabetic peripheral neuropathy, zenarestat effects on, 1395-1399
Diabetic state, NIDDM progression to overt, 684-688
Diaphragmatic tissue, TNF-α in, 1313, 1314
Diastolic pressure, *see* Blood pressure
Diazoxide, effects of, on beta cell function of transplanted pancreatic islets in STZ-DM subjects, 657-661
Diazoxonase, activity of serum, in NIDDM, PON1 gene polymorphisms and, 1400-1405
Dibutyryl cAMP (cyclic adenosine monophosphate), effects of, on MeAIB uptake, 876
Diet
effects of, on insulin and nutrient metabolism in mesenteric lymph node cells, splenocytes, and pancreatic islets, 1111-1117
effects of, on insulin secretion, inositol phosphate, and PLC isozymes in pancreatic islets, 1158
effects of insulin and changes in, at weaning, on intestinal galactosyltransferase activity regulation during postnatal development, 526-531
see also Energy intake; Feeding; Food intake by obese NIDDM subjects, troglitazone effects on; Meals; Nutritional status; Restricted food intake; Supplementation; Thermic effect of food; Total parenteral nutrition *entries beginning with terms*: Dietary, Fasting *specific food groups, food substances, and types of diets; for example*: Low-fat diet; Western diet
Dietary carbohydrate, *see* Carbohydrate intake
Dietary cholesterol (C)
and delayed effects of exercise on plasma leptin concentrations, 396
effects of short-term variation in dietary fat and CHOs on, 1151
in high-monounsaturated fat diet and olive oil diet, 1513
see also Dietary cholesterol, soy protein effects on
Dietary cholesterol (C), soy protein effects on
of LF diet with soluble fiber and soy and vegetable protein, 68
of soy-based breakfast cereal, 1497
Dietary ethanol, *see* Alcohol intake
Dietary fat
and delayed effects of exercise on plasma leptin concentrations, 396
intake of, by cachexic cancer subjects, 933
metformin and troglitazone effects on, in STZ-DM, 1390-1394
in obesity-inducing diet, 1296
PP lipemia after short-term variation in CHOs and, 1150-1155
restricted energy intake effects on liver cell PL FA membrane related to, 977-983
in soy protein diet, *see* Dietary fat in soy protein diet
in starch diet, 765
see also High-fat diet; Low-fat diet *and specific types of dietary fat*
Dietary fat in soy protein diet
hyperlipidemia and, 538
in soy-based breakfast cereal, 1497
and soy protein effects on arterial LDL concentration, 1189
Dietary fatty acids, *see* Fatty acid(s)
Dietary glutamine (Gln), effects of, on endogenous glutamine turnover, 141-145
Dietary protein intake
by cachexic cancer subjects, 933
and delayed effects of exercise on plasma leptin concentrations, 396
in high-monounsaturated fat diet and olive oil diet, 1513
in high-S diet with dexamethasone, 1290
insulin sensitivity as predictor of glycemia after, 1-5
in LF diet, 732
in obesity-inducing diet, 1296
in short-term variation of dietary fat and CHOs on, 1152
in soy protein diet, 1189
by young women on OCs, 1079
Dietary protein intake (*Continued*)
see also Protein-energy malnutrition; Soy protein *and specific proteins*
Dihydroxyacetone (DHA), effects of, on beta cell insulin secretion in NIDDM, 93
1,25-Dihydroxycholecalciferol, *see* Vitamin D_3
Dihydroxyvitamin D_3 [$25(OH)_2D_3$] in HIV infection, bone metabolism and, 1137
N,N,-Dimethylbiguanide, *see* Metformin
Δ_4-DIONE, *see* Androstenedione
(Z)-1,4-bis{4-(3,5-Dioxo-1,2,4-oxadiazolidin-2-yl)phenoxy}but-2-ene (YM440), effects of, on hyperglycemia without AT weight change in NIDDM, pioglitazone and troglitazone effects compared with, 411-417
Diphosphate, fructose-1-6-, in healthy subjects, 698-703
Dismutase, *see* Superoxide dismutase
Diuretics, effects of HCTZ and furosemide on BMSCs, compared, 17-21
Diurnal variation in plasma leptin concentrations, HF diet effects on, 503-507
DM, *see* Diabetes mellitus
Docosahexaenoic acid, RBC and SM membrane, 1165
Docosapentaenoic acid, RBC and SM membrane, 1165
Docosatetraenoic acid, RBC and SM membrane, 1165
Dose
BDNF, BDNF effects and, 129-130
low epinephrine, effects of, on plasma glucose in elderly NIDDM subjects, 195-202
see also entries beginning with terms: High-dose
Drainage site, effects of systemic and/or portal venous, on post-pancreas transplantation, insulin action, insulin resistance, risk of atherosclerosis and, 458-466
Dual-energy x-ray absorptiometry (DXA)
of subcutaneous central AT in men, 1379-1385
in underweight chronic gastrointestinal disease subjects with BIA, SF, TBW-^3H_2O and, compared, 360-366
DXA, *see* Dual-energy x-ray absorptiometry
Dyslipidemia in NIDDM
with obesity, reversal and prevention of defective insulin secretion and histologic abnormalities in, with CS-045, 1167-1175
Western diet effects on, 22-31

E, *see* Epinephrine
E_2, *see* Estradiol
EC(s) (endothelial cells), NOS of aortic, insulin effects on, 147-150
Ectopic adrenocorticotropic hormone (ACTH; corticotropin) syndrome in Cushing's syndrome, testosterone production and, 230
EE, *see* Energy expenditure
Egg yolk in soy protein diet, 1189
Eicosapentaenoic acid (EPA)
effects of, on oxidized LDLs, and lysophosphatidylcholine-induced migration in VSMCs, 560-562
RBC and SM membrane, 1165
see also Long-term eicosapentaenoic acid ethyl ester
Elderly, the, *see* Aging, effects of *and entries beginning with term*: Older
Electron spin resonance of gliclazide effects on hydroxyl and superoxide radicals, S1:14-16
Electrophoresis
capillary, of agouti-related protein(83-132) crossing of BBB, 1444-1448
nondenaturing gradient gel, of plasma Lps in dyslipidemic NIDDM, 23
Endothelial cell(s), FA activation of, 1006-1013

Endothelial cell nitric oxide synthase (EC NOS), aortic, insulin effects on, 147-150
Endothelin(s) (ET)
immunoreactive, SNP effects on, 374, 375
plasma, menstrual cycle modulation of, 648-650
see also Endothelin$_A$; Endothelin-1
Endothelin$_A$ (ET_A), PKC and, in ET-1-potentiated insulin secretion, 264-269
Endothelin-1 (ET-1)
effects of NO and, on GK activity in hepatocytes, 73-80
insulin secretion potentiated by, PKC and ETA in, 264-269
OA and LA effects on binding and action of, in aortic smooth muscle cells, 1386-1389
relationship between metabolic alterations and concentrations of, in IRS, 748-751
Endothelium, monocyte adhesion to, in NIDDM, gliclazide effects on, S1:17-22
Endotoxemia, metabolic effects of insulin and IGF-I in, during TPN, 611-615
End-stage renal disease (ESRD), vitamin B_{12} effects on plasma HcY in HD subjects with, 215-219
Endurance exercise
fat metabolism in, 122-128
see also Genetic measurement, pre-and post-endurance exercise
Energy expenditure (EE)
and exercise effects on plasma leptin concentrations, 396
HF diet effects on, 505
in NIDDM, ALC effects and, 705
pioglitazone and CS-045 effects on, 1301-1308
resting, *see* Resting energy expenditure
Energy intake
and delayed effects of exercise on plasma leptin concentrations, 397
with dietary fat and CHOs, 1151
effects of restricted, related to fat type on PL FA liver cell membrane, 977-983
with obesity-inducing diet, 1297
with soy protein diet, 538
and tyrosine effects on Phe hydroxylation, 445
by young women on OCs, 1079
see also Diet; Protein-energy malnutrition
Energy storage in IBAT, pioglitazone and CS-045 effects on, 1301-1308
EPA, *see* Eicosapentaenoic acid
EPA-E (eicosapentaenoic acid ethyl ester), *see* Long-term eicosapentaenoic acid ethyl ester
EPG (endogenous glucose production) in NIDDM, indomethacin effects on, 839-844
Epinephrine (E; EPI)
effects of, on lipolytic β_3-adrenergic agonist response to hyperinsulinemia in adipocytes of pregnant and nonpregnant subjects, 1180-1187
low-dose, effects of, on plasma glucose in elderly NIDDM subjects, 195-202
plasma, *see* Plasma epinephrine
see also Epinephrine in hypoglycemia
Epinephrine (E; EPI) in hypoglycemia
and hypothermic response to hypoglycemia, 796, 797
in STZ-DM, IP and/or SC insulin effects on, 985-986
Erythrocyte(s) (red blood cell; RBC)
malaria-parasitized, NIDDM reversed with, 937-941
see also entries beginning with term: Erythrocyte
Erythrocyte(s) (red blood cell; RBC) fatty acids (FAs), composition of, as index of SM membrane FA composition, 1164-1166
Erythrocyte (red blood cell; RBC) galactose-1-phosphate, plasma galactose relationship to, in GALT deficiency galactosemia, 1464
Erythrocyte (red blood cell; RBC) Mg (magnesium)
Mg supplementation effects on intestinal absorption of $^{45}CaCl_2$ in women with low, 1092-1098
and risk of atherosclerosis after pancreas transplantation, 463
Erythrocyte (red blood cell; RBC) Na/K (sodium/potassium) ATPase (adenosine triphosphatase) in IDDM, insulin and C-peptide effects on, 868-872
Erythrocyte sedimentation rate (ESR) in methionine-induced hyperhomocysteinemia, 225
ESRD (end-stage renal disease), vitamin B_{12} effects on plasma HcY in HD subjects with, 215-219
Estradiol (E_2)
OCs containing, urinary Ca excretion and bone turnover in young women taking, 1078-1084
in postmenopausal women on estrogen alone or estrogen with progestin, 785
in premenopausal women, 1102
race and effects of, on lipids, in boys, 1124-1129
serum, *see* Serum estradiol
17β (beta)-Estradiol, effects of cyclical oral NETA with oral and/or transdermal, on insulin sensitivity, insulin secretion, and insulin elimination in postmenopausal women, 742-747
Estrogen
alone or with progestin in postmenopausal women with or without hypercholesterolemia, 784-789
race and effects of, on lipids in boys, 1124-1129
soy protein effects on, 540
Estrone, serum, rIGF-I and hCG effects on concentrations of, in ovaries, 316
ET, *see* Endothelin(s)
Ethanol, *see* Alcohol intake
Ethnicity, *see* Race and ethnicity
European men, plasma lipid relationship to FFAs, AT, and insulin resistance in Afro-Caribbean, South Asian and, variation in NIDDM and CHD risk and, 245-252
Evening meal, effects of voglibose before, on nocturnal hypoglycemia in IDDM subjects on intensive insulin therapy, 440-443
Excision of parathyroid adenoma in primary hyperparathyroidism, effects of, on IL-2 receptors and IL-6 levels, 192-194
Exendin-4, central versus peripheral effects of, on satiety and weight loss in NIDDM, 709-717
Exercise
acute slow lanreotide effects on microalbuminuria induced by, in active acromegaly, 634-639
at altitude, women's sympathoadrenal response to, 1036-1042
cycle-ergometer, blood lipid response to, race and, 513-520
effects of, on Lp(a) and LDL modifications in IDDM, 640-647
effects of, on plasma HDL CE, 826-832
endurance, *see* Endurance exercise
glucose and, *see* Glucose, and exercise
short-term effects of, on leptin and insulin, 858-861
SM and, *see* Skeletal muscle, exercise and
see also Men, exercising; Non-insulin-dependent diabetes mellitus, exercise effects in
Exposure
to cold, effects of acute, on plasma leptin in women, 421-423
long-term pancreatic cell, to palmitate, glucose concentration effects on insulin gene expression and, 532-536
Extrapancreatic tissues, sensitivity of ATP-sensitive K^+ channels of, to sulfonylureas, S2:3-6

F, *see* Fructose
FA(s), *see* Fatty acid(s)

FABP (fatty acid-binding protein) mRNA (messenger ribonucleic acid), YM440, troglitazone, and pioglitazone effects on, compared, 413
Factor VII coagulant activity (FVIIc), effects of LF diet with starchy foods or sucrose on, 731-735
Familial combined hyperlipidemia (FCH), Lp phenotype and insulin resistance in, 1627-1631
Familial hypertriglyceridemia (FHTG), VLDL apo E and platelet function in, 942-949
Familial non-insulin-dependent diabetes mellitus (NIDDM) in African Americans, molecular analysis of HNF1α *TCF1* gene in, 280-284
Fast protein liquid chromatography (FPLC) of plasma lipids and Lps in dyslipidemic NIDDM, 23, 25
Fasting
  apo A-I mRNA induced by, ketosis, KBs and, 1572-1578
  see also entries beginning with term: Fasting
Fasting beta (β) cell function, Ultralente insulin effects on, in healthy subjects, 1243-1246
Fasting blood glucose (FBG)
  in IDDM before and after glycemia control and after vitamin E supplementation, oxidative stress and, 161, 162
  in NIDDM, *see* Fasting blood glucose in NIDDM
  in relatives of NIDDM subjects, 835
Fasting blood glucose (FBG) in NIDDM
  effects of high-monounsaturated fat diet and olive oil diet on, 1513
  following vitamin E supplementation and before and after glycemia control, oxidative stress and, 161, 162
  with nephropathy, TGF-β_1 activation and, 355
  and voglibose effects on beta cell mass, 348
Fasting cholesterol (C), serum, variation in NIDDM and CDH risk and, 248
Fasting cortisol (hydrocortisone) in liver transplantation recipients, S_G and, 368
Fasting C-peptides (connecting peptides)
  in postmenopausal women, effects of 17β-estradiol with cyclical oral NETA and, 743, 745
  see also Fasting C-peptides in NIDDM
Fasting C-peptides (connecting peptides) in NIDDM
  apo E polymorphism, leptin and, 725, 726
  HDL_3 binding to leukocytes and, 691
  indomethacin effects on, 840
Fasting free fatty acids (FFAs; nonesterified fatty acids)
  effects of thermic response of young and older women to caffeine on, 103
  HTN and antihypertensive therapy effects on, SNS role in, 81-87
Fasting glucagon (hyperglycemic factor; hyperglycemic-glycogenolytic factor) in liver transplantation recipients, S_G and, 368
Fasting glucose
  blood, *see* Fasting blood glucose
  exercise effect on, 860
  and lack of linkage between VLDL receptor gene and fasting insulin, 294
  in liver transplantation recipients, 368
  morning cortisol levels and, 306, 307
  in NIDDM, *see* Fasting glucose in NIDDM
  plasma, *see* Fasting plasma glucose
  in postmenopausal women, effects of 17β-estradiol with cyclical oral NETA on, 743
  post-pancreas transplantation, effects of systemic and/or portal venous drainage site on insulin action and, 461
  and thermic response of young and older women to caffeine, 103
Fasting glucose in NIDDM
  apo E polymorphism, leptin and, 725, 726
  and BK effects on exercise-induced glucose uptake and GT4 translocation in SM, 923
Fasting glucose in NIDDM (*Continued*)
  HDL_3 binding to leukocytes and, 691
  with PPARγ2 Pro12Ala gene, 1268, 1269
  TGs, BMI and, in insulin-resistant and insulin-sensitive NIDDM, 1002, 1003
Fasting glycemia, tissue insulin sensitivity and beta cell contribution to, 1318-1325
Fasting insulin
  exercise effects on, 860
  in healthy and/or preeclamptic pregnancy, leptin relationship to serum insulin and insulin sensitivity and, 260
  in NIDDM, *see* Fasting insulin in NIDDM
  plasma, *see* Fasting plasma insulin
  in postmenopausal women, effects of 17β-estradiol with cyclical oral NETA on, 743, 745
  S_G and, *see* Fasting insulin, S_G and
  serum, *see* Fasting serum insulin
  TEF and, *see* Fasting insulin, TEF and
Fasting insulin, S_G and
  in liver transplantation recipients, 368
  and morning cortisol levels and, 306, 307
  and seasonal variation in S_I and S_G in men, 34
Fasting insulin, TEF and
  and relationship of PP RMR and TEF to body composition and AT distribution in lean and obese subjects, 7, 8
  and thermic response of young and older women to caffeine, 103
Fasting insulin in NIDDM
  and BK effects on exercise-induced glucose uptake and GT4 translocation in SM, 923
  apo E polymorphism, leptin and, 725, 726
  HDL_3 binding to leukocytes and, 691
  TGs, BMI and, in insulin-resistant and insulin-sensitive NIDDM, 1002, 1003
Fasting plasma glucose (FPG)
  in depressive disorders, 1146
  in DM, AGE product levels in liver and kidney and, 568; *see also* Fasting plasma glucose in NIDDM
  effects of regular moderate wine consumption by moderately obese women on, 1475
  fasting plasma leptin, plasma insulin and, 500
  in HTG, JTT-501 effects on, 575
  in HTN, 82, 1525
  in IGT, 1319-1322
  in insulin resistance, 1507, 1508
  in insulin sensitivity, 2, 1502
  in obesity, 1215, 1525
  OGTT correlated with, in South Indians, 455-457
  and RBC FA composition, 1165
Fasting plasma glucose (FPG) in NIDDM
  bezafibrate therapy effects on, 333
  indomethacin effects on, 840
  in obese Japanese adolescents, glucose intolerance and, 187
  TNF-α G308A gene polymorphism, insulin resistance and, in young, old, and NIDDM Japanese men, 1616-1618
Fasting plasma insulin (FPI)
  fasting plasma leptin and, in healthy subjects, 500
  during high-intensity exercise by men, 124-125
  in HTG, JTT-501 effects on, 575
  in IGT, 1319, 1322
  indomethacin effects on, 840
  and insulin resistance correlation with increased SFAs in SM TGs, 222
  in obesity, HTN and, 1525
  in relatives of NIDDM subjects, 835
Fasting plasma leptin in healthy subjects, plasma insulin and, 499-502

Fasting plasma triglycerides (TGs) in HTG, JTT-501 effects on, 575
Fasting serum apolipoprotein(a) [apo(a)], variation in NIDDM and CHD risk and, 248
Fasting serum apolipoprotein A-I (apo A-I), variation in NIDDM and CHD risk and, 248
Fasting serum apolipoprotein A-II (apo A-II), variation in NIDDM and CHD risk and, 248
Fasting serum apolipoprotein B (apo B), variation in NIDDM and CHD risk and, 248
Fasting serum cholesterol (C), variation in NIDDM and CHD risk and, 248
Fasting serum high-density lipoprotein-cholesterol (HDL-C), variation in NIDDM and CHD risk and, 248
Fasting serum high-density lipoprotein$_2$-cholesterol (HDL_2-C), variation in NIDDM and CHD risk and, 248
Fasting serum high-density lipoprotein$_3$-cholesterol (HDL_3-C), variation in NIDDM and CHD risk and, 248
Fasting serum insulin
  lack of linkage between VLDL receptor gene and HOMA insulin resistance index or, 293-297
  in obesity, 1215
Fasting serum low-density lipoprotein-cholesterol (LDL-C), variation in NIDDM and CHD risk and, 248
Fasting serum triglycerides (TGs), variation in NIDDM and CHD risk and, 248
Fasting serum very-low-density lipoprotein-cholesterol (VLDL-C), variation in NIDDM and CHD risk and, 248
Fasting somatotropic hormone (STH) in liver transplantation recipients, S_G and, 368
Fat
  metabolism of, in endurance exercise, 122-128
  see also Dietary fat *entries beginning with terms*: Fat, Fatty *elements*: Adip-, Lip-, *and specific fats*
Fat-free mass (FFM)
  in cachexic cancer subjects, 933
  genome-wide search for genes of, 203-207
  in IGT subjects, 1319
  and insulin resistance correlation with increased SFAs in SM TGs, 221
  in NIDDM, *see* Fat-free mass in NIDDM
  in NIDDM subjects' relatives, 834
  in obese subjects, GH therapy, weight loss and, 907
  relationship between serum leptin, sex steroid levels, insulin levels and, 1278-1284
  and seasonal variation of S_I and glucose effectiveness in men, 33
  in underweight chronic gastrointestinal disease subjects, 362
  see also Fat-free mass, TEF and
Fat-free mass (FFM), TEF and
  and kinetics of TEF, 1342-1344
  and relationship of PP RMR and TEF to body composition and AT distribution in lean and obese subjects, 7, 8
  and thermic response of young and older women to caffeine, 103
Fat-free mass (FFM) in NIDDM
  ALC effects and, 705
  variation in CHD and NIDDM risk and, 247, 249, 250
Fat mass (FM)
  in cachexic cancer subjects, 933
  GH therapy, weight loss and, 907
  in IGT subjects, 1319
  and insulin resistance correlation with increased SFAs in SM TGs, 221
  kinetics of TEF relationship to, 1342-1344
  leptin and, *see* Fat mass, leptin and
  in NIDDM, *see* Fat mass in NIDDM
Fat mass (FM) (*Continued*)
  and PP RMR and TEF relationship to body composition and AT distribution, 7, 8
  relationship between serum leptin, sex steroid levels, insulin levels and, 1278-1284
  in underweight chronic gastrointestinal disease subjects, 362
Fat mass (FM), leptin and
  exercise effects on leptin and FM, 859
  in obese children and adolescents, relationship between PAI-1-Ag and tPA-Ag and, 890-895
Fat mass (FM) in NIDDM
  ALC effects and, 705
  total, variation in CHD and NIDDM risk and, 247
Fatty acid(s) (FAs)
  composition, *see* Fatty acid composition
  endothelial cell activation by, 1006-1013
  free, *see* Free fatty acids
  in NIDDM with obesity, and thiazolidinedione effects on oxidation of liver and SM, 521-525
  PL, *see* Phospholipid fatty acid(s)
  saturated, *see* Saturated fatty acids
  unsaturated, *see* Unsaturated fatty acids
Fatty acid (FA) composition
  effects of, on lipolytic β_3-adrenergic agonist response to hyperinsulinemia in adipocytes of pregnant and nonpregnant subjects, 1180-1187
  PC and PE FAs, NA-induced changes in composition of, associated with SM insulin responsiveness in healthy subjects, 232-238
  in RBCs, as index of SM membrane FA composition, 1164-1166
Fatty acid-binding protein (FABP) mRNA (messenger ribonucleic acid) in NIDDM, YM440, troglitazone, and pioglitazone effects on, compared, 413
Fatty acid (FA) synthase in SAT, 596, 597
Fatty liver in NIDDM, inheritance of, 653
FBG, *see* Fasting blood glucose
FCH (familial combined hyperlipidemia), Lp phenotype and insulin resistance in, 1627-1631
FDP (fructose-1-6-diphosphate) in healthy subjects, 698-703
Feeding
  preoperative, effects of, on postoperative SM insulin resistance, 486-491
  see also Diet
Female subjects
  effects of acute and chronic GAL administration on hypothalamic GAL synthesis in, long-loop GAL autofeedback and, 778-783
  see also Sex; Women
Fetal body weight (BW) in relation to expression of insulin genes I and II, 616-620
FFAs, *see* Free fatty acids
FFM, *see* Fat-free mass
FHTG (familial hypertriglyceridemia), VLDL apo E and, platelet function in, 942-949
Fiber
  in high-monounsaturated fat diet and olive oil diet, 1513
  in short-term variation of dietary fat and CHOs, 1152
  in young women's diet on OCs, 1079
  see also Soluble fiber, soy protein and
Fibrinogen
  contribution of Lps and, to plasma viscosity in HCL and HTG, 810-813
  effects of LF diet with starchy foods or sucrose on, 731-735
  see also Fibrinolysis in obesity

Fibrinolysis
4G/4G polymorphism of PAI-1 gene and risk of pregnancy complications due to, 845-852
long-term EPA-E effects on, 918
in NIDDM, troglitazone effects on, 662-665
see also Fibrinolysis in obesity
Fibrinolysis in obesity
in children and adolescents, leptin and, 890-895
in infantile obesity, 672-675
Fibroblasts, C efflux from TD and normal, into normal, HDL-deficient, and apo E-deficient plasmas, 770-777
First-degree relatives, *see* Relatives of NIDDM subjects, beta cells in healthy
Fish oil, effects of, on lipolytic β_3-adrenergic agonist response to hyperinsulinemia in adipocytes of pregnant and nonpregnant subjects, 1180-1187
Fitness
aerobic, and thermic response to caffeine in older and young women, 101-107
cardiovascular, subcutaneous central AT associated with risk of CV disease independently of total AT and, 1379-1385
see also Exercise
5′-Flanking region of glucocorticoid receptor gene locus, polymorphism of, associated with basal cortisol secretion in men, 1197-1199
FM, *see* Fat mass
Folate, effects of MTHFR gene 677C → T mutation on plasma HcY response to intake of, by elderly women, 1440-1443
Folic acid, effects of, in hyperhomocysteinemic ESRD subjects on HD, vitamin B_{12} effects compared with, 215-219
Follicle-stimulating hormone (FSH)
and bone metabolism in HIV infection, 1136
in postmenopausal women on estrogen alone or estrogen with progestin, 785
see also Follicle-stimulating hormone in hypercholesterolemic men
Follicle-stimulating hormone (FSH) in hypercholesterolemic men
pravastatin effects on, 119
simvastatin effects on, 119, 1236
Food intake
effects of rosiglitazone and rexinoids on, 1611
see also Food intake by obese NIDDM subjects, troglitazone effects on; Restricted food intake
Food intake by obese NIDDM subjects, troglitazone effects on
CS-O45 effects, 1168
on FA oxidation in SM and liver, 522
YM440, CS-045, and pioglitazone effects on, compared, 413
Formalin-fixed *Plasmodium yoelii* (*P yoelii*) malaria, NIDDM reversed with, 937-941
4G/4G polymorphism of PAI-1 gene, as risk factor for pregnancy complications, 845-852
FPG, *see* Fasting plasma glucose
FPI, *see* Fasting plasma insulin
FPLC (fast protein liquid chromatography) of plasma lipids and Lps in dyslipidemic NIDDM, 23, 25
Free cortisol index, morning cortisol levels, S_G and, 306, 307
Free fatty acids (FFAs; nonesterified fatty acids)
effects of dietary FA composition on, in pregnant and nonpregnant subjects, 1182
effects of long-term high-S diet with dexamethasone on, 1291, 1292
effects of short-term variation in dietary fat and CHOs on, 1152, 1153
fasting, *see* Fasting free fatty acids
glucagon dosage effects on concentrations of, 41, 45
HF diet-induced insulin resistance and, 1519
in hyperlipidemia, 1628
in hypoglycemia of STZ-DM, IP and/or SC insulin effects on, 986
Free fatty acids (FFAs; nonesterified fatty acids) (*Continued*)
in hypopituitarism, GH therapy effects on, 565, 566
insulin resistance and, *see* Insulin resistance, FFAs and
IRS-1 and PI 3K effects on, 956
leptin and, *see* Free fatty acids, leptin and
masoprocol effects on, in F-induced HTG, 1107
metformin effects on, 1621
in NIDDM, *see* Free fatty acids in NIDDM
pioglitazone and CS-045 effects on, 1303
plasma, *see* Plasma free fatty acids
serum, *see* Serum free fatty acids
vagotomy effects on, 13
Free fatty acids (FFAs; nonesterified fatty acids), leptin and
effects of triacsin, palmitate, 2-bromopalmitate, and FFAs on adipocyte leptin, 326-330
isoproterenol- but not FFA-induced acute leptin suppression despite lipolysis inhibition by ACX, 335-339
Free fatty acids (FFAs; nonesterified fatty acids) in NIDDM
JTT-501 effects on, 864
low-dose epinephrine effects on, 197, 198
with obesity, thiazolidinedione effects on oxidation of liver and SM, 522
plasma lipid relationship to insulin resistance, AT and, in Afro-Caribbean, European, and South Asian men, variation in NIDDM and CHD risk and, 245-252
serum, CS-045 effects on, 1168-1170
TNF-α G308A gene polymorphism and, 1617
Free leptin in normal and preeclamptic pregnancy, 1043-1048
Free radicals (reactive oxygen species)
definitions and sources of, S1:3
nicorandil scavenging activity on LPO and, in STZ-DM, 427-431
tissue damage due to, *see* Tissue damage, free radical-mediated
see also Free radicals in NIDDM; Scavenging activity
Free radicals (reactive oxygen species) in NIDDM
AGE products and formation of, S1:9-13
see also Gliclazide scavenging activity in NIDDM; Oxidative stress in NIDDM
Free testosterone (T)
in 10-to-15-year-old boys, race and variation in, 1126
see also Free testosterone in hypercholesterolemic men
Free testosterone (T) in hypercholesterolemic men
pravastatin effects on, 118, 119
simvastatin effects on, 118, 119, 1236
Free thyroxine (T_4)
and leukocyte generation of ROS, 800
in sepsis, 754
see also Free thyroxine in hypothyroidism
Free thyroxine (T_4) in hypothyroidism
in hypothyroidic infants, 1178
serum, 1286, 1287
Free triiodothyronine (T_3) in hypothyroidism
in hypothyroidic infants, 1178
serum, 1286
Frequently sampled intravenous glucose tolerance test (FSIVGTT)
of Japanese obese NIDDM adolescents, 186-191
in liver transplantation recipients for cirrhosis, 367-372
of NIDDM subjects' children, 1219-1223
of seasonal variation in S_I and glucose effectiveness in men, 32-38
serum cortisol levels prior to, correlated with S_G, 305-307
Fructosamine
in diabetic and nondiabetic subjects, soy protein effects on, 1191
in IDDM and NIDDM, exercise effects on, 643
in obesity, rheological disorders and skin vasoconstrictive response to sympathetic activation and, 601

Fructose (F)
masoprocol effects on hypertriglyceridemia induced by, 1106-1110
peripheral glucose and, in healthy subjects, 1565-1571
Fructose-1-6-diphosphate (FDP) in healthy subjects, 698-703
FVIIc (factor VII coagulant activity), effects of LF diet with starchy foods or sucrose on, 731-735
FSH, *see* Follicle-stimulating hormone
FSIVGTT, *see* Frequently sampled intravenous glucose tolerance test
[2,3^{13}C]Fumarate, hepatocyte, effects of glycerol-1,2,3-tris(methyl-[2,3^{13}C]succinate) on, 179
Furosemide
effects of, on plasma and urinary concentrations of adenosine, uridine, and purine bases, 886-889
effects of hydrochlorothiazide and, on BMSCs, compared, 17-21

GADPH mRNA (glyceraldehyde-3-phosphate dehydrogenase messenger ribonucleic acid), AT, GH effects on, 240
GAL (galanin), *see* Growth hormone secretion, GAL effects in
Galactitol, plasma, in galactosemia due to GALT deficiency, 1460-1466
Galactose, plasma, in galactosemia due to GALT deficiency, 1460-1466
Galactose-1-phosphate, RBC, plasma galactose relationship to, in GALT deficiency galactosemia, 1464
Galactose-1-phosphate uridyltransferase (GALT) deficiency, plasma galactose and galactitol in galactosemia due to, 1460-1466
Galactosemia due to GALT deficiency, plasma galactose and galactitol in, 1460-1466
α-D-Galactosidase, plasma, at onset of IDDM with obesity and in healthy subjects during IVGTT, 1352-1355
Galactosyltransferase, activity of intestinal, during postnatal development, effects of insulin and dietary changes on, at weaning, 526-531
Galanin, *see* Growth hormone secretion, GAL effects in
GALT (galactose-1-phosphate uridyltransferase) deficiency, plasma galactose and galactitol in galactosemia due to, 1460-1466
Gas chromatography/mass spectrometry (GC/MS) of plasma galactose and galactitol concentrations in galactosemia due to GALT deficiency, 1460-1466
Gastrointestinal disease, chronic, in underweight subjects, DXA, BIA, SF, and TBW-^3H_2O in determination of body composition in, compared, 360-366
GC/MS (gas chromatography/mass spectrometry) of plasma galactose and galactitol concentrations in galactosemia due to GALT deficiency, 1460-1466
Gel electrophoresis, nondenaturing gradient, of plasma Lps in dyslipidemic NIDDM, 23
Gemfibrozil, effects of, in FHTG, 945-946
Gemfibrozil metabolite, effects of, on LDL oxidation and on oxidized LDL-induced cytotoxicity, 479-485
Gender, *see* Sex
Gene(s)
α_2- and β_3-AR, interaction between obesity phenotype and, 1063-1070
β_2-AR, *see* β_2-Adrenergic receptor gene
calcitonin gene-related peptide in cirrhosis, circulating CT relationship to severity of cirrhosis and, 47-52
FFM, genome-wide search for, 203-207
insulin, *see* Insulin gene
LPL, *see* Adipose tissue, LPL gene and
MTHFR, *see* Homocysteine, MTHFR gene and
NIDDM, *see* Gene(s) in NIDDM
VLDL receptor, lack of linkage between fasting serum insulin and HOMA insulin resistance index or, 293-297
see also Allele frequency; Haplotype; mRNA; Mutations; Phenotypes; Polymorphism
Gene(s) in NIDDM
GH and insulin gene regions in relation to metabolic control of NIDDM, 424-426
PPARγ2 Pro12Ala, BMI and, 1267-1270
see also Molecular analysis of NIDDM; mRNA, insulin gene; Polymorphism in NIDDM
Genetic measurement, pre- and post-endurance exercise
of DHEAS in long-term endurance exercise, 298-304
of SHBG, 1014-1020
Genetics, *see* Children; Gene(s); Genetic measurement, pre- and post-endurance exercise; Genome-wide search; Genotype; Relatives of NIDDM subjects, beta cells in healthy *and entries beginning with terms*: Familial, Heritable
Genistein in soy protein diet, 538
Genistin in soy protein diet, 538
Genome-wide search for FFM genes, 203-207
Genotype in depressive disorder, TH gene microsatellite polymorphism and, 1146, 1147
GF (growth factor), *see* Platelet-derived growth factor BB; Transforming growth factor-β_1 *and entries beginning with terms*: Insulin-like growth factor
GFR (glomerular filtration rate) in IDDM, IGFBP-2 protease activity and, 627, 629
GH, *see* Growth hormone
GHb (glycosylated hemoglobin), *see* Hb
GHb_{1c} (glycosylated hemoglobin A_{1c}), *see* HbA_{1c}
GHRH (growth hormone-releasing hormone), galanin effects on secretion of, in anorexia nervosa, 155-159
GIIS, *see* Glucose-induced insulin secretion
GK, *see* Glucokinase
Glibenclamide
effects of, on fibrinolysis of NIDDM, troglitazone effects compared with, 662-665
scavenging activity of gliclazide and, compared, S1:23-26
Gliclazide in NIDDM
once-daily administration of, S2:7-11, S2:21-25
vascular benefits of, S2:17-20
see also Gliclazide scavenging activity in NIDDM
Gliclazide scavenging activity in NIDDM, S1:14-26
clinical assessment of, S1:23-26
glibenclamide activity compared with, S1:23-26
on hydroxyl and superoxide radicals, S1:14-16
LDL oxidation, monocyte adhesion to endothelium and, S1:17-22
Gln, *see* Glutamine; Gln/Arg 192 polymorphism; Gln27Glu polymorphism of β_2-AR gene
Gln/Arg 192 polymorphism, PON1 gene, differential effects of smoking on risk of myocardial infarction according to, 557-559
Gln27Glu polymorphism of β_2-AR gene
Arg16Gly and, lack of association between obesity and, in Japanese men, 1215-1218
obesity phenotype and, and interaction between α_2-AR gene, β_3-AR gene and, 1063-1070
Globulin
cortisol-binding, morning cortisol levels, S_G and, 306, 307
sex hormone-binding, *see* Sex hormone-binding globulin
thyroxine-binding, consumption of, during CABG, 270-274
Glomerular filtration rate (GFR) in IDDM, IGFBP-2 protease activity and, 627, 629
GLP-1 (glucagon-like peptide-1), insulin secretion stimulated by, via Ca^{2+}-independent mechanisms in DM, 1579-1587
GLP-1 (glucagon-like peptide-1) receptor agonist, central versus peripheral effects of, on satiety and weight loss in NIDDM, 709-717
Glu, *see* Glutamate
Glucagon (hyperglycemic factor; hyperglycemic-glycogenolytic factor)
BCAA effects on plasma uridine not mediated by insulin or, 97-100

Glucagon (hyperglycemic factor; hyperglycemic-glycogenolytic factor) (*Continued*)
BK effects on secretion of, BK_2 receptors and, 1370-1373
fasting, in liver transplantation recipients, S_G and, 368
glucagon dose effects on glucose production and gluconeogenesis, 39-46
and glycemia after protein ingestion, 2
IP versus SC insulin effects on, in hypoglycemia of STZ-DM, 984-989
in NIDDM, JTT-501 effects on, 864
plasma, *see* Plasma glucagon
Glucagon-like peptide-1 (GLP-1), insulin secretion stimulated by, via Ca^{2+}-independent mechanisms in DM, 1579-1587
Glucagon-like peptide-1 (GLP-1) receptor agonist, central versus peripheral effects of, on satiety and weight loss in NIDDM, 709-717
Glucocorticoid receptor gene locus, polymorphism of 5′-flanking region of, associated with basal cortisol secretion in men, 1197-1199
Glucokinase (GK)
ET-1 and NO effects on activity of, in hepatocytes, 73-80
hepatic, vagotomy effects on, 14, 15
Gluconeogenesis
high- and low-dose glucagon effects on, in healthy subjects, 39-46
in lean IDDM subjects, vanadate effects on hepatic G6Pase, G6PDH, and PEPCK in, 321-325
phenylacetate effects on, 1211-1214
Glucose
blood, *see* Blood glucose
concentrations of, and effects of long-term exposure of beta cells to palmitate on insulin gene expression, 532-536
diet effects on, *see* Glucose, diet effects on
and exercise, *see* Glucose, and exercise
fasting, *see* Fasting glucose
FDP effects on, 701
glucagon effects on production of, in healthy subjects, 39-46
glycerol-1,2,3-tris(methyl[2,3^{13}C]succinate) effects on, 180
GS antisense ODN effects on, 964-966
hepatic, *see* Hepatic glucose production; Hepatic glucose uptake
in HTN, one- and two-compartment minimal model analysis of, 1529-1536
in IDDM, *see* Glucose in IDDM
and insulin resistance, *see* Glucose, and insulin resistance
intracellular mesangial cell, troglitazone effects on glycolysis and metabolism of, in 308-313
in metabolic syndrome subjects, 749
metformin and, *see* Metformin, glucose and
myocardial, in CHD, 1366
in NIDDM, *see* Glucose in NIDDM
in obesity, *see* Glucose in obesity
peripheral, fructose and, in healthy subjects, 1565-1571
phenylacetate effects on production of, 1211-1214
plasma, *see* Plasma glucose
serum leptin, sex steroid levels, insulin levels and, 1279
and SM insulin responsiveness to NA-induced changes in PC and PE FAs, 233
total, vagotomy effects on, 14
see also [U^{13}]Glucose; Glucose effectiveness; Glucose-induced insulin secretion; Glucose-6-phosphate dehydrogenase; Glucose tolerance; Glucose transport; Gold-thioglucose; Hepatic glucose-6-phosphatase; Hyperglycemia; Hypoglycemia; Insulin-mediated glucose uptake *and entries beginning with element*: Gluc-, Glyc-
[U^{13}]Glucose, vagotomy and incorporation of, into hepatic glucokinase, 15
Glucose, diet effects on
and dietary FA composition, 1182, 1183
effects of short-term variation in dietary fat and CHOs on, 1152, 1153, 1160
metabolic effects, 1112-1114
of soy protein, 1191
Glucose, and exercise
α-adrenergic antagonist effects on regulation of, during and after high-intensity exercise, 386-394
in NIDDM, *see* Glucose in NIDDM, exercise and
Glucose, and insulin resistance
glucose oxidation and insulin resistance correlated with increased SFAs in SM TGs, 222
in insulin-resistant nondiabetic lean and obese subjects, 287
postoperative glucose transport and insulin resistance in SM, 488
Glucose effectiveness (S_G)
cortisol and, *see* Cortisol, S_G and
following liver transplantation for cirrhosis, 367-372
in HTN, 1532
seasonal variation of S_i and, in men, 32-38
Glucose in IDDM
exercise effects on, 643
plasma, voglibose effects on, 441
see also Blood glucose in IDDM
Glucose-induced insulin secretion (GIIS)
ET-1 effects on, 265
loss of, in dysfunctional beta cells, elevated plasma lipid or beta cell TGs and, 755-759
in men, effects of Intralipid-induced plasma FFA elevation on basal and, 450-454
troglitazone effects on hypertriglyceridemia and patterns of, 1346-1351
Glucose intolerance
in obese Japanese adolescents with NIDDM, 186-191
see also Glucose tolerance
Glucose in NIDDM
ALC and glucose disposal, 704-708
CS-045 effects on, 1170-1171
exercise and, *see* Glucose in NIDDM, exercise and
indomethacin effects on EPG in, 839-844
JTT-501 effects on peripheral glucose uptake and NHGB, 862-867
and MTHFR gene 719, 721
see also Blood glucose in NIDDM; Fasting blood glucose in NIDDM; Glucose in NIDDM with obesity; Plasma glucose in NIDDM
Glucose in NIDDM, exercise and
BK effects on exercise-induced glucose uptake and GLUT4 translocation in SM in NIDDM, 920-930
exercise effects on, 643
Glucose in NIDDM with obesity
in Japanese adolescents, pathogenic factors of glucose intolerance in, 186-191
metformin and intermittent BDNF effects on metabolism of, compared, 129-133
thiazolidinedione effects on, 522
weight loss effects on, 1454, 1455
Glucose in obesity
in infantile obesity, 673
see also Glucose in NIDDM with obesity
Glucose-6-phosphatase, *see* Hepatic glucose-6-phosphatase
Glucose-6-phosphate dehydrogenase (G6PDH)
hepatic, vanadate effects on PEPCK, hepatic G6Pase and, in lean IDDM subjects, 321-325
in SAT, 596, 597

Glucose tolerance
impaired, *see* Impaired glucose tolerance
normal, and TH gene microsatellite polymorphism associated with insulin resistance in depressive disorder, 1145-1149
pioglitazone and CS-045 effects on, 1303
see also Intravenous glucose tolerance test; Oral glucose tolerance test
Glucose transport
postoperative, and insulin resistance in SM, 488
see also entries beginning with acronym: GLUT
α-D-Glucosidase, plasma, at onset of IDDM with obesity and during IVGTT of healthy subjects, 1352-1355
α (alpha)-Glucosidase inhibitors, beta cell mass in NIDDM reduced by, 347-352
β-D-Glucuronidase, plasma, at onset of IDDM with obesity and during IVGTT of healthy subjects, 1352-1355
GLUT1, GS antisense ODN effects on, 966
GLUT1 mRNA (messenger ribonucleic acid), GLUT3 mRNA and GLUT4 mRNA and subcellular distribution of their proteins in muscle compared with, 1604-1609
GLUT2, renal Na^+-, effects of inhibition of T-1095 with, on hyperglycemia of STZ-DM, 990-995
GLUT3 mRNA (messenger ribonucleic acid), GLUT1 mRNA and GLUT4 mRNA and subcellular distribution of their proteins in muscle compared with, 1604-1609
GLUT4
GS antisense ODN effects on, 966
SM, BK effects on exercise-induced translocation of, 920-930; *see also* mRNA, GLUT4, in SM
Glutamate (Glu)
effects of, on system A transport of MeAIB in mammary gland, 875, 876
hyperammonemia effects on metabolism of, 1332, 1333
metformin effects on, 1623
myocardial plasma, in CHD, 1366
Glutamine (Gln)
effects of, on system A transport of MeAIB in mammary gland, 875, 876
effects of dietary, on turnover of, 141-145
hyperammonemia effects on metabolism of, 1332, 1333
IV, effects of, on mixed muscle protein synthesis in healthy young men and women, 1555-1560
metformin effects on, 1623
myocardial plasma, in CHD, 1366
see also Gln/Arg 192 polymorphism; Gln27Glu polymorphism of β_2-AR gene
Glutathione, *see* Reduced glutathione
Gly, *see* Glycine
Glycation, *see* Advanced glycation end product(s) in DM; Advanced glycation end product receptors; HbA_{1c}
Glycemia
fasting, tissue S_I and beta cell contribution to, 1318-1325
see also Glycemia, S_I and; High-glycemic index starch diet; Hyperglycemia; Hypoglycemia; Normoglycemia *and entries beginning with terms*: Glycemic control
Glycemia, S_I and
S_I as predictor of glycemia after protein intake, 1-5
tissue S_I and beta cell contribution to glycemia, 1318-1325
see also Glycemic control, and oxidative stress in NIDDM; Glycemic control in IDDM; High-glycemic index starch diet; Hyperglycemia; Hypoglycemia; Normoglycemia
Glycemic control, and oxidative stress in NIDDM, S1:27-34
and CHD, S1:30-34
evaluation of oxidative stress before and after glycemic control and after vitamin E supplementation, 160-162
Glycemic control, and oxidative stress in NIDDM (*Continued*)
role of oxidative stress in, S1:27-29
see also specific antiglycemic agents
Glycemic control of IDDM
effects of, on microvascular disease and platelet function abnormalities, 88-91
oxidative stress evaluation before and after, and after vitamin E supplementation, 160-162
see also specific antiglycemic agents
Glycemic control of NIDDM
leukocyte binding by HDL_3 following weight loss and improved, 692-696
see also Glycemic control, and oxidative stress in NIDDM
Glyceraldehyde, effects of, on insulin secretion in NIDDM, 93
Glyceraldehyde-3-phosphate dehydrogenase (GADPH) mRNA (messenger ribonucleic acid) in AT, GH effects on, 240
Glycerol
in cachexic cancer subjects, 934
effects of elevated plasma FFAs on, in men, 451, 452
effects of long-term high-S diet with dexamethasone on, 1291, 1292
in lean and obese exercising men, 582-583
metformin effects on, 1621
plasma, *see* Plasma glycerol
and SM insulin responsiveness to NA-induced changes in PC and PE FAs, 233
see also Triacylglycerol, diet effects on
Glycerol 1,2,3-tris(methyl[2,3^{13}C]succinate), hepatocyte, metabolism of, 178-185
[1,3-^{13}]Glycerol-1,2,3-tris(methylsuccinate), hepatocyte, metabolism of, 178-185
Glycine (Gly)
effects of, on system A transport of MeAIB in mammary gland, 875, 876
in glutamine-containing diet, 142
IV glutamine effects on synthesis of muscle, 1556, 1557
metformin effects on, 1623
see also Arg16Gly polymorphism; Plasma glycine; D,L-Propargylglycine
Glycitein in soy protein diet, 538
Glycitin in soy protein diet, 538
Glycogen
effects of antisense ODNs of, on GS protein expression, 962-968
hepatic, *see* Hepatic glycogen
Glycogen synthase (GS) protein, insulin resistance in SM cells induced by downregulated expression of, 962-968
Glycogenolysis, and metformin effects on glucose production, 1619-1626
Glycohydrolase, plasma, at onset of IDDM with obesity and during IVGTT of healthy subjects, 1352-1355
Glycolysis, troglitazone effects on intracellular glucose metabolism and, in mesangial cells, 308-313
Glycosylated (glycated) hemoglobin, *see* HbA_{1c}
Gold-thioglucose (GTG), effects of, on insulin resistance but not hyperinsulinemia, in obesity with SM GLUT4 overexpression, 340-346
Gonadal function in hypercholesterolemic men, simvastatin and pravastatin effects on, 115-121
Gonadal steroidogenesis, high-dose simvastatin effects on adrenal and, in hypercholesterolemic men, 1234-1238
Gonadotropin, human chorionic, synergistic effects of rIGF-I and, in ovaries, 314-320
G6Pase (glucose-6-phosphatase), *see* Hepatic glucose-6-phosphatase
G6PDH, *see* Glucose-6-phosphate dehydrogenase
Growth and development *see* Postnatal growth and development

Growth factor, *see* Platelet-derived growth factor BB; Transforming growth factor β_1 *and entries beginning with terms*: Insulin-like growth factor
Growth hormone (GH)
in acute acromegaly, lanreotide effects on, 636
aging effects on, 1119, 1121
glucagon dosage effects on concentrations of, 41, 45
leptin biosynthesis and AT lipolysis regulated by, 239-244
in PEM children, 819-825
see also Growth hormone gene regions; Growth hormone secretion, GAL effects in; Growth hormone therapy effects
Growth hormone (GH) gene regions, insulin gene regions and, in relation to metabolic control of NIDDM, 424-426
Growth hormone-releasing hormone (GHRH), galanin effects on secretion of, in anorexia nervosa, 155-159
Growth hormone (GH) secretion, GAL effects in
in anorexia nervosa, 155-159
and effects of acute and chronic GAL administration on hypothalamic GAL synthesis in male and female subjects, long-loop GAL autofeedback and, 778-783
Growth hormone (GH) therapy effects
on muscle, AT HSL, and AT LPL gene during weight loss, 906-911
on VLDL apo B100 in hypopituitarism, 563-566
GS (glycogen synthase) protein, insulin resistance in SM cells induced by downregulated expression of, 962-968
GSH, *see* Reduced glutathione
GTG (gold-thioglucose), effects of, on insulin resistance but not hyperinsulinemia in obesity with SM GLUT4 overexpression, 340-346
G308A gene, *see* Tumor necrosis factor-α G308A gene polymorphism
GTT (glucose tolerance test), *see* Intravenous glucose tolerance test; Oral glucose tolerance test

Haloperidol, effects of, on plasma PRL secretion, aging and, 255-256
Haplotype, $RT1^u$, metabolic syndrome in spontaneous HTG with, 1140-1144
Hb (hemoglobin)
in cachexic cancer subjects, 934
in cirrhosis, circulating CT and, 48
in DM, *see* Hb in DM
in ESRD subjects on HD, vitamin B_{12} effects on plasma HcY and, 217
following vitamin E supplementation and before and after glycemia control, oxidative stress and, 161
in metabolic syndrome, 749, 750
in methionine-induced hyperhomocysteinemia, 225
soy protein effects on, 1191
see also entries beginning with acronym: Hb
Hb (hemoglobin) in DM
AGE product levels in liver and kidney and, 568; *see also* Hb in NIDDM
soy protein effects on, 1191
Hb (glycosylated hemoglobin) in NIDDM
following vitamin E supplementation and before and after glycemia control, oxidative stress and, 161
low-dose epinephrine effects on, 196
HbA_1 (hemoglobin A_1) in NIDDM
gliclazide and glibenclamide effects on, S1:24
in Japanese obese adolescents, glucose intolerance and, 187
see also HbA_{1c} in NIDDM
HbA_{1c} (hemoglobin A_{1c})
bezafibrate therapy effects on, 333
cerivastatin effects on, 1050
in diabetic nephropathy, *see* HbA_{1c} in diabetic nephropathy
in IGT subjects, 1319
HbA_{1c} (hemoglobin A_{1c}) (*Continued*)
in NIDDM subjects' relatives, beta cell function and, 834, 897
in STZ-DM, T-1095 effects on, 991-992
see also HbA_{1c} in IDDM; HbA_{1c} in NIDDM; HbA_{1c} in obesity
HbA_{1c} (hemoglobin A_{1c}) in diabetic nephropathy
and pulsatile IV insulin effects on diabetic nephropathy progression, 1493, 1494
serum AGE products in, 1031
HbA_{1c} (hemoglobin A_{1c}) in IDDM
exercise effects on, 643
and IGFBP-2 protease activity, 627, 629
and insulin and C-peptide effects on RBC Na/K ATPase, 869
in nocturnal hypoglycemia associated with intensive insulin therapy, 441
TGs, BMI and, 1002, 1003
HbA_{1c} (hemoglobin A_{1c}) in NIDDM
bezafibrate therapy effects on, 332, 333
and BK effects on exercise-induced glucose uptake and GT4 translocation in SM, 923
carotid IMT and, 719, 721
exercise effects on, 643
with fibrinolysis, troglitazone effects on, 665
GH and insulin gene regions and, 425
HDL_3 binding to leukocytes and, 691
leptin and apo E polymorphism and, 725, 726
and metabolic effects of $VOSO_4$, 400-410
with nephropathy, TGF-β_1 activation and, 355
with PPARγ2 Pro12Ala gene, 1268, 1269
TNF-α G308A gene polymorphism and, 1617
see also HbA_{1c} in NIDDM with obesity
HbA_{1c} (hemoglobin A_{1c}) in NIDDM with obesity
in Japanese adolescents, glucose intolerance and, 187
weight loss effects on, 1454, 1455
HbA_{1c} (hemoglobin A_{1c}) in obesity
in rheological disorders, skin vasoconstrictive response to sympathetic activation and, 601
see also HbA_{1c} in NIDDM with obesity
hCG (human chorionic gonadotropin), synergistic effects of rIGF-I and, in ovaries, 314-320
HCL, *see* Hypercholesterolemia
HCTZ (hydrochlorothiazide), effects of furosemide and, on BMSCs, compared, 17-21
HcY, *see* Homocysteine, MTHFR gene and
HD (hemodialysis) for ESRD, vitamin B_{12} effects on plasma HcY in subjects on, 215-219
HDL, *see* High-density lipoprotein
HDL-C, *see* High-density lipoprotein-cholesterol
Healthy pregnancy, relationship of leptin to serum insulin and insulin sensitivity during and after preeclamptic and, 259-263
Healthy (normal) subjects
diet effects in, *see* Healthy subjects, diet effects in
exercising, *see* Healthy subjects, exercising
FDP in, 698-703
furosemide effects on plasma and urinary excretion of purine bases, adenosine, and uridine, 886-889
galanin effects on GH and PRL secretion in, 155-159
glucagon in, *see* Healthy subjects, glucagon in
GSH synthesis in response to methionine in, 1434-1439
GTT of, *see* Healthy subjects, GTT of
hyperinsulinemic hypoglycemia in, effects of oral glucose on systemic glucose metabolism during, 1598-1603
hypothermic response to hypoglycemia in, 794-798
IMGU in, *see* Healthy subjects, IMGU in
insulin regulation of splanchnic and renal substrate supply in, 676-683

Healthy (normal) subjects (*Continued*)
insulin-resistant, *see* Healthy subjects, insulin-resistant
insulin secretion in, *see* Healthy subjects, insulin secretion in
insulin sensitivity in, *see* Healthy subjects, insulin sensitivity in
IV glutamine effects on synthesis of mixed muscle proteins in, 1555-1560
lipolysis and lipid oxidation in, 931-936
morning levels of cortisol in, S_G and, 305-307
^{31}P-MRS of D-tagatose effects on liver metabolism in, 1335-1339
peripheral, *see* Peripheral glucose
plasma galactose and galactitol concentrations in nongalactosemic, 1460-1466
plasma leptin in, *see* Plasma leptin in healthy subjects
skin vasoconstrictive response to sympathetic activation in, 600-606
SM of, *see* Healthy subjects, SM of
stanol ester effects on PP squalene and retinyl palmitate in, 473-478
subcutaneous central AT and risk of CV disease in, 1379-1385
T_3 effects on ROS in, 799-803
T_4 and TBG effects in, during sepsis, 753-754
D-tagatose effects in, 969-976
TEF in, *see* Healthy subjects, TEF in, and body composition
TGs in, *see* Healthy subjects, TGs in
tyrosine effects on Phe hydroxylation in, 444-449
Ultralente insulin effects on fasting and postbreakfast beta cell function in, 1243-1246
urea cycle in, 621-625
see also Men; Relatives of NIDDM subjects, beta cells in healthy; Women
Healthy (normal) subjects, diet effects in
LF diet effects on blood lipids, FVIIc, and fibrinogen in, 731-735
urinary excretion and concentration of serum mevalonic acid during acute alcohol intake by, 62-66
Healthy (normal) subjects, exercising
BK effects on glucose uptake and GLUT4 translocation in SM and, 920-930
blood lipid response to cycle-ergometer exercise in, 513-520
DHEAS measurement before and after long-term endurance exercise by, 298-304
SHBG measurement before and after exercise, 1014-1020
Healthy (normal) subjects, glucagon in
BCAA effects on plasma uridine not mediated by glucagon or insulin in, 97-100
glucagon dosage effects on glucose production and gluconeogenesis in, 39-46
Healthy (normal) subjects, GTT of
FSIVGTT, 367-372
plasma glycohydrolase during IVGTT of, 1352-1355
Healthy (normal) subjects, IMGU in
with relatively low plasma Mg concentrations, 418-420
SNP effects on insulin-mediated blood flow and IMGU in, 373-378
Healthy (normal) subjects, insulin-resistant
insulin resistance in SM cells of, induced by GS protein expression downregulation, 962-968
with muscle insulin resistance, insulin regulation of plasma FFAs in, 151-154
plasma NO in, 959-961
SFAs in SM TGs and, 220-224
Healthy (normal) subjects, insulin secretion in
inhibitory effects of insulin and hypoglycemia on, 950-953
Intralipid infusion effects on basal insulin secretion or GIIS in, 450-454
Healthy (normal) subjects, insulin sensitivity in
insulin sensitivity as predictor of glycemia following protein ingestion, 1-5
Healthy (normal) subjects, insulin sensitivity in (*Continued*)
tissue insulin sensitivity and beta cell contribution to glycemia in, 1318-1325
Healthy (normal) subjects, SM of
GS protein expression in SM, 962-968
HKII expression in SM, 814-818
NA-induced changes in PC and PE FAs associated with SM insulin responsiveness in, 232-238
Healthy (normal) subjects, TEF in, and body composition
kinetics of TEF and its relationship to body composition in, 1340-1345
PP RMR and TEF relationship to body composition and AT distribution in, 6-10
Healthy (normal) subjects, TGs in
SFAs in SM TGs, insulin resistance and, 220-224
TG concentration and relationship between HDL-C, apo B, and apo A-I levels, 53-61
Heart
SERP-1 distribution to, 1452
TNF-α in, 1313, 1314
see also Coronary heart disease; Heart failure; Heart rate; Left ventricular hypertrophy *entries beginning with term*: Heart *and elements*: Card-, Myocard-
Heart failure, interaction between ANP and BNP metabolic clearance in, 1228-1233
Heart rate (HR)
in acute acromegaly, lanreotide effects on, 636
in Cushing's syndrome, 761
of insulin-resistant healthy subjects, 960
in obesity, HTN and, 1525
of older hypertensive subjects with LVH, 1357
SNP effects on, 374
see also Heart rate in exercise; Heart rate in NIDDM
Heart rate (HR) in exercise
α-adrenergic antagonist effects on, 387
by IDDM and NIDDM subjects, 642
by lean and obese men, and postexercise lipolytic response to β-adrenergic receptor stimulation, 580, 581
Heart rate (HR) in NIDDM
in exercising subjects, 642
low-dose epinephrine effects on, 198
Height
of exercising men, *see* Height of exercising men
and insulin resistance correlation with increased SFAs in SM TGs, 221
and kinetics of TEF, 1342
of NIDDM subjects' children, insulin sensitivity and, 1220
of PEM subjects, 820
of postmenopausal women, effects of estrogen alone or estrogen with progestin and, 785
and seasonal variation of S_I and glucose effectiveness in men, 33
serum leptin, body composition and, 1279
of 10-to-15-year-old boys, race and estradiol and estrogen effects on lipids in, race and, 1125, 1126
thermic response of young and older women to caffeine and, 103
and tyrosine effects on Phe hydroxylation, 445
Height of exercising men
AT metabolism and, 123
high-intensity exercise, 387
lean and obese, and post-exercise stimulation of lipolytic response to β-AR, 580
Hemodialysis (HD) for ESRD, vitamin B_{12} effects on plasma HcY in subjects on, 215-219
Hemoglobin, *see* Hb
Heparin, *see* Postheparin lipase activity

Hepatic blood flow (BF)
metformin effects on, 1621
in NIDDM, JTT-501 effects on, 864-865
Hepatic cholesterol (C), aging and content of, in HHL, 553
Hepatic glucokinase (GK), vagotomy effects on, 14, 15
Hepatic glucose
chronic intraperitoneal insulin effects on uptake of, in STZ-DM, 1411-1416
JTT-501 effects on NHGB and peripheral glucose uptake, 862-866
role of hepatic vagus nerve in production and uptake of, 11-18
Hepatic glucose-6-phosphatase (G6Pase)
PAT5A effects on, 1420
vanadate effects on PEPCK, hepatic G6PDH and, in lean IDDM subjects, gluconeogenesis and, 321-325
Hepatic glucose-6-phosphatase (G6Pase) system, microsomal, ontogeny of G6Pase transporter proteins and catalytic subunit p36 of, 1200-1203
Hepatic glucose-6-phosphate dehydrogenase (G6PDH), vanadate effects on PEPCK, hepatic G6Pase and, in lean IDDM subjects, gluconeogenesis and, 321-325
Hepatic glucose production (HGP), role of hepatic vagus nerve in, 11-18
Hepatic glucose uptake
JTT-501 effects on NHGB and peripheral glucose uptake, 862-866
role of hepatic vagus nerve in HGP and, 11-18
Hepatic glycogen
vagotomy effects on, 14, 15
vanadate effects on stores of, in lean IDDM subjects, 322
Hepatic insulin, glucagon effects on concentrations of, dosage and, 41
Hepatic methylenetetrahydrofolate (MTHFR) mRNA (messenger ribonucleic acid), CβS and, and effects of HF diet with sucrose on metabolism of, 736-741
Hepatic phosphoenolpyruvate carboxykinase (PEPCK), vanadate effects on hepatic G6Pase, hepatic G6PDH and, in lean IDDM subjects, gluconeogenesis and, 321-325
Hepatic vagus nerve, role of, in HGP and liver glucose uptake, 11-18
Hepatocyte(s)
effects of ω3-PUFAs and chronic ethanol consumption on C uptake by, 510-511
ET-1 and NO effects on GK activity in, 73-80
glycerol-1,2,3-tris(methyl[2,3^{13}C]succinate) and [1,3-^{13}]glycerol-1,2,3-tris(methylsuccinate) metabolism in, 178-185
Hepatocyte nuclear factor 1α (HNF1α) *TCF1* gene in African Americans with familial NIDDM, molecular analysis of, 280-284
Heredity, *see* Children; Gene(s); Genetic measurement, pre- and post-endurance exercise; Genome-wide search; Genotype; Relatives of NIDDM subjects, beta cells in healthy *and entries beginning with terms*: Familial, Heritable
Heritable hyperlipidemia, homozygous, aging effects on C metabolism and plasma C in, 552-556
Hexokinase II (HKII), expression of, in SM, 814-818
Hexose in mesangial cells, troglitazone effects on uptake and consumption of, 309-310
HF, *see* High-fat diet
HGP (hepatic glucose production), role of hepatic vagus nerve in, 11-18
HHL (homozygous heritable hyperlipidemia), aging effects on C metabolism and plasma C in, 552-556
High-density lipoprotein (HDL; α-lipoprotein)
of alcoholics, impaired RTC in, 1406-1410
C efflux from TD and normal fibroblasts into plasmas deficient in, 770-777
in hypercholesterolemic men, simvastatin and pravastatin effects on, 117
insulin resistance effects on, in nondiabetic lean and obese women, 285-292
High-density lipoprotein (HDL; α-lipoprotein) (*Continued*)
see also High-density lipoprotein in NIDDM; High-density lipoprotein-cholesterol; High-density lipoprotein$_3$; Lipoprotein(a); Serum high-density lipoprotein
High-density lipoprotein (HDL; α-lipoprotein) in NIDDM
and carotid IMT, 719, 721
with dyslipidemia, effects of Western diet on particle size of, 27-28
effects of weight loss by obese subjects on subfraction distribution of, 1453-1459
see also Serum high-density lipoprotein-cholesterol in NIDDM
High-density lipoprotein-cholesterol (HDL-C)
in atherosclerosis, *see* High-density lipoprotein-cholesterol, atherosclerosis and
cerivastatin effects on, 1050
diet effects on, *see* High-density lipoprotein-cholesterol, diet effects on
exercise and, *see* High-density lipoprotein-cholesterol, exercise and
in hyperlipidemia, 1628
in hypopituitarism, GH therapy effects on, 565, 566
insulin resistance and, *see* High-density lipoprotein-cholesterol, insulin resistance and
and lack of linkage between VLDL receptor gene and fasting serum insulin, 294
and LPL gene, 434, 435
in metabolic syndrome, 749, 1023
in nephrotic syndrome, NO-1886 effects on, 589
in NIDDM, *see* High-density lipoprotein-cholesterol in NIDDM
in normolipidemia, 1208
in obesity, *see* High-density lipoprotein-cholesterol in obesity
and plasma viscosity in HCL, 811
in postmenopausal women on estrogen alone or estrogen with progestin, 785, 787
in premenopausal women, 1103
and RBC FA composition, 1165
serum, *see* Serum high-density lipoprotein-cholesterol
subcutaneous central AT, risk of CV disease and, 1380, 1383
in TD, 771
in 10-to-15-year-old boys, race and variation in, 1126, 1127
TGs and, *see* High-density lipoprotein-cholesterol, TGs and
see also High-density lipoprotein$_2$-cholesterol; High-density lipoprotein$_3$-cholesterol; High-density lipoprotein$_4$-cholesterol; High-density lipoprotein$_5$-cholesterol; Lipoprotein(a)-cholesterol
High-density lipoprotein-cholesterol (HDL-C), atherosclerosis and
and LDL oxidation, 1272
and risk of atherosclerosis after pancreas transplantation, 463
High-density lipoprotein-cholesterol (HDL-C), diet effects on
effects of variation in CHOs and HDL-C, 1152
of LF diet with sucrose and starchy foods, 733
see also High-density lipoprotein-cholesterol, soy effects on
High-density lipoprotein-cholesterol (HDL-C), exercise and
exercise effects on HDL-C, 829
in IDDM, and HDL-C modifications, 643
plasma HDL-C response to cycle-ergometer exercise, 516, 517
High-density lipoprotein-cholesterol (HDL-C), insulin resistance and
CV risk factors and, 1248, 1249, 1251
in healthy subjects, 960
HOMA insulin resistance index and, 294
and TNF-α gene polymorphism, 1507, 1508
High-density lipoprotein-cholesterol (HDL-C), soy effects on
on arterial LDL, 1191
of soy-based breakfast cereal, 1498
High-density lipoprotein-cholesterol (HDL-C), TGs and
BMI and, 1002, 1003
TG concentration and relationship between apo B and apo A-I level and, 53-61

High-density lipoprotein-cholesterol (HDL-C), TGs and (*Continued*)
see also High-density lipoprotein-cholesterol in HTG
High-density lipoprotein-cholesterol (HDL-C) in HTG
in FHTG, 944-946
and plasma viscosity, 811
High-density lipoprotein-cholesterol (HDL-C) in NIDDM
apo E polymorphism, leptin and, 725, 726, 728
effects of high-monounsaturated fat diet and olive oil diet on, 1513, 1514
exercise effects on, 643
with fibrolysis, troglitazone effects on, 663
TNF-α G308A gene polymorphism and, 1617
weight loss effects by obese NIDDM subjects on, 1454
High-density lipoprotein-cholesterol (HDL-C) in obese women
in insulin-resistant obese nondiabetic women, 287, 289
moderately obese women, effects of regular moderate wine consumption on HDL-C in, 1475
prevalence of paradoxically normal serum cholesterol in, 608, 610
High-density lipoprotein-cholesterol (HDL-C) in obesity
GH therapy, weight loss and, 907
HTN and, 1525
and interaction between α_2-, β_2-, and β_3-AR genes and obesity phenotype, 1067, 1068
lack of association between β_2-AR gene and, 1215
skin vasoconstrictive response to sympathetic activation and, 601
weight loss effects by obese NIDDM subjects, 1454
see also High-density lipoprotein-cholesterol in obese women
High-density lipoprotein cholesteryl ester (HDL CE), plasma, exercise effects on, 826-832
High-density lipoprotein$_1$, *see* Lipoprotein(a)
High-density lipoprotein$_1$-cholesterol (HDL_1-C; Lp(a)-C), effects of regular moderate wine consumption by moderately obese women on, 1475
High-density lipoprotein$_2$-cholesterol (HDL_2-C)
effects of regular moderate wine consumption by moderately obese women on, 1475
fasting serum, variation in NIDDM and CHD risk and, 248, 249
insulin resistance, CV risk factors and, 1248, 1249, 1251
and LPL gene, 434, 435
plasma, response of, to cycle-ergometer exercise, 516
High-density lipoprotein$_3$ (HDL_3)
leukocyte binding to, following weight loss and improved glycemic control in NIDDM, 692-697
see also High-density lipoprotein$_3$-cholesterol
High-density lipoprotein$_3$-cholesterol (HDL_3-C)
effects of regular moderate wine consumption by moderately obese women on, 1475
fasting serum, variation in NIDDM and CHD risk and, 248
insulin resistance, CV risk factors and, 1248, 1249, 1251
and LPL gene, 434, 435
plasma, response of, to cycle-ergometer exercise, 516
High-density lipoprotein$_4$-cholesterol (HDL_4-C), effects of regular moderate wine consumption by moderately obese women on, 1475
High-density lipoprotein$_5$-cholesterol (HDL_5-C), effects of regular moderate wine consumption by moderately obese women on, 1475
High-dose glucagon (hyperglycemic factor; hyperglycemic-glycogenolytic factor), effects of, on glucose production and gluconeogenesis in healthy subjects, 39-46
High-dose simvastatin, effects of, on adrenal and gonadal steroidogenesis, 1234-1238
High-fat (HF) diet
effects of, on diurnal variation in plasma leptin concentrations, 503-507
High-fat (HF) diet (*Continued*)
effects of insulin resistance induced by, on IAAP and insulin mRNA, 1518-1522
high-monounsaturated fat diet, effects of olive oil diet and, on metabolic profile in NIDDM, high-CHO diet effects compared with, 1511-1517
with sucrose, effects of, on MTHFR mRNA and CβS in HcY metabolism, 736-741
High-glycemic index starch diet, chronic, leptin regulation by, 764-769
High-intensity exercise by men
α-adrenergic antagonist effects on glucose regulation during and after, 386-394
AT metabolism during, 122-128
High-monounsaturated fat diet, effects of olive oil diet and on metabolic profile in NIDDM, effects of high-CHO diet compared with 1511-1517
High-performance liquid chromatography (HPLC) of agouti-related protein(83-132) BBB crossing, 1444-1449
High-sucrose diet, *see* Sucrose-rich diet
Histidine (His)
effects of, on system A transport of MeAIB in mammary gland, 875, 876
in glutamine-containing diet, 142
hyperammonemia effects on metabolism of, 1332
IV glutamine effects on synthesis of muscle, 1556, 1557
Histology and histopathology
nephrotic syndrome, NO-1886 effects on, 589
see also Histology and histopathology of NIDDM *and specific conditions*
Histology and histopathology of NIDDM
of liver and pancreas, restricted diet and, 111-112
with obesity, reversal and prevention of abnormalities in, with CS-045, 1167-1175
HIT-T15 cells, glucose-dependent effects of palmitate on insulin gene expression in, 532-536
HIV (human immunodeficiency virus) infection, calciotropic hormones in, and bone metabolism, 1134-1139
HKII (hexokinase II), expression of, in SM, 814-818
HMG-CoA reductase, *see* 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase
HNF1α (hepatocyte nuclear factor 1α) *TCF1* gene in African Americans with familial NIDDM, molecular analysis of, 280-284
HOMA insulin resistance index, *see* Homeostasis model assessment insulin resistance index
Homeostasis model assessment (HOMA) insulin resistance index
in depressive disorder, 1145-1149
in Japanese subjects, *see* Homeostasis model assessment insulin resistance index in Japanese subjects
lack of linkage between VLDL receptor gene and fasting serum insulin VLDL receptor or, 293-297
in metabolic syndrome, 748-750
Homeostasis model assessment (HOMA) insulin resistance index in Japanese subjects
obese subjects, 1215
with TNF-α gene polymorphism, 1507, 1508
Homocysteine (HcY), MTHFR gene and
effects of HF diet with sucrose on metabolism of hepatic MTHFR mRNA, CβS and, 736-741
MTHFR gene 677C → T mutation effects on plasma HcY response to folate intake by elderly women, 1440-1443
in NIDDM, lack of association between carotid IMT, MTHFR gene polymorphism, or serum HcY, 718-723
plasma, *see* Plasma homocysteine
see also Hyperhomocysteinemia

Homocystinuria due to CβS deficiency, methionine transamination in, 1071-1077
Homoserine, effects of, on system A transport of MeAIB in mammary gland, 875, 876
Homozygous heritable hyperlipidemia (HHL), aging effects on plasma C and C metabolism in, 552-556
Hong Kong Chinese, normoglycemic, obesity independent of insulin resistance in, as blood pressure determinant, 1523-1528
Hormone replacement therapy (HRT)
with estrogen alone or estrogen with progestin in postmenopausal women with or without hypercholesterolemia, 784-789
with oral or transdermal 17β-estradiol with cyclical oral NETA, effects of, on insulin secretion, sensitivity, and elimination, 742-747
relationship between serum leptin, sex steroid levels, body composition, insulin levels and, 1278-1284
Hormone-sensitive lipase (HSL) gene, regulation of LPL and, in AT and muscle by GH therapy during weight loss in obesity, 906-911
HP (hypopituitarism), GH therapy effects on turnover of VLDL-apo B100 in, 563-566
HPLC (high-performance liquid chromatography) of agouti-related protein(83-132) BBB crossing, 1444-1449
HPT (hyperparathyroidism), parathyroid adenoma in primary, effects of excision of, on levels of IL-6 and IL-2Rs, 192-194
HR, *see* Heart rate
HRT, *see* Hormone replacement therapy
HSL (hormone-sensitive lipase) gene, GH therapy effects on LPL and, in AT and muscle during weight loss in obesity, 906-911
HTG, *see* Hypertriglyceridemia
HTN, *see* Hypertension
Human chorionic gonadotropin (hCG), synergistic effects of rIGF-I and, in ovaries, 314-320
Human growth hormone, *see* Growth hormone
Human immunodeficiency virus (HIV) infection, calciotropic hormones in, and bone metabolism, 1134-1139
HUMTH101 (tyrosine hydroxylase gene microsatellite), polymorphism of, associated with insulin resistance in depressive disorder, 1145-1149
Hydralazine, effects of vasodilation with, on ATBF in lean and obese exercising men, 583
Hydrochlorothiazide (HCTZ), effects of furosemide and, on BMSCs, compared, 17-21
Hydrocortisone, *see* Cortisol
Hydrolase, plasma glycohydrolase at onset of IDDM with obesity and during IVGTT of healthy subjects, 1352-1355
β-Hydroxy-5-androsten-17-one, *see* Dehydroepiandrosterone
Hydroxybutyrate, plasma FFA effects on, in men, 452, 453
β (beta)-Hydroxybutyrate, serum, correlation between apo A-I mRNA and, 1574-1575
3-Hydroxybutyrate, effects of variation in dietary fat and CHOs on, 1152
N-(2-Hydroxyethyl)-nicotinamide nitrate (nicorandil), scavenging activity of, on free radicals and LPO in STZ-DM, 427-431
Hydroxyl free radicals, gliclazide effects on, S1:14-16
Hydroxylase, polymorphism of tyrosine hydroxylase gene microsatellite associated with insulin resistance in depressive disorder, 1145-1149
7α (alpha)-Hydroxylase, C, aging and activity of, in HHL, 553-554
Hydroxylation, Phe, tyrosine effects on, in men, 444-449
3-Hydroxy-3-methyl-glutaryl coenzyme A reductase (HMG-CoA)
activity of, in homozygous heritable hyperlipidemia, 553
inhibitors of, *see* Atorvastatin; Cerivastatin; Pravastatin; Simvastatin effects in hypercholesterolemic men
Hydroxyproline, effects of, on system A transport of MeAIB in mammary gland, 875, 876
25-Hydroxyvitamin D in young women using OCs, 1079
Hyperammonemia, effects of, on leucine and protein metabolism, 1330-1334
Hypercatabolism, ubiquitin-proteasome pathway in muscle proteolysis and, 689-691
Hypercholesterolemia (HCL)
fibrinogen and Lp contribution to plasma viscosity in, 810-813
postmenopausal women on estrogen alone or estrogen with progestin with or without, 784-789
see also Hypercholesterolemic men
Hypercholesterolemic men
pravastatin effects on gonadal function in, 115-121
simvastatin effects on, *see* Simvastatin effects in hypercholesterolemic men
Hyperglycemia
leptin release by AT in, 807
in NIDDM, YM440 normalizing, without AT weight change, pioglitazone and troglitazone effects compared with, 411-417; *see also* Non-insulin-dependent diabetes mellitus
oxidative stress and, S1:27
in STZ-DM, T-1095 effects on, 990-995 *see also* Streptozotocin-induced diabetes mellitus
see also Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; *and entries beginning with terms*: Glycemic control
Hyperglycemic factor, *see* Glucagon
Hyperhomocysteinemia
in ESRD subjects on HD, vitamin B_{12} effects on, 215-219
methionine-induced, peroxidation indices and total plasma antioxidant capacity in, 225-228
Hyperinsulinemia
effects of, on myocardial BCAA uptake in CHD, 1365-1369
effects of dietary FA composition on lipolytic β_3-adrenergic agonist response to, in adipocytes of pregnant and nonpregnant subjects, 1180-1187
IGT and, and plasma leptin in women, 1055-1062
see also Hyperinsulinemia in obesity
Hyperinsulinemia in obesity
and LPL activity in obese STZ-DM subjects, 134-140
with SM GLUT4 overexpression, lack of GTG effects on, 340-346
Hyperinsulinemic hypoglycemia in healthy subjects, effects of oral glucose on systemic glucose metabolism during, 1598-1603
Hyperleptinemia, *see* Leptin
Hyperlipidemia
familial combined, Lp phenotype and insulin resistance in, 1627-1631
heritable homozygous, aging effects on C metabolism and plasma C in, 552-556
soy protein effects on LDL oxidation and sex hormone receptor activity in, 537-543
see also Hypercholesterolemia; Hypertriglyceridemia
Hypermethioninemia
S-adenosylmethionine and choline measurement in, 1542-1547
methionine transamination in, 1074
Hyperparathyroidism (HPT), parathyroid adenoma in primary, effects of excision of, on levels of IL-6 and IL-2Rs, 192-194
Hyperplasia, congenital adrenal, lipids in, 790-793
Hypertension (HTN)
bone turnover in, 1130-1133
effects of antihypertensive therapy and, on fasting FFAs, SNS role in, 81-87
insulin resistance, CV risk factors and, 1248
kinetics of TEF in, 1342, 1344
one- and two-compartment minimal model analysis of glucose metabolism in, 1529-1536

Hypertension (HTN) (*Continued*)
temocapril effects on LVH and BNPs in elderly subjects with, 1356-1360
see also Blood pressure
Hyperthyroidism, serum leptin and, 1285-1288
Hypertriglyceridemia (HTG)
atorvastatin effects on lipid distribution, apo distribution and composition in, 167-177
CS-045 effects on GIIS patterns and, 1346-1351
F-induced, masoprocol effects on, 1106-1110
familial, VLDL apo E and platelet function in, 942-949
fibrinogen and Lp contribution to plasma viscosity in, 810-813
in NIDDM, *see* Hypertriglyceridemia in NIDDM
in obesity, *see* Hypertriglyceridemia in obesity
spontaneous, with RT1^u haplotype, metabolic syndrome in, 1140-1144
Hypertriglyceridemia (HTG) in NIDDM
with obesity, insulin effects on, 1424-1430
restricted food intake effects on NIDDM and HTG, 108-114
Hypertriglyceridemia (HTG) in obesity
with NIDDM, insulin effects on, 1424-1430
with and without ventromedial hypothalamus lesions, JTT-501 effects on, 574-578
Hypertrophy, left ventricular, temocapril effects on circulating BNPs and, in hypertensive elderly subjects, 1356-1360
Hypoglycemia
hyperinsulinemic, in healthy subjects, effects of oral glucose on systemic glucose metabolism during, 1598-1603
hypothermic response to, after antecedent hypoglycemia, 794-798
insulin and, *see* Hypoglycemia, insulin effects on
nocturnal, in IDDM subjects on intensive insulin therapy, effects of pre-evening meal voglibose on, 440-443
Hypoglycemia, insulin effects on
inhibitory effects of insulin and hypoglycemia on insulin secretion, 950-953
IP versus SC insulin effects on glucose and glucagon in, 984-989
Hypopituitarism (HP), GH therapy effects on turnover of VLDL-apo B100 in, 563-566
Hypothalamic galanin (GAL), effects of acute and chronic GAL administration on synthesis of, in male and female subjects, long-loop GAL autofeedback and, 778-783
Hypothalamic leptin receptor mRNA (messenger ribonucleic acid) and protein, leptin resistance and downregulation of, 1479-1484
Hypothalamic lesions in HTG with obesity, effects of JTT-501 on, 574-578
Hypothermic response to hypoglycemia, 794-798
Hypothyroidism, plasma CETP in infants with, thyroid hormones in, 1176-1179
Hypoxanthine, *see* Plasma hypoxanthine

IAAP (islet amyloid polypeptide; amylin), effects of HF diet-induced insulin resistance on insulin mRNA and, 1518-1522
IAT, *see* Intraabdominal adipose tissue in NIDDM
IBAT, *see* Intercapsular brown adipose tissue
IDDM, *see* Insulin-dependent diabetes mellitus
IDL (intermediate-density lipoprotein) in NIDDM, HDL_3 binding to leukocytes and, 691
IDL-C (intermediate-density lipoprotein-cholesterol), and plasma viscosity in HCL or HTG, 811
IGF, *see entries beginning with terms*: Insulin-like growth factor
IGFBP, *see entries beginning with terms*: Insulin-like growth factor-binding protein
IGT, *see* Impaired glucose tolerance
IL-2Rs (interleukin-2 receptors), effects of parathyroid adenoma excision in primary hyperparathyroidism on levels of IL-6 and, 192-194
IL-6, *see* Interleukin-6
IL-11 (interleukin-11), HCTZ and furosemide effects on production of, 18-19
Ile, *see* Isoleucine
IMGU, *see* Insulin-mediated glucose uptake
Immunochemistry of liver and kidney, AGE product levels in DM, 567-573
Immunoreactive endothelins (irETs), SNP effects on, 374, 375
Impaired glucose tolerance (IGT)
hyperinsulinemia and, and plasma leptin in women, 1055-1062
insulin resistance, CV risk factors and, 1248
kinetics of TEF in, 1342
tissue insulin sensitivity and beta cell contribution to, 1318-1325
Impedance analysis, bioelectrical, determination of body composition of underweight chronic gastrointestinal disease subjects with DXA, SF, TBW-^3H_2O and, compared, 360-366
IMT (intima-media thickness), carotid, in NIDDM, lack of association between MTHFR gene polymorphism, serum HcY or, 718-723
Indomethacin, effects of, on insulin secretion and glucose in NIDDM, 839-844
Infant(s)
hypothyroidic, thyroid hormones and plasma CETP in, 1176-1179
see also Infantile obesity; Postnatal growth and development
Infantile obesity, risk of atherothrombosis and, 672-675
Infarction, myocardial, differential effects of smoking on risk of, according to Gln/Arg 192 polymorphism of PON1 gene, 557-559
Inheritance, *see* Children; Gene(s); Genetic measurement, pre-and post-endurance exercise; Genome-wide search; Genotype; Relatives of NIDDM subjects, beta cells in healthy *and entries beginning with terms*: Familial, Heritable
Injury, *see* Trauma and injury
Inorganic phosphate (orthophosphate; P_i), BCAA effects on, not mediated by glucagon or insulin, 98, 99
Inositol phosphate, insulin secretion, PLC isozymes, α-KIC and, in pancreatic islets, 1156-1163
Insulin
BCAA effects on plasma uridine not mediated by glucagon or, 97-100
diet effects on, *see* Insulin, diet effects on
effects of, on aortic endothelial cell NOS, 147-150
effects of oral or transdermal 17β-estradiol with cyclical oral NETA on, in postmenopausal women, 742-747
fasting, *see* Fasting insulin
glucagon dosage effects on concentrations of, 41, 45
and leptin, *see* Insulin, and leptin
masoprocol effects on, in F-induced HTG, 1107
in obesity, *see* Insulin in obesity
oxidative stress effects on action of, S1:27
in PEM children, 819-825
pioglitazone and CS-045 effects on, 1303
plasma, *see* Plasma insulin
renal and splanchnic substrate supply regulation by, 676-683
serum, *see* Serum insulin
SM and, *see* Skeletal muscle, insulin and
Ultralente, effects of, on fasting and postbreakfast beta cell function in healthy subjects, 1243-1246
vagotomy effects on, 13
in young women on OCs, 1079
see also Hyperinsulinemia; Insulin-dependent diabetes mellitus; Insulin gene; Insulin-mediated glucose uptake; Insulin mRNA; Insulin receptor substrate-1, PI 3K and; Insulin release and secretion; Insulin resistance; Insulin sensitivity; mRNA, insulin; Non-insulin-dependent diabetes mellitus; Preproinsulin *and entries beginning with terms*: Insulin-like growth factor

Insulin, diet effects on
and dietary FA composition in pregnant and nonpregnant subjects, 1182, 1183
effects of short-term variation in dietary fat and CHOs on insulin, 1152, 1153
on nutrient and insulin metabolism in mesenteric lymph node cells, splenocytes and pancreatic islets, 1111-1117
role of dietary changes and, at weaning, in regulation of intestinal galactosyltransferase activity during postnatal development, 526-531
soy protein effects, 1191
Insulin, and leptin
leptin relationship to S_I and serum insulin during and after preeclamptic and healthy pregnancy, 259-263
relationship between serum leptin, sex steroids, and insulin levels, 1278-1284
short-term exercise effects on leptin and, 858-861
see also Insulin, and leptin in AT
Insulin, and leptin in AT
GH and, and leptin biosynthesis in AT, 240-242
isoproterenol and insulin stimulating leptin release by AT, 804-809
Insulin-dependent diabetes mellitus (IDDM; type 1 diabetes mellitus)
exercise effects on Lp(a) and LDL modifications in, 640-647
gluconeogenesis in lean subjects with, vanadate effects on hepatic G6Pase, hepatic G6PDH, and PEPCK in, 321-325
glycemic control in, *see* Glycemic control in IDDM
insulin and C-peptide effects on RBC Na/K ATPase in, 868-872
intensive insulin therapy for, and effects of pre-evening meal voglibose on nocturnal hypoglycemia of, 440-443
with obesity, plasma glycohydrolase at onset of, 1352-1355
serum and urinary IGFBPs and IGFBP-2 protease activity in, 626-633
Insulin gene
GH gene regions and regions of, in relation to metabolic control of NIDDM, 424-426
see also mRNA, insulin gene
Insulin-like growth factor-I (IGF-I)
and IGFBP-2 protease activity in IDDM, 626-633
metabolic effects of insulin and, in endotoxemia during TPN, 611-615
in obesity, GH therapy, weight loss and, 907
in PEM children, 819-825
synergistic effects of hCG and, in ovaries, 314-320
Insulin-like growth factor-II (IGF-II), and IGFBP-2 protease activity in IDDM, 626-633
Insulin-like growth factor-binding protein(s) (IGFBP)
serum, *see* Serum insulin-like growth factor-binding proteins
urinary, and IGFBP-2 protease activity in IDDM, 626-633
Insulin-like growth factor-binding protein-2 (IGFBP-2) protease, serum and urinary IGFBPs and activity of, in IDDM, 626-633
Insulin-mediated glucose uptake (IMGU)
in healthy subjects with relatively low plasma Mg concentrations, 418-420
SNP effects on insulin-mediated skeletal blood flow and, in the elderly, 373-378
Insulin in obesity
GH therapy, weight loss and, 907
infantile obesity, 673
see also Hyperinsulinemia in obesity
Insulin receptor substrate-1 (IRS-1), PI 3K and
aging and decrease in, in SM, exercise effects on, 954-958
effects of preoperative feeding on activity of, 486-491
Insulin release and secretion
aging effects on, 1118-1123
CV risk factors and impaired, 1247-1254
Insulin release and secretion (*Continued*)
in DM, stimulated by GLP-1 via Ca^{2+}-independent mechanisms, 1579-1587; *see also* Insulin release and secretion in NIDDM
effects of oral or transdermal 17β-estradiol with cyclical oral NETA on, in postmenopausal women, 742-747
ET-1-potentiated, ET_A and PKC in, 264-269
glucose-induced, *see* Glucose-induced insulin secretion
inositol phosphate, PLC isozymes, α-KIC and, in pancreatic islets, 1156-1163
insulin and hypoglycemia inhibitory effects on, compared, 950-953
in NIDDM subjects' children, 1219-1223
see also Alpha cells; Beta cells
Insulin release and secretion in NIDDM
indomethacin effects on, 839-844
with obesity, reversal and prevention of dyslipidemia, histologic abnormalities, and defective, with CS-045, 1167-1175
Insulin resistance, 959-968, 1247-1260
CV risk factors and impaired, 1247-1254
depression and, *see* Depression and depressive disorders, insulin resistance in
in FCH, Lp phenotype and, 1627-1631
FFAs and, *see* Insulin resistance, FFAs and
GS protein expression downregulation inducing, in SM cells, 962-968
in healthy subjects, plasma NO in, 959-961
HF diet-induced, effects of, on IAAP and insulin mRNA, 1518-1522
in Japanese subjects, *see* Japanese subjects, insulin resistance in
Lps and, *see* Lipoprotein(s), insulin resistance and
in NIDDM, *see* Insulin resistance in NIDDM
in obesity, *see* Nondiabetic lean and obese subjects, insulin resistance in; Skeletal muscle insulin resistance in obesity
oxidative stress and, S1:27
SM, *see* Skeletal muscle insulin resistance
and systemic and/or portal venous drainage site effects on insulin action after pancreas transplantation, 458-466
see also Homeostasis model assessment insulin resistance index; Insulin sensitivity; Metabolic syndrome
Insulin resistance, FFAs and
insulin regulation of plasma FFAs concentrations in insulin-resistant healthy subjects, 151-154
plasma lipid relationship to FFAs, AT, and insulin resistance in Afro-Caribbean, South Asian, and European men, variation in NIDDM and CHD risk and, 245-252
Insulin resistance in NIDDM
with obesity, thiazolidinedione effects on liver and SM FA oxidation in, 521-525
TGs and BMI in, 1001-1005
TNF-α G308A gene polymorphism, fasting plasma glucose and, in young, old, and NIDDM Japanese men, 1616-1618
$VOSO_4$ effects on, 404
Insulin resistance syndrome, *see* Metabolic syndrome
Insulin sensitivity (S_I)
aging effects on, 1118-1123
effects of dietary FA composition in pregnant and nonpregnant subjects on, 1183
effects of oral or transdermal 17β-estradiol with cyclical oral NETA on, in postmenopausal women, 742-747
glycemia and, *see* Glycemia, S_I and
in HTN, 1532
iPTH and, 1501-1505
leptin relationship to serum insulin and, during and after preeclamptic or healthy pregnancy, 259-263
in NIDDM, *see* Insulin sensitivity in NIDDM
in obesity, *see* Insulin sensitivity in obesity
and S_G, *see* Insulin sensitivity, S_G and

Insulin sensitivity (S_I) (*Continued*)
tissue, contribution of beta cells and, to IGT, 1318-1325
Insulin sensitivity (S_I), S_G and
morning cortisol levels and, 306, 307
seasonal variation of, in men, 32-38
Insulin sensitivity (S_I) in NIDDM
with obesity, thiazolidinedione effects on liver and SM FA oxidation in, 521-525
in offspring of NIDDM subjects, 1219-1223
role of TGs and BMI in, 1001-1005
$VOSO_4$ effects on, 404
Insulin sensitivity (S_I) in obesity
in moderately obese women, effects of regular moderate wine consumption on, 1473-1478
with NIDDM, thiazolidinedione effects on liver and SM FA oxidation in, 521-525
Intact parathyroid hormone (iPTH)
and insulin sensitivity, 1501-1505
serum, effects of Mg supplementation on intestinal absorption of $^{45}CaCl_2$ in women with low erythrocyte Mg, 1092-1098
Intercapsular brown adipose tissue (iBAT)
in obese STZ-DM subjects, 135
pioglitazone and CS-045 effects on energy storage in, 1301-1308
Interleukin-2 receptors (IL-2Rs), effects of parathyroid adenoma excision in primary hyperparathyroidism on levels of IL-6 and, 192-194
Interleukin-6 (IL-6)
HCTZ and furosemide effects on production of, 18-19
parathyroid adenoma excision effects on levels of IL-2 receptors and, in primary hyperparathyroidism, 192-194
Interleukin-11 (IL-11), HCTZ and furosemide effects on production of, 18-19
Intermediate-density lipoprotein (IDL) in NIDDM, HDL_3 binding to leukocytes and, 691
Intermediate-density lipoprotein-cholesterol (IDL-C), and plasma viscosity in HCL or HTG, 811
Intermittent brain-derived neurotrophic factor (BDNF), effects of metformin and, on glucose metabolism in obese NIDDM subjects, compared, 129-133
Intestinal absorption of $^{45}CaCl_2$ in women with low erythrocyte Mg, Mg supplementation effects on, 1092-1098
Intestinal galactosyltransferase, activity of, during postnatal development, role of insulin and dietary changes at weaning on, 526-531
Intestinal tissue, TNF-α in, 1313, 1314
Intestines, apo A-I mRNA in, 1573
Intima-media thickness (IMT), carotid, in NIDDM, lack of association between MTHFR gene polymorphism or serum HcY and, 718-723
Intolerance and tolerance, *see* Tolerance and intolerance
Intraabdominal adipose tissue (IAT) in NIDDM
restricted diet effects on weight of, 110
YM440, troglitazone, and pioglitazone effects on, compared, 412, 413
Intracellular glucose in mesangial cells, troglitazone effects on glycolysis and metabolism of, 308-313
Intracellular lactate in mesangial cells, troglitazone effects on metabolism of, 310-311
Intracellular protein, effects of AGE products on, S1:9
Intracellular pyruvate in mesangial cells, troglitazone effects on metabolism of, 310-311
Intracellular sorbitol in mesangial cells, troglitazone effects on metabolism of, 311
Intralipid, effects of plasma FFA elevated induced by, on basal insulin secretion or GIIS in men, 450-454
Intramuscular lipids in lean, obese, and obese NIDDM subjects, effects of weight loss on, 467-472
Intraperitoneal (IP) insulin in STZ-DM
effects of chronic, on hepatic glucose metabolism, 1411-1416
with hypoglycemia, glucagon and glucose response to, 984-989
Intrauterine growth retardation (IUGR), collagen cross-links and early postnatal growth of infants with, 1467-1472
Intravenous glucose tolerance test (IVGTT)
in healthy and/or preeclamptic pregnancy, 260
of healthy subjects, plasma glycohydrolase at onset of IDDM with obesity during, 1352-1355
in HTN, 1529-1536
in NIDDM, CS-045 effects on, 1170-1171
of NIDDM subjects' relatives, 898-899
and plasma lipid relationship to insulin resistance, FFAs, and AT in Afro-Caribbean, South Asian, and European men, 246-252
in postmenopausal women on 17β-estradiol with cyclical oral NETA, 743-747
see also Frequently sampled intravenous glucose tolerance test *and specific conditions*
Intravenous (IV) glutamine (Gln), effects of, on mixed muscle protein synthesis in healthy young men and women, 1555-1560
Intravenous (IV) insulin, pulsatile, effects of, on diabetic nephropathy progression, 1491-1495
IP insulin, *see* Intraperitoneal insulin in STZ-DM
iPTH, *see* Intact parathyroid hormone
irETs (immunoreactive endothelins), SNP effects on, 374, 375
IRS-1, *see* Insulin receptor substrate-1, PI 3K and
Islet amyloid polypeptide (IAPP; amylin), effects of HF diet-induced insulin resistance on insulin mRNA and, 1518-1522
Islets of Langerhans, *see* Pancreatic islets
Isoflavones in soy protein diet, 1189
Isoflavonoids, urinary excretion of, with soy protein diet, 539
Isoforms, effects of long and short leptin receptor, in PBMCs on leptin, 1537-1541
Isoleucine (Ile)
effects of, on system A transport of MeAIB in mammary gland, 875, 876
in glutamine-containing diet, 142
hyperammonemia effects on metabolism of, 1332
IV glutamine effects on synthesis of muscle, 1556, 1557
plasma, *see* Plasma isoleucine
Isoprenaline, effects of, on ATBF in lean and obese exercising men, 583
Isoproterenol
effects of, on ATBF in lean and obese men, 583
effects of, on lipolytic β_3-adrenergic agonist response to hyperinsulinemia in adipocytes of pregnant and nonpregnant subjects, 1180-1187
see also Isoproterenol, leptin and
Isoproterenol, leptin and
acute leptin suppression by isoproterenol but not by FFAs despite ACX-induced lipolysis inhibition, 335-339
insulin and isoproterenol stimulating leptin release by AT, 804-809
Isozymes, PLC, inositol phosphate, insulin secretion, α-KIC and, in pancreatic islets, 1156-1163
IUGR (intrauterine growth retardation), collagen cross-links and early postnatal growth of infants with, 1467-1472
IV (intravenous) glutamine (Gln), effects of, on mixed muscle protein synthesis in healthy young men and women, 1555-1560
IV (intravenous) insulin, pulsatile, effects of, on diabetic nephropathy progression, 1491-1495
IVGTT, *see* Intravenous glucose tolerance test

Japanese subjects, insulin resistance in
*Nco*I TNF-α gene polymorphism effects on insulin tolerance, 1506-1509
with NIDDM, TGs and BMI in, 1001-1005
Japanese subjects, NIDDM
insulin-sensitive, TGs and BMI in, 1001-1005
obese NIDDM adolescent, glucose intolerance in, 186-191
TNF-α G308A gene polymorphism, insulin resistance, and fasting plasma glucose in young, old, and NIDDM Japanese men, 1616-1618
Japanese subjects, obese
glucose intolerance in obese NIDDM adolescents, 186-191
with NIDDM, lack of association between Gln27Gly and Arg16Gly polymorphism of β_2-AR gene in, 1215-1218
JTT-501 4-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl]-3,5-isoxazolidinedione
effects of, on NHGB and peripheral glucose uptake, in NIDDM, 862-867
effects of, in obese subjects with and without ventromedial hypothalamus lesions, 574-578

K (potassium)
insulin and C-peptide effects on RBC Na/K ATPase in IDDM, 868-872
in obesity, HTN and, 1525
total body, in underweight chronic gastrointestinal disease subjects DXA, BIA, SF, and TBW-^3H_2O measurement of, compared, 360-366
K^+ (potassium) channels, ATP-sensitive
from beta cells and extrapancreatic tissues, sensitivity of, to sulfonylureas, S2:3-6
stevioside effects on beta cell insulin secretion independent of activity of cAMP and, 208-214
Kaliuretic peptides, effects of long-acting vessel dilators, natriuretic peptides and, on urinary excretion of β_2-microglobulin, 1592-1597
α (alpha)-Ketoisocaproate (KIC)
IV glutamine effects on, 1558
PLC isozymes, inositol phosphate, insulin secretion and, in pancreatic islets, 1156-1163
Ketone(s), blood, effects of elevated plasma FFAs on, in men, 451-453
Ketone bodies, and fasting-induced apo A-I mRNA expression, 1572-1578
Ketosis, and fasting-induced apo A-I mRNA expression, 1572-1578
KIC, *see* α-Ketoisocaproate
Kidney(s)
in DM, immunochemical assays of AGE product levels in, 567-573
nicorandil effects on XOD and SOD in, in STZ-DM, 428, 429
SERP-1 distribution to, 1452
TNF-α in, 1313, 1314
weight of, *see* Organ weight, kidney
see also entries beginning with term: Renal *element*: Nephr- *and specific conditions*
Kinase, *see* Glucokinase; Insulin receptor substrate-1, PI 3K and; Phosphoenolpyruvate carboxykinase; Protein kinase C
Kinetics
apo B, in normolipidemia, 1204-1210
of chylomicron clearance, 493-494
glucose, *see* Kinetics, glucose
Mg, in Mg-sufficient and Mg-deficient subjects, 1326-1329
muscle protein, in endotoxemia, TPN effects on, 614
plasma FFA, in men during high-intensity exercise, 123-124
of TEF, and its relationship to body composition, 1340-1345
Kinetics, glucose
in HTN, 1534-1535
Kinetics, glucose (*Continued*)
metformin effects on, 1621-1623
kl/kl mutation, effects of, on insulin secretion and insulin sensitivity, 1118-1123
KRP-297, effects of, on reduced SM and liver FA oxidation in NIDDM with obesity, 521-525

LA, *see* Linoleic acid
Lactalbumin in soy protein diet, 1189
Lactate
blood, exercise at high altitude and, 1039
fructose effects on, 1568
intracellular mesangial cell, troglitazone effects on metabolism of, 310-311
metformin effects on, 1621
plasma, *see* Plasma lactate
short-term variation in dietary fat and CHOs on, 1153
[1-^{13}C]Lactate, hepatocyte, effects of glycerol-1,2,3-tris(methyl-[2,3^{13}C]succinate) on, 179
[2-^{13}C]Lactate, hepatocyte, effects of glycerol-1,2,3-tris(methyl-[2,3^{13}C]succinate) on, 179
[3-^{13}C]Lactate, hepatocyte, effects of glycerol-1,2,3-tris(methyl-[2,3^{13}C]succinate) on, 179
Lactate dehydrogenase (LDH) in SAT, 596, 597
Lactic acid, BCAA effects on, not mediated by glucagon or insulin, 98-100
Lactose in high-S diet with dexamethasone, 1290
LANPs (long-acting natriuretic peptides), effects of vessel dilators, kaliuretic peptides and, on urinary excretion of β_2-microglobulin, 1592-1597
Lanreotide, acute effects of slow, on exercise-induced microalbuminuria in active acromegaly, 634-639
Lard in soy protein diet, 1189
Lathosterol, acute alcohol intake effects on, 64
Δ7 (delta7)-Lathosterol, serum, stanol ester effects on, 474
Δ7 (delta7)-Lathosterol/sitosterol, serum, stanol ester effects on, 474
LCAT (lecithin:cholesterol acyltransferase) in TD, normolipidemic, and HDL- and apo E-deficient subjects, 771
LDH (lactate dehydrogenase) in SAT, 596, 597
LDL, *see* Low-density lipoprotein
LDL-C, *see* Low-density lipoprotein-cholesterol
Lean body mass, *see* Fat-free mass
Lean subjects
with DM, antidiabetic effects of nicotinamide in, 1548-1554
with IDDM, vanadate effects on hepatic G6Pase, hepatic G6PDH, and PEPCK in, gluconeogenesis and, 321-325
insulin resistance correlation with increased SFAs in SM TGs of, 220-224
weight loss effects on intramuscular lipid increase in, 467-472
see also Men, lean and obese; Nondiabetic lean and obese subjects, insulin resistance in; Women, lean and obese
Lecithin:cholesterol acyltransferase (LCAT) in TD, normolipidemic, and HDL- and Apo E-deficient subjects, 771
Left ventricular hypertrophy (LVH), temocapril effects on circulating BNPs and, in hypertensive elderly subjects, 1356-1360
Leptin
AT and, *see* Leptin in AT
in children, *see* Children, leptin in
chronic high-glycemic index starch diet regulation of, 764-769
effects of long and short leptin receptor isoforms in PBMCs on, 1537-1541
fat mass and, *see* Fat mass, leptin and
FFAs and, *see* Free fatty acids, leptin and
HF diet-induced insulin resistance effects on, 1519
insulin and, *see* Insulin, and leptin

Leptin (*Continued*)
isoproterenol and, *see* Isoproterenol, leptin and
in NIDDM, TNF-α G308A gene polymorphism and, 1617
in obesity, *see* Leptin in obesity
plasma, *see* Plasma leptin
in pregnancy, *see* Pregnancy, leptin in preeclamptic
serum, *see* Serum leptin
short-term exercise effects on, 858-861
testosterone and, in older African American men, 1085-1091
see also mRNA, leptin
Leptin in AT
insulin and, *see* Insulin, and leptin in AT
in NIDDM, metabolic parameters, AT distribution and, and apo E polymorphism, 724-730
see also Leptin in AT, dexamethasone and; Serum leptin in AT
Leptin in AT, dexamethasone and
GH regulation of leptin biosynthesis in AT, 239-240
troglitazone regulation of leptin in AT, 1485-1490
Leptin in obesity
in obese children and adolescents, relationship between PAI-1-Ag and tPA-Ag, fat mass, and leptin, 890-895
in obese women, prevalence of paradoxically normal serum C and, 610
Leptin resistance, hypothalamic leptin receptor mRNA and protein downregulation and, 1479-1484
Lesions, ventromedial hypothalamus, in obesity, effects of JTT-501 on, 574-578
Leucine (Leu)
effects of, on system A transport of MeAIB in mammary gland, 875, 876
hyperammonemia effects on metabolism of, 1330-1334
IV glutamine effects on synthesis of muscle, 1556, 1557
see also Plasma leucine
Leukocytes
HDL_3 binding to, following weight loss and improved glycemic control in NIDDM, 692-697
T_3 effects on oxidative damage indices, antioxidant reserve, and ROS generation by, 799-803
LF (low-fat diet) with sucrose or starchy foods, effects of, on blood lipids, FVIIc, and fibrinogen, 731-735
LH, *see* Luteinizing hormone
Lignoceric acid, RBC and SM membrane, 1165
Linoleic acid (LA)
effects of OA and, on ET-1 binding and action of, in aortic smooth muscle cells, 1386-1389
RBC and SM membrane, 1165
in SM TGs in insulin-resistant obese and lean subjects, 222
Lipase, *see* Hormone-sensitive lipase gene; Lipoprotein lipase; Phospholipase isozymes; Postheparin lipase activity
Lipemia (lipidemia), *see* Dyslipidemia in NIDDM; Hyperlipidemia; Normolipidemia; Postprandial lipemia
Lipid(s)
blood, *see* Blood lipids
in CAH, 790-793
effects of long-term high-S diet with dexamethasone on AT depots, liver steatosis, and fluxes of, through retroperitoneal and splanchnic areas, 1289-1291
estradiol and estrogen effects of, in boys, race and, 1124-1129
plasma, *see* Plasma lipids
in premenopausal women, men, and postmenopausal women, compared, 1101-1105
reduction of, with LDL apheresis, 1431-1433
serum, *see* Serum lipids
weight loss effects on intramuscular, in lean, obese, and obese NIDDM subjects, 467-472
Lipid(s) (*Continued*)
see also Dyslipidemia in NIDDM; Hyperlipidemia; Lipid peroxides; Normolipidemia; Oxidation, lipid; Phospholipid(s); Postprandial lipemia *and specific lipids*
Lipid peroxides (LPOs)
in IDDM before and after glycemia control and post-vitamin E supplementation, oxidative stress and, 161
in NIDDM, *see* Lipid peroxides in NIDDM
in STZ-DM, scavenging activity of nicorandil and, 427-431
Lipid peroxides (LPOs) in NIDDM
following vitamin E supplementation and before and after glycemia control, oxidative stress and, 161
gliclazide and glibenclamide effects on, S1:24, S1:33
Lipogenic potential of AT, 594-599
Lipolysis
ACX-induced inhibition of, isoproterenol- but not FFA-induced acute leptin suppression despite 335-339
leptin and, *see* Lipolysis, leptin and, in AT
and lipid oxidation in cancer cachexia syndrome, 931-936
and lipolytic response to β-adrenergic receptor stimulation and delayed increase in AT blood flow in lean and obese men, after exercise, compared, 579-587
in NIDDM with dyslipidemia, 25-26
Lipolysis, leptin and, in AT
and GH regulation of leptin in AT, 239-244
leptin release by AT, 807
Lipolytic β (beta)$_3$-adrenergic agonist, response of, to hyperinsulinemia in adipocytes of pregnant and nonpregnant subjects, effects of dietary FA composition on, 1180-1187
Lipoprotein(s) (Lp)
cerivastatin effects on TGs and PP apo B-48 and B-100-containing, in NIDDM, 1049-1054
contribution of fibrinogen and, to plasma viscosity in HCL and HTG, 810-813
plasma, *see* Plasma lipoprotein(s)
in premenopausal women, postmenopausal women, and men, compared, 1101-1105
serum, *see* Serum lipoproteins
subcutaneous central AT, risk of CV disease and, 1380, 1383
see also Apolipoprotein(s); High-density lipoprotein; Intermediate-density lipoprotein; Lipoprotein(a); Lipoprotein lipase; Low-density lipoprotein; Very-low-density lipoprotein(s)
Lipoprotein(s) (Lp), insulin resistance and
insulin resistance impact on subpopulations of, in lean and obese nondiabetic women, 285-292
Lp phenotype and insulin resistance in familial combined hyperlipidemia, 1627-1631
Lipoprotein (Lp) phenotype, insulin resistance and, in FCH
Lipoprotein(a) (Lp(a); high-density lipoprotein$_1$)
in diabetic and nondiabetic subjects, soy protein effects on, 1191
exercise effects on modifications of, in IDDM and NIDDM, 640-647
and plasma viscosity in HCL or HTG, 811
in premenopausal women, 1103
Lipoprotein(a)-cholesterol (Lp(a)-C; high-density lipoprotein$_1$-cholesterol), effects of regular moderate wine consumption by moderately obese women on, 1475
Lipoprotein lipase (LPL)
effects of NO-1886 as activator of, on Adriamycin-induced nephrotic syndrome, 588-593
triacsin C effects on, 327
see also Adipose tissue, LPL gene and; Lipoprotein lipase activity
Lipoprotein lipase (LPL) activity
in NIDDM, restricted diet effects on, 110
in obese STZ-DM subjects, 134-140
see also Plasma lipoprotein lipase activity; Postheparin lipase activity

Lipoprotein lipase gene, *see* Adipose tissue, LPL gene and
Liquid chromatography
fast protein, of plasma lipid and Lps in dyslipidemic NIDDM, 23, 25
high-performance, of agouti-related protein(83-132) BBB crossing, 1444-1449
Liver
apo A-I mRNA in, 1573
cirrhotic, *see* Cirrhosis
LDL receptor and LDL receptor-related protein expression by, in young and older subjects, chylomicron clearance from circulation and, 492-498
SERP-1 distribution to, 1452
TNF-α in, 1313, 1314
see also Liver cell membrane phospholipid fatty acids; Liver in DM; Liver metabolism; Liver in NIDDM; Liver steatosis; Liver transplantation; Organ weight, liver *and entries beginning with element*: Hepat-
Liver cell membrane phospholipid (PL) fatty acids (FAs), effects of dietary fat and energy intake on composition of, 977-983
Liver in DM
immunochemical assays of AGE product levels in, 567-573
in STZ-DM, nicorandil effects on XOD and SOD in, 428
see also Liver in NIDDM
Liver metabolism, ^{31}P-MRS of D-tagatose effects on, 1335-1339
Liver in NIDDM
fatty, inheritance of, 653
with obesity, thiazolidinedione effects on SM and liver FA oxidation, 521-525
restricted diet effects on, 110-112
Liver steatosis, effects of long-term high-S diet with dexamethasone on, 1289-1291
Liver transplantation for cirrhosis, S_G following, 367-372
Long-acting natriuretic peptides (LANPs), effects of vessel dilators, kaliuretic peptides and, on urinary excretion of β_2-microglobulin, 1592-1597
Long leptin receptor isoforms in PBMCs, effects of, on leptin, 1537-1541
Long-loop galanin (GAL) autofeedback, effects of acute and chronic GAL administration on hypothalamic GAL synthesis in male and female subjects, 778-783
Long-term eicosapentaenoic acid ethyl ester (EPA-E)
DM and DM-related coagulation abnormalities prevented with, 912-919
effects of, on dysfunctional vascular endothelial cells and smooth muscle cells, 1588-1591
Long-term endurance exercise, genetic measurement of DHEAS before and after, 298-304
Long-term exposure of pancreatic beta cells to palmitate, glucose concentration effects on insulin gene expression and, 532-536
Long-term high-sucrose (S) diet with dexamethasone, effects of, on AT depots, liver steatosis, and lipid fluxes through retroperitoneal and splanchnic areas, 1289-1291
Low-density lipoprotein (LDL; β-lipoprotein)
in alcoholics, impaired RTC and, 1408
arterial, soy protein effects on, 1188-1196
effects of regular moderate wine consumption by moderately obese women on, 1475
hepatic expression of LDL receptor-related protein and receptor of, in older and young subjects, delayed chylomicron clearance from circulation and, 492-498
in hypercholesterolemic men, simvastatin and pravastatin effects on, 117
in IDDM, exercise effects on modifications of, 640-647
insulin resistance effects on, in nondiabetic lean and obese women, 285-292
Low-density lipoprotein (LDL; β-lipoprotein) (*Continued*)
lipid reduction with apheresis of, 1431-1433
in NIDDM, *see* Low-density lipoprotein in NIDDM
oxidation of, *see* Oxidation, LDL
serum, *see* Serum low-density lipoprotein
see also Low-density lipoprotein-cholesterol
Low-density lipoprotein (LDL; β-lipoprotein), particle size of, in NIDDM
with dyslipidemia, effects of Western diet on, of, 27-28
variation in CHD and NIDDM risk and, 248, 249
Low-density lipoprotein (LDL; β-lipoprotein) in NIDDM, S1:31-33
exercise effects on modifications of, 640-647
gliclazide effects on oxidation of, S1:17-22
importance of lowering, S1:31
small dense, oxidative stress and, S1:32-33
see also Low-density lipoprotein, particle size of, in NIDDM
Low-density lipoprotein-cholesterol (LDL-C)
apheresis of LDLs and, 1432
cerivastatin effects on, 1050
diet effects on, *see* Low-density lipoprotein-cholesterol, diet effects on
exercise and, *see* Low-density lipoprotein-cholesterol, exercise and
in hyperlipidemia, 1628
in hypopituitarism, GH therapy effects on, 566
insulin resistance and, *see* Low-density lipoprotein-cholesterol, insulin resistance and
in insulin resistance syndrome, 1023
in insulin-sensitive healthy Japanese subjects, 960
in NIDDM, *see* Low-density lipoprotein-cholesterol in NIDDM
in normolipidemia, 1208
in obesity, *see* Low-density lipoprotein-cholesterol in obesity
and plasma viscosity in HCL, 811
in postmenopausal women on estrogen alone or estrogen with progestin, 785, 787
in premenopausal women, 1103
risk of atherosclerosis after pancreas transplantation and, 463
serum fasting, variation in CHD and NIDDM risk and, 248
in TD, 771
in 10-to-15-year-old boys, race and variation in, 1126, 1127
TGs and, *see* Low-density lipoprotein-cholesterol, TGs and; Low-density lipoprotein-cholesterol in HTG
Low-density lipoprotein-cholesterol (LDL-C), diet effects on
of sucrose and starchy food diets, 733
see also Low-density lipoprotein-cholesterol, soy protein effects on
Low-density lipoprotein-cholesterol (LDL-C), exercise and
exercise effects on modifications of, in IDDM and NIDDM, 643
plasma HDL-C effects on, 829
Low-density lipoprotein-cholesterol (LDL-C), insulin resistance and
CV risk factors and, 1248, 1249, 1251
in healthy Japanese subjects, 960
in lean and obese nondiabetic women, 287, 289
variation in NIDDM and CHD risk and, 248
Low-density lipoprotein-cholesterol (LDL-C), soy protein effects on
effects of, on LDL-C delivery to arteries of diabetic and nondiabetic subjects, 1188-1196
of soy-based breakfast cereal, 1498
Low-density lipoprotein-cholesterol (LDL-C), TGs and
BMI and, 1002, 1003
concentration and relationship between apo B and apo A-I level and, 53-61
see also Low-density lipoprotein-cholesterol in HTG
Low-density lipoprotein-cholesterol (LDL-C) in HTG
in FHTG, 944-946
and plasma viscosity, 941

Low-density lipoprotein-cholesterol (LDL-C) in NIDDM
apo E polymorphism, leptin and, 725, 726
effects of high-monounsaturated fat diet and olive oil diet on, 1513, 1514
exercise effects on, 643
TNF-α G308A gene polymorphism and, 1617
variation in NIDDM and CHD risk and, 248
weight loss effects by obese NIDDM subjects on, 1454
Low-density lipoprotein-cholesterol (LDL-C) in obese women
in insulin-resistant nondiabetic women, 287, 289
and prevalence of paradoxically normal serum in obese women, 608, 610
Low-density lipoprotein-cholesterol (LDL-C) in obesity
α_2-, β_2-, and β_3-AR genes and obesity phenotype, 1067, 1068
HTN and, 1525
see also Low-density lipoprotein-cholesterol in obese women
Low-dose epinephrine (E), effects of, on plasma glucose in elderly NIDDM subjects, 195-202
Low-dose glucagon (hyperglycemic factor; hyperglycemic-glycogenolytic factor), effects of, on glucose production and gluconeogenesis in healthy subjects, 39-46
Low-fat (LF) diet with sucrose or starchy foods, effects of, on blood lipids, FVIIc, and fibrinogen, 731-735
Lp(s), *see* Lipoprotein(s)
LPI (lysinuric protein intolerance), lysine effects on urea cycle in, 621-625
LPL, *see* Lipoprotein lipase
LPOs, *see* Lipid peroxides
Lungs
SERP-1 distribution to, 1452
TNF-α in, 1313, 1314
Lutein/zeaxanthin, T_3 effects on reserve of, 801
Luteinizing hormone (LH)
and bone metabolism in HIV infection, 1136
in hypercholesterolemic men, *see* Luteinizing hormone in hypercholesterolemic men
in premenopausal women, 1102
Luteinizing hormone (LH) in hypercholesterolemic men
pravastatin effects on, 119
simvastatin effects on, 119, 1236
LVH (left ventricular hypertrophy), temocapril effects on circulating BNPs and, in hypertensive elderly subjects, 1356-1360
Lymph node cells, mesenteric, diet effects on insulin and nutrient metabolism in splenocytes, pancreatic islets and, 1111-1117
Lymphocyte count in methionine-induced hyperhomocysteinemia, 225
Lymphopenia, T, in NIDDM with obesity, 1261-1266
Lysine (Lys)
effects of, on urea cycle in LPI, 621-625
in glutamine-containing diet, 142
hyperammonemia effects on metabolism of, 1332
IV glutamine effects on synthesis of muscle, 1556, 1557
Lysinuric protein intolerance (LPI), lysine effects on urea cycle in, 621-625
Lysophosphatidylcholine (lyso-PC), EPA effects on oxidized LDLs and migration in VSMCs induced by, 560-562

M1, effects of, on MeOAMVN-mediated LDL oxidation and oxidized LDL cytotoxicity, 479-485
Macrophages/monocytes
effects of ω3-PUFAs and chronic ethanol consumption on C efflux from, 510-511
in NIDDM, gliclazide effects on adhesion of, to endothelium, S1:17-22
Magnesium, *see* Mg
^{31}P-Magnetic resonance spectroscopy (MRS) of D-tagatose effects on liver metabolism, 1335-1339
Malaria (*Plasmodium yoelii*)-parasitized erythrocytes (RBCs; red blood cells), NIDDM reversed with, 937-941
[2-^{13}C]Malate, hepatocyte, effects of glycerol-1,2,3-tris(methyl-[2,3^{13}C]succinate) on, 179
Malate-aspartate (Asp) shuttle in NIDDM beta cells, 92-96
Malate dehydrogenase in SAT, 596, 597
Male subjects
diabetic and nondiabetic, soy protein effects on arterial LDL and on LDL-C delivery to arteries of, 1188-1196
effects of acute and chronic GAL administration on hypothalamic GAL synthesis in, long-loop GAL autofeedback and, 778-783
see also Men; Sex
Malic enzyme in SAT, 596, 597
Malnutrition
protein-energy, in children, serum leptin in, 819-825
see also Diet
Malondialdehyde (MDA), plasma, in methionine-induced hyperhomocysteinemia, 226
Malonyl daidzin in soy protein diet, 538
Malonyl glycitin in soy protein diet, 538
Mammary gland, system transport of MeAIB in, 873-879
MAP (mean arterial pressure), *see* Blood pressure
Masoprocol, effects of, on serum TGs in fructose-induced hypertriglyceridemia, 1106-1110
Mass spectrometry, GC/, of plasma galactose and galactitol concentrations in galactosemia due to GALT deficiency, 1460-1466
Maternal-paternal effects on NIDDM phenotypes, 651-656
Matrix-cell interaction, effects of AGE products on, and oxidative stress in NIDDM, S1:9-10
Matrix-matrix interaction, effects of AGE products on, and oxidative stress in NIDDM, S1:9-10
Maximal aerobic capacity, *see* $\dot{V}O_2$max
MCP-1 (monocyte chemoattractant protein-1) mRNA (messenger ribonucleic acid), TNF-α-induced expression of, in mesangial cells, troglitazone effects on, 163-166
MDA (malondialdehyde), plasma, in methionine-induced hyperhomocysteinemia, 226
MeAIB (methylaminoisobutyric acid), system A transport of, in mammary gland, 873-879
Meals
effects of voglibose administered before evening, on nocturnal hypoglycemia in IDDM subjects on intensive insulin therapy, 440-443
see also entries beginning with term: Postprandial
Mean arterial pressure, *see* Blood pressure
Men
basal cortisol secretion in, polymorphism of 5′-flanking region of glucocorticoid receptor gene locus associated with, 1197-1199
effects of Intralipid-induced plasma FFA elevation on basal insulin secretion or GIIS in, 450-454
exercising, *see* Men, exercising
hypercholesterolemic, *see* Hypercholesterolemic men
lipids and Lps in premenopausal women, postmenopausal women and, compared, 1101-1105
normoglycemic, leptin release by AT in, 807
older, *see* Older men; Older subjects
risk of CV disease in, *see* Risk of CV disease in men
seasonal variation of S_I and glucose effectiveness in, 32-38
tyrosine effects on Phe hydroxylation in, 444-449
young, *see* Young men
see also Healthy subjects; Male subjects; Sex *and specific conditions*

Men, exercising
delayed effects of exercise on plasma leptin concentrations in, 395-399
endurance exercising, genetic measurement of DHEAS before and after, 298-304
high-intensity exercise, *see* High-intensity exercise by men
lean and obese, postexercise lipolytic response to β-adrenergic receptor stimulation and delayed increase in AT blood flow in, compared, 579-587
see also Exercise
Men, lean and obese
postexercise lipolytic response to β-adrenergic receptor stimulation and delayed increase in AT blood flow in, compared, 579-587
PP RMR and TEF relationship to body composition and AT distribution in, 6-10
see also Lean subjects; Men, obese
Men, obese
Japanese, lack of association between Gln27Glu and Arg16Gly polymorphism of β_2-AR gene and obesity, 1215-1218
see also Men, lean and obese; Obesity
Menopause, *see* Postmenopausal women; Premenopausal women
Menses, irregular, in Cushing's syndrome, testosterone production and, 230
Menstrual cycle
plasma ET modulated by, 648-650
variations in Lps and lipids during phases of, 1101-1105
see also Postmenopausal women; Premenopausal women
MeOAMVN [2,2-azobis(4-methoxy-2,4-dimethylvaleronitrile)]-mediated low-density lipoprotein (LDL; β-lipoprotein) oxidation, M1 effects on, 479-485
Mesangial cells, *see* Troglitazone, effects of, in mesangial cells
Mesenteric lymph node (MLN) cells, diet effects on insulin and nutrient metabolism in splenocytes, pancreatic islets and, 1111-1117
Messenger ribonucleic acid, *see* mRNA
Met, *see* Methionine
Metabolic control of NIDDM, insulin and GH gene regions in relation to, 424-426
Metabolic syndrome (MS; insulin resistance syndrome; syndrome X)
NEFA metabolism as mediator between HTN and, 81-87
relationship between ET-1 concentrations and metabolic alterations in, 748-751
in spontaneous HTG with RT1^u haplotype, 1140-1144
TNF-α G308A gene polymorphism in, 1021-1024
Meta-tyrosine (Tyr), T_3 effects on reserve of, 801
Metformin (*N,N,*-dimethylbiguanide)
and dietary fat in STZ-DM, 1390-1394
see also Metformin, glucose and
Metformin (*N,N,*-dimethylbiguanide), glucose and
effects of intermittent BDNF and metformin on glucose metabolism in obese NIDDM subjects, compared, 129-133
metformin effects on glucose production, glycogenolysis inhibition and, 1619-1626
Methionine (Met)
effects of, on system A transport of MeAIB in mammary gland, 875, 876
in glutamine-containing diet, 142
GSH synthesis in response to, in cirrhosis, 1434-1439
hyperammonemia effects on metabolism of, 1332
hyperhomocysteinemia induced by, peroxidation indices and total plasma antioxidant capacity in, 225-228
IV glutamine effects on synthesis of muscle, 1556, 1557
transamination of, in homocystinuria due to CβS deficiency, 1071-1077
see also Hypermethioninemia
DL-Methionine
in diet of hyperinsulinemic subjects, 1181
in soy protein diet, 1189
Methylaminoisobutyric acid (MeAIB), system A transport of, in mammary gland, 873-879
Methylenetetrahydrofolate reductase gene, *see* Homocysteine, MTHFR gene and
Methyl-glutaryl coenzyme A, *see* 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase
4-[4-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl]-3,5-isoxazolidinedione, *see* JTT-501
Mevalonic acid, serum, urinary excretion and concentration of, during acute alcohol intake, 62-66
Mg (magnesium)
erythrocyte, *see* Erythrocyte Mg
kinetics of, in Mg-sufficient and Mg-deficient subjects, 1326-1329
plasma, IMGU in healthy subjects with low, 418-420
Microalbuminuria, exercise-induced, in active acromegaly, acute slow lanreotide effects on, 634-639
β (beta)$_2$-Microglobulin, effects of long-acting vessel dilators, natriuretic peptides, and kaliuretic peptides on urinary excretion of, 1592-1597
Microsomal hepatic glucose-6-phosphatase (G6Pase) system, ontogeny of G6Pase transporter proteins and catalytic subunit p36 of, 1200-1203
Microvascular disease in IDDM, effects of glycemic control on platelet function abnormalities and, 88-91
Minerals
in HF diet, 504
in soy protein diet, 1189
in starch diet, 765
see also specific minerals
Minimal model analysis
of insulin resistance in depression, 1255-1260
one- and two-compartment, of glucose metabolism in HTN, 1529-1536
Mixed muscle protein, IV glutamine effects on synthesis of, in healthy young men and women, 1555-1560
MLN (mesenteric lymph node) cells, diet effects on insulin and nutrient metabolism in splenocytes, pancreatic islets and, 1111-1117
Molar ratio of cortisol/DHEA, circadian rhythms of serum DHEA, cortisol and, in young and older subjects, compared, 548-551
Molecular analysis of NIDDM
of HNF1α *TCF1* gene in familial NIDDM among African Americans, 280-284
of mutations in dyslipidemic NIDDM, 22-31
Monocyte(s), *see* Mononuclear cells
Monocyte chemoattractant protein-1 (MCP-1) mRNA (messenger ribonucleic acid), TNF-α-induced expression of, in mesangial cells, troglitazone effects on, 163-166
Mononuclear cells
peripheral blood, effects of long and short leptin receptor isoforms in, on leptin, 1537-1541
see also Macrophages/monocytes; Monocyte chemoattractant protein-1 mRNA
Monophosphate, *see* cAMP
Monounsaturated fat diet, effects of olive oil diet and high-, on metabolic profile in NIDDM, effects of high-CHO diet compared with 1511-1517
Monounsaturated fatty acids (MUFAs)
effects of FA composition in pregnant and nonpregnant subjects on, 1183
effects of restricted, on cell liver membrane PL, 977, 979, 980
in hyperlipidemia, 538, 539
in LF diet, 68, 732

Monounsaturated fatty acids (MUFAs) (*Continued*)
in obesity-inducing diet, 1296
soy protein and, *see* Monounsaturated fatty acids, soy protein and
Monounsaturated fatty acids (MUFAs), soy protein and
and arterial LDL delivery, 1189
in soy-based breakfast cereal, 1497
Morning cortisol levels, S_G and, 305-307
Morphology, ovarian, effects of rIGF-I and hCG on, 315-316
mRNA (messenger ribonucleic acid)
β-actin, triacsin C effects on, 327
apo A-I, *see* Apolipoprotein A-I gene mRNA
apo B, apo B-48, and apo B-100, in dyslipidemic NIDDM, 25
apo E, *see* Apolipoprotein E mRNA
AT and muscle LPL and HSL gene regulation with GH therapy during weight loss, 906-911
of cardiac AC isoforms, T_3 and T_4 effects on, 276-277
GLUT4, *see* mRNA, GLUT4, in SM
hepatic MTHFR, CβS and, and effects of HF diet with sucrose on metabolism of HcY, 736-741
HKII, in SM, 814-818
insulin, *see* mRNA, insulin
leptin, *see* mRNA, leptin
long and short leptin receptor isoform in PBMCs, effects of, on leptin, 1537-1541
LPL, *see* Adipose tissue, LPL gene and
protein, *see* mRNA, protein
troglitazone effects on, *see* mRNA, troglitazone effects on
uncoupling protein isoform, effects of rosiglitazone and rexinoids on obesity and, 1610-1615
mRNA (messenger ribonucleic acid), GLUT4, in SM
GLUT1, GLUT3, and GLUT4 mRNA and subcellular distribution of their proteins in, compared, 1604-1609
GTG effects on insulin resistance but not hyperinsulinemia in obesity with overexpression of, 340-346
kl/kl mutation and, 1118-1123
mRNA (messenger ribonucleic acid), insulin
effects of HF diet-induced insulin resistance on IAPP and, 1518-1522
see also mRNA, insulin gene
mRNA (messenger ribonucleic acid), insulin gene
AGE product receptor effects on, S1:9-10
glucose concentrations and effects of long-term exposure of beta cells to palmitate on, 532-536
insulin genes I and II, fetal body weight in relation to, 616-620
mRNA (messenger ribonucleic acid), leptin
GADPH and leptin mRNA in AT, GH effects on, 240
of hypothalamic leptin receptor and protein, leptin resistance and downregulation of, 1479-1484
mRNA (messenger ribonucleic acid), protein
rosiglitazone effects on isoforms of uncoupling mixed protein mRNA, 1610-1615
troglitazone effects on TNF-α-induced MCP-1 mRNA in mesangial cells, 163-166
see also mRNA, protein, downregulation of
mRNA (messenger ribonucleic acid), protein, downregulation of
GS protein, effects of, on insulin resistance in SM cells, 962-968
LDL receptor-related protein, hepatic expression of LDL receptor and, 492-498
mRNA (messenger ribonucleic acid), troglitazone effects on
on FABP mRNA, 413
on TNF-α-induced MCP-1 mRNA in mesangial cells, 163-166
^{31}P-MRS (magnetic resonance spectroscopy) of D-tagatose effects on liver metabolism, 1335-1339
MS, *see* Metabolic syndrome
MTHFR (methylenetetrahydrofolate reductase), *see* Homocysteine, MTHFR gene and
MUFAs, *see* Monounsaturated fatty acids
Muscle
cardiac, *see* Myocardial infarction; Myocardium
insulin regulation of plasma FFA regulation in healthy subjects with muscle insulin resistance, 151-154; *see also* Skeletal muscle insulin resistance
SERP-1 distribution to, 1452
weight loss effects on, *see* Muscle, weight loss effects on
see also Muscle protein; Skeletal muscle; Smooth muscle cells, vascular
Muscle, weight loss effects on
of GH therapy-induced weight loss on muscle and LPL gene in obesity, 906-911
on intramuscular lipids in lean, obese, and obese NIDDM subjects, 467-472
Muscle protein
IV glutamine effects on synthesis of mixed, in healthy young men and women, 1555-1560
kinetics of, in endotoxemia, TPN effects on, 614
proteolysis in, ubiquitin-proteasome pathway in, 689-691
Mutations
kl/kl, effects of, on insulin secretion and insulin sensitivity, 1118-1123
MTHFR gene 677C → T, effects of, on plasma HcY response to folate intake by elderly women, 1440-1443
in NIDDM with dyslipidemia, 22-31
see also Polymorphism
Myocardial branched-chain amino acids (BCAAs), hyperinsulinemia effects on uptake of, in CHD, 1365-1369
Myocardial glucose, hyperinsulinemia effects on, 1366
Myocardial infarction, differential effects of smoking on risk of, according to Gln/Arg 192 polymorphism of PON1 gene, 557-559
Myocardium
nicorandil effects on SOD and XOD of, in STZ-DM, 428-429
see also entries beginning with term: Myocardial
Myristic acid, SM TG, in insulin-resistant obese and lean subjects, 222

NA (nicotinic acid), changes induced by, in PC and PE FA composition and associated with SM insulin responsiveness in healthy subjects, 232-238
Na (sodium)
intake of, and thermic response of young and older women to caffeine, 103
in obesity, HTN and, 1525
serum, in cirrhosis, circulating CT and, 48
see also Na^+-GLUT2; Na/K ATPase; Natriuretic peptides
Na^+ (sodium)-GLUT2, renal, effects of inhibition of T-1095 with, on hyperglycemia of STZ-DM, 990-995
Na/K (sodium/potassium) ATPase (adenosine triphosphatase), RBC, in IDDM, insulin and C-peptide effects on, 868-872
Natriuretic peptides
effects of long-acting vessel dilators, kaliuretic peptides and, on urinary excretion of β_2-microglobulin, 1592-1597
see also Atrial natriuretic peptides; Brain natriuretic peptides
*Nco*I tumor necrosis factor-α (TNF-α) gene polymorphism, effects of, on insulin resistance in Japanese subjects, 1506-1509
NE, *see* Norepinephrine in hypoglycemia
NEFAs (nonesterified fatty acids), *see* Free fatty acids
Nephropathy
diabetic, *see* Diabetic nephropathy
ESRD as, vitamin B_{12} effects on plasma HcY in HD subjects with, 215-219
Nephrotic syndrome, NO-1886 effects on Adriamycin-induced, 588-593
Nervonic acid, RBC and SM membrane, 1165

Nervous system, *see* Brain; Sympathetic nervous system *and entries beginning with element*: Neur-
Net hepatic glucose balance (NHGB), JTT-501 effects on peripheral glucose uptake and, in NIDDM, 862-877
NETA (norethindrone acetate), effects of oral or transdermal 17β-estradiol with cyclical oral, on insulin sensitivity, secretion, and elimination in postmenopausal women, 742-747
Neuropathy, diabetic peripheral, zenarestat effects on, 1395-1399
Neurotrophic factor, brain-derived, effects of metformin and intermittent, on glucose metabolism in obese NIDDM subjects, compared, 129-133
NGT (normal glucose tolerance), and TH gene microsatellite polymorphism associated with insulin resistance in depressive disorder, 1145-1149
NH_3 (ammonia)
in glutamine-containing diet, 142
hyperammonemia effects on leucine and protein metabolism, 1330-1344
NHGB (net hepatic glucose balance), JTT-501 effects on peripheral glucose uptake and, in NIDDM, 862-867
Nicorandil (*N*-[2-hydroxyethyl]-nicotinamide nitrate), scavenging activity of, on free radicals and LPOs in STZ-DM, 427-431
Nicotinamide, development of DM in obese subjects accelerated by, antidiabetic effects in non-obese subjects compared with, 1548-1554
Nicotine, *see* Smoking
Nicotinic acid (NA), changes induced by, in PC and PE FA composition and associated with SM insulin responsiveness in healthy subjects, 232-238
NIDDM, *see* Non-insulin-dependent diabetes mellitus
Nitric oxide (NO)
effects of ET-1 and, on GK activity in hepatocytes, 73-80
plasma, in healthy insulin-resistant subjects, 959-961
Nitric oxide synthase (NOS), aortic endothelial cell, insulin effects on, 147-150
Nitrite, immunoreactive, SNP effects on, 374, 375
Nitrogen, *see* BUN
NO, *see* Nitric oxide
NO-1886, effects of, on Adriamycin-induced nephrotic syndrome, 588-593
Nocturnal hypoglycemia in IDDM subjects on intensive insulin therapy, effects of pre-evening meal voglibose on, 440-443
Nondenaturing gradient gel electrophoresis of plasma Lps in dyslipidemic NIDDM, 23
Nondiabetic lean and obese subjects, insulin resistance in
correlated with increased SFAs in SM TGs, 220-224
insulin resistance impact on Lp subpopulations in nondiabetic lean and obese women, compared, 285-292
obesity independent of insulin resistance in normoglycemic Hong Kong Chinese, as blood pressure determinant, 1523-1528
Nondiabetic subjects
liver transplantation in, S_G in, 367-372
NA-induced changes in PC and PE FAs associated with SM insulin responsiveness in, 232-238
soy protein effects on arterial LDL and LDL-C delivery to arteries in, 1188-1196
see also Nondiabetic lean and obese subjects, insulin resistance in
Nonesterified fatty acids, *see* Free fatty acids
Nonhypoglycemic effects of gliclazide, S2:18
Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus)
apo E in, *see* Apolipoprotein E in NIDDM
AT in, *see* Adipose tissue in NIDDM
beta cells in, *see* Beta cells in NIDDM
BMI in, *see* Body mass and body mass index of NIDDM subjects
Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) (*Continued*)
CHD and, *see* Coronary heart disease, NIDDM and
dyslipidemia in, *see* Dyslipidemia in NIDDM; Hypertriglyceridemia in NIDDM
effects of high-monounsaturated fat and olive oil diet on metabolic profiles of, high-CHO diet effects compared with, 1511-1517
exercise effects in, *see* Non-insulin-dependent diabetes mellitus, exercise effects in
FFAs in, *see* Free fatty acids in NIDDM
genes in, *see* Gene(s) in NIDDM
glucose in, *see* Glucose in NIDDM
glycemic control of, *see* Glycemic control of NIDDM
insulin resistance and, *see* Insulin resistance in NIDDM
insulin sensitivity in, *see* Insulin sensitivity in NIDDM
in Japanese subjects, *see* Japanese subjects, NIDDM
LDLs in, *see* Low-density lipoprotein in NIDDM
metabolic effects of $VOSO_4$ in, 400-410
model of, *see* Streptozotocin-induced diabetes mellitus
nephropathy due to, TGF-β_1 activation in, 353-359
and obesity, *see* Non-insulin-dependent diabetes mellitus, obesity and
oxidation in, *see* Oxidation in NIDDM
pancreas in, *see* Pancreas in NIDDM
phenotypes of, maternal-paternal effects on, 651-656
plasma lipids in, *see* Plasma lipids in NIDDM
polymorphism in, *see* Polymorphism in NIDDM
progression of, to overt state, 684-688
reversal of, with malaria-parasitized RBCs, 937-941
sulfonylureas in, *see* Sulfonylureas in NIDDM
troglitazone in, *see* Troglitazone, effects of, in NIDDM
vanadate effects in, 321-325
weight loss in, *see* Weight loss in NIDDM
Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), food intake in
restricted food intake effects, 108-114
see also Food intake by obese NIDDM subjects, troglitazone effects on
Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), exercise effects in
on glucose uptake and GLUT4 translocation in SM, 920-930
on Lp(a) and LDL modifications, 640-647
Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), obesity and
and insulin effects on HTG, 1424-1430
metabolic control of, insulin and GH gene regions in relation to, 424-426
thiazolidinedione effects on, *see* Troglitazone, effects of, in NIDDM with obesity
weight loss effects on, *see* Weight loss in NIDDM
see also Glucose in NIDDM with obesity
Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), TGs and
in obesity, and insulin effects on HTG, 1424-1430
PP apo B-48 and B-100-containing Lps in, cerivastatin effects on TGs and NIDDM and, 1049-1054
restricted diet effects on TGs, 108-114
see also Hypertriglyceridemia in NIDDM
Non-obese subjects, *see* Lean subjects
Nonpregnant subjects, effects of dietary FA composition on lipolytic β_3-adrenergic agonist response to hyperinsulinemia in adipocytes of, 1180-1187
Norepinephrine, *see* Norepinephrine in hypoglycemia; Plasma norepinephrine
Norepinephrine (NE) in hypoglycemia
and hypothermic response to hypoglycemia, 796
of STZ-DM, IP and/or SC insulin effects on, 985-986

Norethindrone acetate (NETA), effects of oral or transdermal 17β-estradiol with cyclical oral, on insulin sensitivity, secretion, and elimination in postmenopausal women, 742-747
Normal fibroblasts, C efflux from TD and, into normal, HDL-deficient, and apo E-deficient plasmas, 770-777
Normal glucose tolerance (NGT), and TH gene microsatellite polymorphism associated with insulin resistance in depressive disorder, 1145-1149
Normal plasma, C efflux from TD and normal fibroblasts into HDL-deficient, apo E-deficient and, 770-777
Normal pregnancy, free leptin in, 1043-1048
Normal serum cholesterol (C), prevalence of paradoxically, in obese women, 600-606
Normal subjects, *see* Healthy subjects
Normoglycemia
  in Hong Kong Chinese, obesity independent of insulin resistance as blood pressure determinant in, 1523-1528
  leptin release by AT in, 807
Normolipidemia, apo B kinetics in, 1204-1210
Normoponderal subjects, *see* Lean subjects
NOS (nitric oxide synthase), aortic endothelial cell, insulin effects on, 147-150
Nucleotides, interactions between sulfonylureas and, S2:6
Nutrients
  diet effects on metabolism of, in MLN cells, splenocytes, and pancreatic islets, 1111-1117
  see also Diet
Nutritional status
  effects of sex and, on ethanol metabolism, 379-385
  serum leptin in children with protein-energy malnutrition, 819-825

O_2 (oxygen)
  FDP effects on consumption of, 700
  saturation of arterial, in cirrhosis, circulating CT and, 48
  see also Oxidation; Reactive oxygen species; $\dot{V}O_2$; $\dot{V}O_2$max
OA, *see* Oleic acid
Obesity
  cytokines in, 1295-1300
  DM with, *see* Obesity with DM
  effects of rheological disorders on skin vasoconstrictive response to sympathetic activation in, 600-606
  effects of rosiglitazone and rexinoids on uncoupling protein isoform mRNA and, 1610-1615
  independent of insulin resistance in normoglycemic Hong Kong Chinese, as blood pressure determinant, 1523-1528
  infantile, risk of atherothrombosis and, 672-675
  insulin resistance and, *see* Nondiabetic lean and obese subjects, insulin resistance in; Skeletal muscle insulin resistance in obesity
  insulin sensitivity in, *see* Insulin sensitivity in obesity
  interaction between α_2-AR gene, β_3-AR, and phenotype of, 1063-1070
  kinetics of TEF in, 1342, 1344
  with and without ventromedial hypothalamus lesions, JTT-501 effects on HTG in, 574-578
  see also Adolescents, obese; Fibrinolysis in obesity; Hyperinsulinemia in obesity; Leptin in obesity; Men, obese; Weight loss; Women, obese
Obesity with DM
  in IDDM, plasma glycohydrolase at onset of, 1352-1355
  nicotinamide accelerating DM development in obesity, 1548-1554
  renal protective effects of troglitazone in, 1361-1364
  with STZ-DM, hyperinsulinemia and LPL activity in, 134-140
  see also Non-insulin-dependent diabetes mellitus, obesity and
OCs (oral contraceptives), urinary Ca excretion and bone turnover in young women on, 1078-1084
Octanol/buffer partition coefficient on agouti-related protein(83-132) crossing of BBB, 1446
ODNs (oligonucleotides), GS antisense, effects of, on GS protein expression, 962-968
Offspring, *see* Children
OGTT, *see* Oral glucose tolerance test
$1,25(OH)_2D_3$, *see* Vitamin D_3
$25(OH)_2D_3$ (dihydroxyvitamin D_3) in HIV infection, bone metabolism and, 1137
Oil
  fish, effects of, on lipolytic β_3-adrenergic agonist response to hyperinsulinemia in adipocytes of pregnant and nonpregnant subjects, 1180-1187
  olive, *see* Olive oil
  soybean, in obesity-inducing diet, 1296
Older men
  Japanese, TNF-α G308A gene polymorphism, insulin resistance, and fasting plasma glucose in, 1616-1618
  see also Older subjects; Testosterone, decrease and/or deficiency of, in older men
Older subjects
  calcitonin secretion in, 253-258
  effects of single DHEA administration on circadian rhythms of serum DHEA, cortisol, and cortisol/DHEA molar ratio in younger and, 548-551
  hepatic expression of LDL receptor and LDL receptor-related protein in, delayed chylomicron clearance from circulation and, 492-498
  hypertensive, temocapril effects on LVH and BNPs in, 1356-1360
  insulin-mediated SM blood flow and glucose uptake in, SNP effects on, 373-378
  with NIDDM, low-dose epinephrine effects on plasma glucose in, 195-202
  see also Aging, effects of; Older men
Older women
  MTHFR gene 677C → T mutation effects on plasma HcY response to folate intake, 1440-1443
  thermic effect of caffeine in young and, compared, 101-107
  see also Older subjects
Oleic acid (OA)
  effects of linoleic acid and, on ET-1 binding and action of, in aortic smooth muscle cells, 1386-1389
  RBC and SM membrane, 1165
  in SM TGs in insulin-resistant obese and lean subjects, 222
Oligonucleotides (ODNs), GS antisense, effects of, on GS protein expression, 962-968
Olive oil
  effects of, on lipolytic β_3-adrenergic agonist response to hyperinsulinemia in adipocytes of pregnant and nonpregnant subjects, 1180-1187
  effects of high-monounsaturated fat diet and diet rich in, on metabolic profile in NIDDM, effects of high-CHO diet compared with 1511-1517
Omega3 (ω3)-polyunsaturated fatty acids (ω-3 PUFAs), effects of chronic ethanol consumption and, on RCT, 508-512
Omega6 (ω6)-polyunsaturated fatty acids (ω6-PUFAs), RBC and SM membrane, 1165
Omental adipocytes, effects of TNF-α and TGF-β_1 on PAI-1 secretion by, 666-671
Omental adipose tissue (AT), steady-state level of LPL mRNA in abdominal versus, 1224-1227

Once-daily administration of gliclazide, S2:7-11, S2:21-25
One-compartment minimal model analysis of glucose metabolism in HTN, 1529-1536
Onset of IDDM with obesity, plasma glycohydrolase during IVGTT of healthy subjects and at, 1352-1355
Ontogeny
of catalytic subunit p36 and G6Pase transporter proteins of microsomal hepatic G6Pase system, 1200-1203
see also Postnatal growth and development
Oral contraceptives (OCs), urinary Ca excretion and bone turnover in young women on, 1078-1084
Oral 17β (beta)-estradiol with cyclical oral NETA, effects of, on insulin sensitivity, secretion, and elimination in postmenopausal women, 742-747
Oral glucose, effects of, on systemic glucose metabolism during hyperinsulinemic hypoglycemia in healthy subjects, 1598-1603
Oral glucose tolerance test (OGTT)
aging effects on, 1118-1123
in healthy and/or preeclamptic pregnancy, 260
of IGT subjects, 1318-1325
long-term EPA-E effects on, 917
in metabolic syndrome, 749
of NIDDM subjects' children, 1219-1223
of NIDDM subjects on restricted diet, 110
plasma glucose correlated with FPG during, in South Indians, 455-457
see also Oral glucose tolerance test in NIDDM relatives *and specific conditions*
Oral glucose tolerance test (OGTT) in NIDDM relatives
beta cell dysfunction and, 896-805
physically active relatives, 833-838
Oral norethindrone acetate (NETA), cyclical, effects of oral or transdermal 17β-estradiol with, on insulin sensitivity, secretion, and elimination in postmenopausal women, 742-747
Orchidectomy, aging effects on calcitonin release in, 253-258
Organ weight
AT, *see* Organ weight, AT
heart, in obese STZ-DM subjects, 135
kidney, *see* Organ weight, kidney
liver, *see* Organ weight, liver
pancreas, in NIDDM, voglibose and, 349
Organ weight, AT
of intraabdominal AT, restricted diet effects on, 110
starch diet effects on, 766
see also Organ weight, AT, in NIDDM
Organ weight, AT, in NIDDM
CS-045 effects on, 1171-1172
YM440 normalizing hyperglycemia of NIDDM without changing, pioglitazone and troglitazone effects compared with, 411-417
Organ weight, kidney
in DM, AGE product levels in liver and kidney and, 568
restricted diet effects on, 111
T-1095 effects on, 992
Organ weight, liver
dietary fat and energy intake effects on, 979
in DM, AGE product levels in liver and kidney and, 568
and hepatic insulin resistance, 522
restricted diet effects on, 111
Ornithine, hyperammonemia effects on metabolism of, 1332
Orotic acid, urinary excretion of, in LPI, lysine effects on, 624
Orthophosphate (inorganic phosphate; P_i), BCAA effects on, not mediated by glucagon or insulin, 98, 99
Ortho-tyrosine (Tyr), T_3 effects on reserve of, 801
Osteocalcin
and bone metabolism in HIV infection, 1136, 1137
cellular, HCTZ and furosemide effects on production of, 18
Osteoprogenitor cells, bone marrow stromal, effects of hydrochlorothiazide and furosemide on, compared, 17-21
Ovaries, synergistic effects of rIGF-I and hCG in, 314-320
Overt state of NIDDM, development to, 684-688
Oxidase, xanthine, nicorandil effects of, in STZ-DM, 428
Oxidation
CHO, and SM insulin responsiveness to NA-induced changes in PC and PE FAs, 233
glucose, insulin resistance correlated with increased SFAs in SM TGs and, 222
LDL, *see* Oxidation, LDL
lipid, *see* Oxidation, lipid
in NIDDM, *see* Oxidation in NIDDM
see also Antioxidant(s); Lipid peroxides; Peroxidation; Reactive oxygen species; Redox potential *entries beginning with terms*: Oxidative, Oxidized
Oxidation, LDL
in atherosclerosis, 1271-1277
M1 effects on MeOAMVN-mediated, 479-485
in NIDDM, gliclazide effects on, S1:17-22
soy protein effects on, *see* Soy protein effects on LDL oxidation and lipids
see also Oxidized low-density lipoproteins
Oxidation, lipid
in cancer cachexia syndrome and in healthy subjects, 931-936
and SM insulin responsiveness to NA-induced changes in PC and PE FAs, 233
soy protein effects on, *see* Soy protein effects on LDL oxidation and lipids
see also Oxidation, LDL
Oxidation in NIDDM
with obesity, thiazolidinedione effects on SM and liver FA oxidation in, 521-525
see also Gliclazide in NIDDM; Gliclazide scavenging activity in NIDDM; Oxidative stress in NIDDM; Sulfonylureas in NIDDM
Oxidative damage
T_3 effects on indices of, antioxidant reserve, and ROS generation by, 799-803
see also Tissue damage, free radical-mediated
Oxidative stress
defined, S1:3
free radicals and, *see* Free radicals
in IDDM, evaluation of, before and after glycemic control and after vitamin E supplementation, 160-162
introduction to, S1:1
measurement of, S1:5-6
see also Oxidative stress in NIDDM
Oxidative stress in NIDDM
AGE products and, *see* Advanced glycation end product(s), and oxidative stress in NIDDM
clinical relevance of, S1:30-34
combination therapy for, S1:33
glycemic control and, *see* Glycemic control, and oxidative stress in NIDDM
increase in, S1:6
sulfonylurea therapy of, *see* Sulfonylureas, effects of, on oxidative stress
tissue, $VOSO_4$ effects on, 404-405
Oxidized low-density lipoproteins (LDLs; β-lipoproteins)
cytotoxicity induced by, M1 effects on, 479-485
effects of LF diet with soluble fiber on, 67-72
EPA effects on lysophosphatidylcholine-induced migration in VSMCs and, 560-562

Oxidized low-density lipoproteins (LDLs; β-lipoproteins) (*Continued*)
see also Oxidation, LDL; Soy protein effects on LDL oxidation and lipids
Oxygen, *see* O_2

P (phosphorus) in primary hyperparathyroidism, 193
P yoelii (*Plasmodium yoelii*)-parasitized erythrocytes (red blood cells; RBCs), NIDDM reversed with, 937-941
p36 catalytic subunit and G6Pase transporter proteins of microsomal hepatic G6Pase system, ontogeny of, 1200-1203
P_i (inorganic phosphate), BCAA effects on, not mediated by glucagon or insulin, 98, 99
PA, *see* Pituitary adenoma, and Cushing's syndrome
PAI-1, *see* Plasminogen activator inhibitor-1
Palmitate
in cachexic cancer subjects, 934
glucose concentration and effects of long-term exposure of beta cells to, on insulin gene expression, 532-536
stanol ester effects on PP retinyl, 473, 478
triacsin C, 2-bromopalmitate, and FFAs downregulating adipocyte leptin, 326-330
Palmitic acid, RBC and SM membrane, 1165
Palmitoleic acid
RBC and SM membrane, 1165
in SM TGs in insulin-resistant obese and lean subjects, 222
Pancreas
CS-045 effects on weight of, in NIDDM, 1171
see also Pancreas in NIDDM; Pancreas transplantation; Pancreatic islets
Pancreas in NIDDM
restricted diet effects on, 110-112
weight of, voglibose and, 349
Pancreas transplantation, effects of systemic and/or portal venous drainage site on insulin action after, insulin resistance, risk of atherosclerosis and, 458-466
Pancreatic islets
diet effects on insulin and nutrient metabolism in MLN cells, splenocytes and, 1111-1117
PLC isozymes, inositol phosphate, insulin secretion, and α-KIC in, 1156-1163
see also Alpha cells; Beta cells
Paradoxically normal serum cholesterol in obese women, prevalence of, 600-606
Paraoxonase (PON1) gene polymorphism
Gln/Arg 192, differential effects of smoking on risk of myocardial infarction according to, 557-559
in NIDDM, and activity of serum diazoxonase and arylesterase, 1400-1405
Parathyroid adenoma in primary hyperparathyroidism, effects of excision of, on levels of IL-6 and IL-2 receptors, 192-194
Parathyroid hormone (PTH)
and bone metabolism in HIV infection, 1136, 1137
see also Hyperparathyroidism; Intact parathyroid hormone
Parenteral nutrition, total, metabolic effects of insulin and IGF-I in endotoxemia during, 611-615
Particle size of LDL, *see* Low-density lipoprotein, particle size of, in NIDDM
PAT5A, PPARγ activity of, 1417-1423
Paternal-maternal effects on NIDDM phenotypes, 651-656
Pathogenic factors
of glucose intolerance in obese Japanese adolescents with NIDDM, 186-191
see also specific conditions
PBMCs (peripheral blood mononuclear cells), effects of long and short leptin receptor isoforms in, on leptin, 1537-1541
PC (phosphatidylcholine), EPA effects on oxidized LDLs and lyso-PC-induced migration in VSMCs, 560-562
PC FAs (phosphatidylcholine fatty acids), NA-induced changes in composition of, associated with SM insulin responsiveness in healthy subjects, 232-238
PCR (protein catabolic rate) in methionine-induced hyperhomocysteinemia, 225
PDD (4α-phorbol 12,13-didecanoate), effects of, on pancreatic islets, 266
PDGF (platelet-derived growth factor) BB, EPA suppression of migration in VSMCs induced by, 560-562
PE FAs (phosphatidylethanolamine fatty acids), NA-induced changes in composition of, associated with SM insulin responsiveness in healthy subjects, 232-238
PEM (protein-energy malnutrition), serum leptin in children with, 819-825
PEPCK (phosphoenolpyruvate carboxykinase), hepatic, vanadate effects on hepatic G6Pase, hepatic G6PDH and, in lean IDDM subjects, gluconeogenesis and, 321-325
Peptide(s)
serum, rIGF-1 and hCG effects on ovarian concentrations of, 316
see also Calcitonin gene-related peptide; C-peptides; Glucagon-like peptide-1; Islet amyloid polypeptide; Natriuretic peptides; Polypeptide; Serum peptides *and specific peptides*
Perhydro-1,4-thiazepine-3,5-dicarboxylic (PHTZDC) acid, accumulation of cystathionine, CK and, in brain, D,L-propargylglycine effects on, 1025-1029
Perimenopausal women, serum DHEAS, serum estradiol, and soy protein intake in relation to psychological women in, 1561-1564
Peripheral blood mononuclear cells (PBMCs), effects of long and short leptin receptor isoforms in, on leptin, 1537-1541
Peripheral effects of GLP-1 receptor agonist on satiety and weight loss in NIDDM, central effects versus, 709-717
Peripheral glucose
fructose and, in healthy subjects, 1565-1571
JTT-501 effects on NHGB and uptake of, in NIDDM, 862-877
Peripheral neuropathy diabetic, zenarestat effects on, 1395-1399
Peroxidation, total plasma antioxidant capacity and indices of, in methionine-induced hyperhomocysteinemia, 225-228
Peroxides, *see* Lipid peroxides
Peroxisome proliferator-activated receptorγ, *see* PPARγ
Peroxisome proliferator-activated receptorγ2 (PPARγ2) Pro12Ala gene in NIDDM, BMI and, 1267-1270
Pharmacology of $VOSO_4$, 403
Phe, *see* Phenylalanine
Phenotypes
apolipoprotein E, in TD, 771
in NIDDM, paternal-maternal effects on, 651-656
obesity, interaction between α_2-, β_2-, and β_3-AR genes and, 1063-1070
Phentolamine
effects of, on GIIS, 265
effects of, on glucose regulation during and after high-intensity exercise, 386-394
Phenylacetate, effects of, on glucose production and gluconeogenesis, 1211-1214
Phenylalanine (Phe)
effects of, on system A transport of MeAIB in mammary gland, 875, 876
in glutamine-containing diet, 142
hyperammonemia effects on metabolism of, 1332
IV glutamine effects on synthesis of muscle, 1556, 1557
myocardial plasma, hyperinsulinemia effects on, in CHD, 1366
T_3 effects on reserve of, 801
tyrosine effects on hydroxylation of, in men, 444-449

4α-Phorbol 12,13-didecanoate (PDD), effects of, on pancreatic islets, 266
Phorbol-12-myristate-13-acetate (PMA), effects of, on MeAIB uptake, 876
Phosphatase
vanadate effects on PEPCK, hepatic G6PDH and, in lean IDDM subjects, gluconeogenesis and, 321-325
see also Adenosine triphosphatase; Alkaline phosphatase; Hepatic glucose-6-phosphatase
Phosphate, *see* cAMP; Diphosphate; Fructose-1,6-diphosphate; Galactose-1-phosphate uridyltransferase deficiency; Glucose-6-phosphate dehydrogenase; Glyceraldehyde-3-phosphate dehydrogenase mRNA; Inorganic phosphate; Inositol phosphate; K^+ channels, ATP-sensitive *and entries beginning with element*: Phosph-
Phosphatidylcholine (PC), EPA effects on oxidized LDLs and lysophosphatidylcholine-induced migration in VSMCs, 560-562
Phosphatidylcholine fatty acids (PC FAs), NA-induced changes in composition of, associated with SM insulin responsiveness in healthy subjects, 232-238
Phosphatidylethanolamine fatty acids (PE FAs), NA-induced changes in composition of, associated with SM insulin responsiveness in healthy subjects, 232-238
Phosphatidylinositol 3-kinase, *see* Insulin receptor substrate-1, PI 3K and
Phosphoenolpyruvate carboxykinase (PEPCK), hepatic, vanadate effects on hepatic G6Pase, hepatic G6PDH and, in lean IDDM subjects, gluconeogenesis and, 321-325
6-Phosphogluconate dehydrogenase in SAT, 596, 597
Phospholipase (PLC) isozymes, inositol phosphate, insulin secretion, and α-KIC in pancreatic islets, 1156-1163
Phospholipid(s) (PL)
aging-associated changes in metabolism of, in HHL, 553, 554
in FHTG, 944-946
in NIDDM, HDL_3 binding to leukocytes and, 691
see also Phospholipid fatty acid(s)
Phospholipid fatty acid(s) (PL FAs)
composition of adipocyte, 1182, 1183
liver cell membrane, effects of restricted diet and energy intake on, 977-983
Phosphorus (P) in primary hyperparathyroidism, 193
PHTZDC (perhydro-1,4-thiazepine-3,5-dicarboxylic) acid, accumulation of cystathionine, CK and, in brain, D,L-propargylglycine effects on, 1025-1029
Physical activity
insulin resistance, CV risk factors and, 1248, 1249, 1251
by relatives of NIDDM subjects, beta cell secretion in, 833-838
see also Exercise
Phytosterols, *see specific phytosterols*
PI 3K (phosphatidylinositol 3-kinase), *see* Insulin receptor substrate-1, PI 3K and
Pioglitazone, CS-045 and
effects of, on energy expenditure and energy storage in IBAT, compared, 1301-1308
effects of YM440 and, on hyperglycemia of NIDDM without AT weight change, compared, 411-417
Pituitary adenoma (PA), and Cushing's syndrome
circulating adrenomedullin in ACTH-dependent Cushing's syndrome due to pituitary adenoma, 760-763
testosterone production and, 230
Pituitary gland, *see* Hyperthyroidism; Hypothyroidism; Pituitary adenoma, and Cushing's syndrome
PKC (protein kinase C), ET_A and, in ET-1-potentiated insulin secretion, 264-269
PL(s), *see* Phospholipid(s)
Plasma
normal, HDL- and apo E-deficient, C efflux from TD and normal fibroblasts into, 770-777
viscosity of, in HCL and HTG, contribution of fibrinogen and Lps to, 810-813
Plasma *N*-acetyl-β-D-glucosaminidase at onset of IDDM with obesity and during IVGTT of healthy subjects, 1352-1355
Plasma adenosine, furosemide effects on, 886-889
Plasma alanine (Ala)
glucagon effects on concentrations of, dosage and, 41
myocardial, in CHD, 1366
Plasma amino acids (AAs) in LPI, lysine effects on, 622-623
Plasma antioxidant capacity, peroxidation indices and total, in methionine-induced hyperhomocysteinemia, 225-228
Plasma apolipoprotein(s) (apos)
atorvastatin effects on, 169-170
see also specific plasma apolipoproteins
Plasma apolipoprotein A-I (apo A-I), response of, to cycle-ergometer exercise, 516
Plasma apolipoprotein B (apo B), response of, to cycle-ergometer exercise, 516
Plasma brain natriuretic peptides (BNPs) in older hypertensive subjects with LVH, 1357
Plasma Ca (calcium), aging effects on, 254-256
Plasma caffeine, caffeine ingestion effects on, 103, 104
Plasma calcitonin (CT), haloperidol effects on secretion of, aging and, 255-256
Plasma cholesterol (C)
aging effects on, in HHL, 552-556
cerivastatin effects on, 1050
in HTG, atorvastatin effects on, 170
and LPL gene, 434, 435
in NIDDM, restricted diet effects on, 109, 110
stanol ester effects on, 475
total, response of, to cycle-ergometer exercise, 516
Plasma cholesteryl ester transfer protein (CETP)
and C efflux from TD and normal fibroblasts into normal and HDL- and apo E-deficient plasma, 771
in hypothyroidic infants, thyroid hormones and, 1176-1179
Plasma corticosterone in NIDDM with obesity, exendin-4 effects on, 711, 712
Plasma corticotropin (ACTH; adrenocorticotropic hormone) in Cushing's syndrome, 761
Plasma cortisol
cold exposure effects on, in women, 422
in Cushing's syndrome, 761
morning levels of, S_G and, 306, 307
pre- and post-exercise, 397
Plasma C-peptides (connecting peptides; CPs)
effects of elevated plasma FFAs on, in men, 451-453
fructose effects on, 1566
post-pancreas transplantation, effects of systemic and/or portal venous drainage site on, 461
variation in NIDDM and CHD risk and, 248
Plasma creatinine (Cr) in obesity, exendin-4 effects on, 711, 71[illegible]
Plasma cysteine (Cys) in ESRD patients on HD, vitamin B_{12} e[illegible]ts on, 217
Plasma dopamine in obesity, exendin-4 effects on, 711, 712
Plasma endothelin (ET), menstrual cycle modulation of, 648-650
Plasma epinephrine (E; EPI)
in elderly NIDDM subjects, effects of low-dose epinephrine on, 196-198
and kinetics of TEF, 1344
preoperative feeding effects on, 489
see also Plasma epinephrine in exercising men

Plasma epinephrine (E; EPI) in exercising men
α-adrenergic antagonist effects on, 387
AT metabolism during exercise and, 124-125
Plasma free fatty acids (FFAs; nonesterified fatty acids)
in exercising men, *see* Plasma free fatty acids in exercising men
fructose effects on, 1568
GIIS and, *see* Plasma free fatty acids, GIIS and
insulin regulation of concentrations of, muscle insulin resistance and, 151-154
in NIDDM, restricted diet effects on, 109, 110
preoperative feeding effects on, 489
S-rich diet effects on, 1348
Plasma free fatty acids (FFAs; nonesterified fatty acids), GIIS and
effects of Intralipid-induced elevation in, on basal insulin secretion or GIIS in men, 450-454
GIIS loss in dysfunctional beta cells and elevated beta cell TGs and, 755-759
Plasma free fatty acids (FFAs; nonesterified fatty acids) in exercising men
arterial FFAs in lean and obese exercising men, 582
FFA kinetics during high-intensity exercise, 123-124
Plasma galactitol in galactosemia due to GALT deficiency, 1460-1466
Plasma galactose in galactosemia due to GALT deficiency, 1460-1466
Plasma α-D-galactosidase at onset of IDDM in obese subjects and during IVGTT of healthy subjects, 1352-1355
Plasma glucagon (hyperglycemic factor; hyperglycemic-glycogenolytic factor)
BCAA effects on, not mediated by or insulin, 100
fructose effects on, 1566
Plasma glucose
arterial, vagotomy effects on, 13
BCAA effects on, not mediated by glucagon or insulin, 100
cold exposure effects on, in women, 422
effects of HF diet on, 1519
in endotoxemia, TPN effects on, 613
fasting, *see* Fasting plasma glucose
in IDDM, voglibose effects on, 441
and IMGU with low Mg, 419
in insulin sensitivity, 1502
and kinetics of TEF, 1344
long-term EPA-E effects on, 1589
metabolic effects of diet on, 1112
in metabolic syndrome, 750
in NIDDM, *see* Plasma glucose in NIDDM
in NIDDM subjects' relatives, 898
in obesity, exendin-4 effects on, 711, 712
phenylacetate effects on, 1212
post-pancreas transplantation steady-state, effects of systemic and/or portal venous drainage site on, 461
pre- and post-exercise, 397
S-rich diet effects on, 1348
and seasonal variation in S_I and glucose effectiveness in men, 34
in STZ-DM, *see* Plasma glucose in STZ-DM
Plasma glucose in NIDDM
in elderly subjects, low-dose epinephrine effects on, 195-202
and NIDDM progression to overt state, 685
restricted diet effects on, 109-111
variation in NIDDM and CHD risk and, 248
see also Fasting plasma glucose in NIDDM
Plasma glucose in STZ-DM
with hypoglycemia, IP and/or SC insulin effects on, 985-986
nicorandil effects on, 428
T-1095 effects on, 991-992
Plasma α-D-glucosidase at onset of IDDM and during IVGTT of healthy subjects, 1352-1355
Plasma β-D-glucuronidase at onset of IDDM in obese subjects and during IVGTT of healthy subjects, 1352-1355
Plasma glutamate (Glu), myocardial, hyperinsulinemia effects on, in CHD, 1366
Plasma glutamine (Gln), myocardial, hyperinsulinemia effects on, in CHD, 1366
Plasma glycerol
cold exposure effects on, in women, 422
see also Plasma glycerol in exercising men
Plasma glycerol in exercising men
arterial, in lean and obese exercising men, 582-583
during high-intensity exercise, 123-124
Plasma glycine (Gly)
glucagon dosage effects on concentrations of, 41
myocardial, hyperinsulinemia effects on, in CHD, 1366
Plasma glycohydrolase at onset of IDDM with obesity and during IVGTT of healthy subjects, 1352-1355
Plasma high-density lipoprotein-cholesterol (HDL-C), response of, to cycle-ergometer exercise, 516, 517
Plasma high-density lipoprotein$_2$-cholesterol (HDL_2-C), response of, to cycle-ergometer exercise, 516
Plasma high-density lipoprotein$_3$-cholesterol (HDL_3-C), response of, to cycle-ergometer exercise, 516
Plasma high-density lipoprotein cholesteryl ester (HDL CE), exercise effects on, 826-832
Plasma homocysteine (HcY)
in ESRD subjects on HD, vitamin B_{12} effects on, 215-219
MTHFR gene 677C → T mutation effects on response of, to folate intake by elderly women, 1440-1443
Plasma hormones
arterial, in lean and obese exercising men, 581-582
see also specific hormones
Plasma hypoxanthine
BCAA effects on, not mediated by glucagon or insulin, 97-100
furosemide effects on, 886-889
Plasma insulin
BCAA effects on, 100
cold exposure effects on, in women, 422
in endotoxemia, TPN effects on, 613
FAs and, *see* Plasma insulin, FAs and
fasting, *see* Fasting plasma insulin
and HKII expression in SM, 815
and IMGU with low Mg, 419
and kinetics of TEF, 1344
long-term EPA-E effects on, 1589
metabolic effects of diet on, 1112
in NIDDM, *see* Plasma insulin in NIDDM
in NIDDM subjects' relatives, 898
in obesity, *see* Plasma insulin in obesity
plasma leptin and, *see* Plasma leptin, plasma insulin and, in healthy subjects
post-pancreas transplantation steady-state, and effects of systemic and/or portal venous drainage site on, 461
pre- and post-exercise, 397
in STZ-DM, diazoxide effects on, 658, 659
and thermic response of young and older women to caffeine, 103, 105
Plasma insulin, FAs and
effects of dietary FA composition, 1183
effects of elevated plasma FFAs on plasma insulin in men, 451-453
and RBC FA composition, 1165
Plasma insulin in NIDDM
and NIDDM progression to overt diabetic state, 685
paternal-maternal effects of NIDDM phenotypes and, 654
restricted diet effects on, 109-111
and variation in NIDDM and CHD risk, 248

Plasma insulin in obesity
exendin-4 effects on, 711, 712
impaired skin vasoconstrictive response to sympathetic activation and, 601
Plasma insulin-like growth factor-I (IGF-I)
in endotoxemia, TPN effects on, 613
S-rich diet effects on, 1348
Plasma isoleucine (Ile)
BCAA effects on, not mediated by glucagon or insulin, 98-99
myocardial, in CHD, 1366
Plasma lactate
during high-intensity exercise, 123
plasma FFA concentrations effects on, 453
preoperative feeding effects on, 489
Plasma leptin
in endotoxemia, TPN effects on, 613
in healthy subjects, *see* Plasma leptin in healthy subjects
HF diet effects on diurnal variation in concentrations of, 503-507
in men, delayed effects of exercise on concentrations of, 395-399
in women, hyperinsulinemia and, 1055-1062
Plasma leptin, plasma insulin and, in healthy subjects
fasting, 499-502
link between plasma insulin and plasma leptin and between plasma insulin and BMI, compared, 544-547
Plasma leptin in healthy subjects
with insulin resistance, 959-961
in women, effects of acute cold exposure on, 421-423
see also Plasma leptin, plasma insulin and, in healthy subjects
Plasma leucine (Leu)
BCAA effects on, not mediated by glucagon or insulin, 98-99
glucagon dosage effects on concentrations of, 41
myocardial, in CHD, 1366
Plasma lipids
aging effects on, in HHL, 553
GIIS loss in dysfunctional beta cells and elevated beta cell TGs or, 755-759
and LPL gene association with AT, concentrations of plasma Lp concentrations, and postheparin lipase activity, 432-439
in nephrotic syndrome, NO-1886 effects on, 589
in NIDDM, *see* Plasma lipids in NIDDM
response of, to cycle-ergometer exercise, 515-516
Plasma lipids in NIDDM
with dyslipidemia, 23, 25, 26
EPA-E effects on, 917
relation of, to insulin resistance, FFAs, and AT in Afro-Caribbean, South Asian, and European men, variation in NIDDM and CHD risk and, 245-252
Plasma lipoprotein(s) (Lps)
LPL gene associated with AT, postheparin lipase activity, plasma Lp concentrations, and concentrations of, 432-439
in NIDDM with dyslipidemia, 23, 25-27
Plasma lipoprotein lipase (LPL) activity
aging and, in HHL, 553
LPL gene associated with AT, plasma lipids, plasma Lp concentrations and, 432-439
in NIDDM, restricted diet effects on, 110
Plasma low-density lipoprotein (LDL) in diabetic and nondiabetic subjects, soy protein effects on, 1191
Plasma malondialdehyde (MDA) in methionine-induced hyperhomocysteinemia, 226
Plasma Mg (magnesium), IMGU in healthy subjects with low, 418-420
Plasma NH_3 (ammonia) in LPI, lysine effects on, 624
Plasma nitric oxide (NO) in healthy insulin-resistant subjects, 959-961
Plasma norepinephrine (NE)
cold exposure effects on, in women, 422
Plasma norepinephrine (NE) (*Continued*)
in exercising men, *see* Plasma norepinephrine in exercising men
and kinetics of TEF, 1344
in obesity, exendin-4 effects on, 711, 712
Plasma norepinephrine (NE) in exercising men
α-adrenergic antagonist effects on, 387
and AT metabolism during exercise, 124-125
Plasma phenylalanine (Phe), myocardial, in CHD, 1366
Plasma prolactin (PRL), haloperidol effects on secretion of, aging and, 255-256
Plasma protein
total, in methionine-induced hyperhomocysteinemia, 225
see also specific proteins
Plasma serine (Ser), glucagon dosage effects on concentrations of, 41
Plasma serotonin in obesity, exendin-4 effects on, 711, 712
Plasma testosterone (T)
aging effects on CT secretion and, 254
in Cushing's syndrome subjects, 230
Plasma threonine (Thr), myocardial, hyperinsulinemia effects on, in CHD, 1366
Plasma triglycerides (TGs)
cerivastatin effects on, 1050
exercise effects on, 829
fasting, in HTG, JTT-501 effects on, 575
fructose effects on, 1566
and LPL gene, 434
in NIDDM, progression to overt diabetic state, 685
in obesity, exendin-4 effects on, 711, 712
response of, to cycle-ergometer exercise, 516
S-rich diet effects on, 1348, 1349
stanol ester effects on, 475
Plasma tyrosine (Tyr), myocardial, hyperinsulinemia effects on, in CHD, 1366
Plasma uric acid
BCAA effects on, not mediated by glucagon or insulin, 97-100
furosemide effects on, 886-889
Plasma uridine
BCAA effects on, not mediated by glucagon or insulin, 97-100
furosemide effects on, 886-889
Plasma valine (Val)
BCAA effects on, not mediated by glucagon or insulin, 98-99
myocardial, hyperinsulinemia effects on, in CHD, 1366
Plasma very-low-density lipoprotein-cholesterol (VLDL-C), response of, to cycle-ergometer exercise, 516
Plasma xanthine
BCAA effects on, not mediated by glucagon or insulin, 97-100
furosemide effects on, 886-889
Plasminogen activator inhibitor-1 (PAI-1)
in infantile obesity, 673
in NIDDM with fibrinolysis, troglitazone effects on, 665
TNF-α and TGF-β_1 effects on secretion of, by subcutaneous and omental adipocytes, 666-671
see also Plasminogen activator inhibitor-1 antigen; Plasminogen activator inhibitor-1 gene
Plasminogen activator inhibitor-1 antigen (PAI-1-Ag), leptin, fat mass and, in obese children and adolescents, 890-895
Plasminogen activator inhibitor-1 (PAI-1) gene, 4G/4G polymorphism of, as risk factor for pregnancy complications, 845-852
Plasmodium yoelii (*P yoelii*)-parasitized erythrocytes (red blood cells), NIDDM reversed with, 937-941
Platelet aggregation
long-term EPA-E effects on, 918
in NIDDM, gliclazide and glibenclamide effects on, S1:24, S1:33
Platelet-derived growth factor (PDGF) BB, EPA suppression of migration in VSMCs induced by, 560-562

Platelet function
abnormal, effects of glycemic control of IDDM on microvascular disease and, 88-91
in FHTG, VLDL apo E and, 942-949
Platelet lipids, long-term EPA-E effects on, 917-918
PLC (phospholipase) isozymes, inositol phosphate, insulin secretion, and α-KIC in pancreatic islets, 1156-1163
PMA (phorbol-12-myristate-13-acetate), effects of, on MeAIB uptake, 876
Polymorphism
α_2- and β_3-AR gene, obesity phenotype and, 1063-1070
β_2-AR gene, *see* Gln27Glu polymorphism of β_2-AR gene
of 5`-flanking region of glucocorticoid receptor gene locus associated with basal cortisol secretion in men, 1197-1199
4G/4G, of hypofibrinolytic PAI-1 gene, as risk factor for pregnancy complications, 845-852
LPL S447X, postheparin lipase activity, plasma lipid and plasma Lp concentrations and, 432-439
PON1 gene, *see* Paraoxonase gene polymorphism
TH gene microsatellite, associated with insulin resistance in depressive disorder, 1145-1149
of TNF-α gene, *see* Tumor necrosis factor-α gene polymorphism
see also Polymorphism in NIDDM
Polymorphism in NIDDM, 718-730
apo E, AT distribution, leptin, metabolic parameters and, 724-730
of MTHFR gene, lack of association between carotid IMT with serum HcY or, 718-723
PON1 gene, and activity of serum diazoxonase and arylesterase, 1400-1405
Polypeptide, islet amyloid, effects of HF diet-induced insulin resistance on insulin mRNA and, 1518-1522
Polyunsaturated fatty acids (PUFAs)
effects of dietary FA composition in pregnant and nonpregnant subjects on, 1183
in hyperlipidemia, 538, 539
in LF diet, 68, 732
in obesity-inducing diet, 1296
RBC and SM membrane, 1165
soy protein and, *see* Polyunsaturated fatty acids, and soy protein
see also Fish oil; Olive oil; ω3-Polyunsaturated fatty acids; ω6-Polyunsaturated fatty acids
Polyunsaturated fatty acids (PUFAs), and soy protein
and arterial LDL delivery, 1189
in soy-based breakfast cereal, 1497
ω3 (omega3)-Polyunsaturated fatty acids (ω3-PUFAs)
dietary, effects of chronic ethanol consumption and, on RCT, 508-512
RBC and SM membrane, 1165
ω6 (omega6)-Polyunsaturated fatty acids (ω6-PUFAs), RBC and SM membrane, 1165
PON1, *see* Paraoxonase gene polymorphism
Portal venous drainage site, effects of, on insulin action after pancreas transplantation, insulin resistance, risk of atherosclerosis and, 458-466
Postabsorptive state, *see entries beginning with term*: Postprandial
Postbreakfast beta (β) cell function, Ultralente insulin effects on, in healthy subjects, 1243-1246
Postheparin lipase activity
in dyslipidemic NIDDM, 25-26
in HTG, JTT-501 effects on, 575
LPL gene associated with AT, plasma lipid and plasma Lp concentrations and, 432-439
Postmenopausal women
body composition of, *see* Postmenopausal women, body composition of
HRT of, *see* Hormone replacement therapy
Postmenopausal women (*Continued*)
lipids and Lps in men, premenopausal women and, compared, 1101-1105
serum DHEAS, serum estradiol, and soy protein intake in relation to psychological well-being in women, 1561-1564
Postmenopausal women, body composition of
obese and lean women, PP RMR and TEF relationship to body composition and AT distribution, 6-10
relationship between serum leptin, sex steroid levels, body composition, and insulin levels in, 1278-1284
Postnatal growth and development
collagen cross-links and early, of IUGR infants, 1467-1472
effects of insulin and dietary changes at weaning on intestinal galactosyltransferase activity during, 526-531
Postoperative skeletal muscle (SM) insulin resistance, preoperative feeding effects on, 486-491
Postprandial (PP) apolipoprotein B-48 (apo B-48)-containing lipoproteins (Lps) in NIDDM, cerivastatin effects on TGs and, 1049-1054
Postprandial (PP) apolipoprotein B-100 (apo B-100)-containing lipoproteins (Lps) in NIDDM, cerivastatin effects on TGs and, 1049-1054
Postprandial (PP) blood glucose in IDDM and NIDDM before and after glycemia control and after vitamin E supplementation, oxidative stress and, 161, 162
Postprandial (PP) lipemia
autoantibodies to oxidatively modified LDLs in atherosclerosis and, 1271-1277
after short-term variation in dietary fat and CHOs, 1150-1155
Postprandial (PP) resting metabolic rate (PP RMR), relationship of TEF and, to body composition and AT distribution in obese and lean subjects, 6-10
Postprandial (PP) squalene and retinyl palmitate, stanol ester effects on, 473-478
Postprandial (PP) state, effects of high-CHO diet on metabolic profile in NIDDM, high-monounsaturated fat diet and olive oil diet effects compared with, 1511-1517
Potassium, *see* K
PP, *see entries beginning with term*: Postprandial
PPARγ (peroxisome proliferator-activated receptorγ)
activity of PAT5A, 1417-1423
effects of YM440, pioglitazone, and troglitazone on, compared, 412
PPARγ2 (peroxisome proliferator-activated receptorγ2) Pro12Ala gene in NIDDM, BMI and, 1267-1270
Pravastatin (PV), effects of, on gonadal function in hypercholesterolemic men, 115-121
Prealbumin in weight-losing cancer subjects, 934
Preeclamptic pregnancy
in STZ-DM, 853-857
see also Pregnancy, leptin in preeclamptic
Pregnancy
effects of dietary FA composition on lipolytic β_3-adrenergic agonist response to hyperinsulinemia in adipocytes in, 1180-1187
4G/4G polymorphism of hypofibrinolytic PAI-1 gene as risk factor for complications in, 845-852
see also Preeclamptic pregnancy
Pregnancy, leptin in preeclamptic
free leptin increase in normal and, 1043-1048
relationship to serum insulin and insulin sensitivity during and after, 259-263
Premenopausal women
body composition of, *see* Premenopausal women, body composition of
lipids and Lps in men, postmenopausal women and, compared, 1101-1105

Premenopausal women, body composition of
obese and lean women, PP RMR and TEF relationship to body composition and AT distribution, 6-10
relationship between serum leptin, sex steroid levels, body composition, and insulin levels in, 1278-1284
Preoperative feeding, effects of, on postoperative SM insulin resistance, 486-491
Preproinsulin in STZ-DM, diazoxide effects on, 659
Prevalence
of paradoxically normal serum C in obese women, 600-606
see also specific conditions
Prevention
of DM and DM-related coagulation abnormalities with EPA-E, 912-919
reversal and, of dyslipidemia, defective insulin secretion, and histologic abnormalities in obese NIDDM subjects with CS-045, 1167-1175
Primary hyperparathyroidism (HPT), effects of parathyroid adenoma excision in, on levels of IL-6 and IL-2 receptors, 192-194
PRL, *see* Prolactin
Pro, *see* Proline
Probucol, effects of M1 and, on LDL oxidation and oxidized LDL-induced cytotoxicity, compared, 479-485
Progestin, estrogen with, postmenopausal women with or without hypercholesterolemia on, 784-789
Progression
of diabetic nephropathy, pulsatile IV insulin effects on, 1491-1495
of NIDDM to overt diabetic state, 684-688
Prolactin (PRL)
and aging effects on calcitonin secretion, 253-258
and bone metabolism in HIV infection, 1136
galanin effects on secretion of, in anorexia nervosa, 155-159
Proline (Pro)
effects of, on system A transport of MeAIB in mammary gland, 875, 876
in glutamine-containing diet, 142
IV glutamine effects on synthesis of muscle, 1556, 1557
PPARγ2 Pro12Ala gene in NIDDM, BMI and, 1267-1270
D,L-Propargylglycine, effects of, on accumulation of cystathionine, CK, and PHTZDC acid in brain, 1025-1029
Propranolol
effects of, on ATBF in lean and obese exercising men, 583
effects of, on GIIS, 265
Protease, IGFBP-2, serum and urinary IGFBPs and activity of, in IDDM, 626-633
Proteasome-ubiquitin pathway in muscle proteolysis, hypercatabolism and, 689-691
Protein(s)
agouti-related protein(83-132), blood-brain barrier crossing by 1444-1448
binding, *see* Binding protein
carbonylated, T_3 effects on reserve of, 801
cholesteryl ester transfer, *see* Cholesteryl ester transfer protein
dietary, *see* Dietary protein intake
in FHTG, 944-946
FPLC of plasma lipids and Lps in dyslipidemic NIDDM, 23, 25
GLUT1, GLUT3, and GLUT4, subcellular distribution of, in SM, compared, 1604-1609
hyperammonemia effects on metabolism of, 1330-1334
intracellular, effects of AGE products on, S1:9
kinetics of muscle, in endotoxemia, TPN effects on, 614
mRNA of, *see* mRNA, protein
muscle, *see* Muscle protein
pancreatic islet, 1157-1158
soy, *see* Soy protein
Protein(s) (*Continued*)
total, *see* Total protein
see also Proteinuria; Proteolysis *entries beginning with term*: Protein *and specific proteins*
Protein catabolic rate (PCR) in methionine-induced hyperhomocysteinemia, 225
Protein-energy malnutrition (PEM), serum leptin in children with, 819-825
Protein intolerance, lysinuric, lysine effects on urea cycle in, 621-625
Protein kinase C (PKC), ET_A and, in ET-1-potentiated insulin secretion, 264-269
Protein liquid chromatography, fast, of plasma lipid and Lps in dyslipidemic NIDDM, 23, 25
Protein-1 mRNA (messenger ribonucleic acid), TNF-α-induced expression of monocyte chemoattractant, in mesangial cells, troglitazone effects on, 163-166
Proteinuria
CS-045 effects on, in DM with obesity, 1362
in diabetic nephropathy, 1493, 1494
and leptin relationship to serum insulin and insulin sensitivity during and after healthy and/or preeclamptic pregnancy, 260
in nephrotic syndrome, NO-1886 effects on, 589
in STZ-DM, nicorandil effects on, 428
see also Albuminuria
Proteolysis, muscle, ubiquitin-proteasome pathway in, hypercatabolism and, 689-691
Prothrombin in cirrhosis, 1435
Psychological well-being in perimenopausal and postmenopausal women, serum DHEAS, serum estradiol, and soy protein intake in relation to, 1561-1564
PTH, *see* Parathyroid hormone
PUFAs, *see* Polyunsaturated fatty acids
Pulsatile intravenous (IV) insulin, effects of, on diabetic nephropathy progression, 1491-1495
Pulse rate, *see* Heart rate
Purine bases, *see* Plasma hypoxanthine; Plasma uric acid; Plasma xanthine
PV (pravastatin), effects of, on gonadal function in hypercholesterolemic men, 115-121
Pyruvate, intracellular, in mesangial cells, troglitazone effects on, 310-311
Pyruvic acid, BCAA effects on, not mediated by glucagon or insulin, 97-100

Race and ethnicity
and aging effects on leptin and testosterone in older men, 1085-1091
and blood lipid response to cycle-ergometer exercise, 513-520
and estradiol and estrogen effects on lipids in boys, 1124-1129
of hypercholesterolemic men, simvastatin and pravastatin effects on gonadal function and, 117
in NIDDM, *see* Race and ethnicity, NIDDM and
obesity independent of insulin resistance in normoglycemic Hong Kong Chinese as blood pressure determinant, 1523-1528
plasma glucose during OGTT correlated with FPG in South Indians, 455-457
see also entries beginning with terms: Japanese subjects *and specific conditions*
Race and ethnicity, NIDDM and
in familial NIDDM among African Americans, molecular analysis of HNF1α *TCF1* gene in, 280-284
plasma lipid relationship to insulin resistance, FFAs, and AT in Afro-Caribbean, European, and South Asian men, variation in NIDDM and CHD risk and, 245-252
PPARγ2 Pro12Ala gene and BMI in Taiwanese NIDDM subjects, 1267-1270

RBCs (red blood cells), *see* Erythrocyte(s)
RCT, *see* Reverse cholesterol transport, and alcohol consumption
Reactive oxygen species (ROS)
  T_3 effects on leukocyte generation of, oxidative damage indices, and antioxidant reserve, 799-803
  see also Free radicals
Recombinant insulin-like growth factor-I, *see* Insulin-like growth factor-I
Red blood cells, *see* Erythrocyte(s)
Redox potential, cellular, in mesangial cells, troglitazone effects on, 310-311
Reduced glutathione (GSH)
  in IDDM and NIDDM before and after glycemia control and after vitamin E supplementation, oxidative stress and, 161, 162
  methionine and synthesis of, in healthy and cirrhotic subjects, 1434-1439
Reductase, *see* 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase; Methylenetetrahydrofolate reductase
REE, *see* Resting energy expenditure
Regular alcohol intake, *see* Chronic alcohol intake
Relatives of NIDDM subjects, beta cells in healthy
  beta cell dysfunction in, 896-905
  physically active, lower beta cell secretion in, 833-838
  tissue insulin sensitivity and beta cell contribution to glycemia in, 1322-1323
Renal failure, vitamin B_{12} effects on plasma HcY in subjects on HD for, 215-219
Renal Na^+ (sodium)-GLUT2, effects of inhibition of, with T-1095 on hyperglycemia of STZ-DM, 990-995
Renal protective effects of CS-045 in DM with obesity, 1361-1364
Renal substrate supply, insulin regulation of, 676-683
Reproductive cycle, effects of rIGF-I and hCG on, 315
Resistance
  leptin, hypothalamic leptin receptor mRNA and protein and downregulation of, 1479-1484
  see also Insulin resistance
Respiratory quotient (RQ)
  HF diet effects on, 505
  and relationship of PP RMR and TEF to body composition and AT distribution in lean and obese subjects, 7
Resting energy expenditure (REE)
  in cachexic cancer subjects, 934
  by men during high-intensity exercise, 123, 124
Resting metabolic rate (RMR)
  relationship of PP TEF and, to body composition and AT distribution in lean and obese subjects, 6-10
  and thermic response of young and older women to caffeine, 101-106
Restricted food intake
  effects of, on NIDDM and TGs, 108-114
  effects of, on PL FA liver cell membrane, related to dietary fat type, 977-983
Retinyl palmitate
  in NIDDM, effects of high-monounsaturated fat diet and olive oil diet on, 1514
  stanol ester effects on PP squalene and PP, 473-478
Retroperitoneal area
  effects of long-term high-S diet with dexamethasone on AT depots, liver steatosis, and lipid fluxes in, 1289-1291
  of obese STZ-DM subjects, WAT in, 135
Reversal
  of dyslipidemia, defective insulin secretion, and histologic abnormalities in NIDDM with obesity with CS-045, 1167-1175
  of NIDDM with *P yoelii* parasitized RBCs, 937-941
Reverse cholesterol transport (RCT), and alcohol consumption
  effects of ω3-PUFAs and chronic consumption on RCT, 508-512
  in HDLs of alcoholics, 1406-1410
Reversibility of sulfonylurea inhibition, S2:5
Rexinoids, effects of rosiglitazone and, on obesity and uncoupling protein isoform mRNA, 1610-1615
Rheological disorders, effects of, on skin vasoconstrictive response to sympathetic activation in obesity, 600-606
rIGF-I (recombinant insulin-like growth factor-I), *see* Insulin-like growth factor-I
Ribonucleic acid, *see* mRNA
Risk
  of pregnancy complications, 4G/4G polymorphism of hypofibrinolytic PAI-1 gene and, 845-852
  see also Risk of CV disease
Risk of CV disease
  of atherosclerosis, systemic and/or portal venous drainage site effects on insulin action after pancreas transplantation and, 458-466
  of atherothrombosis in infantile obesity, 672-675
  effects of LF diet with sucrose or starchy foods on, 731-735
  impaired insulin secretion, insulin resistance and, 1247-1254
  of myocardial infarction, differential effects of smoking on, according to Gln/Arg 192 polymorphism of PON1 gene, 557-559
  see also Risk of CV disease in men
Risk of CV disease in men
  of CHD in NIDDM, plasma lipid relationship to insulin resistance, FFAs, and AT in Afro-Caribbean, European, and South Asian men and variation in, 245-252
  subcutaneous central AT associated with, independently of total AT and CV fitness, 1379-1385
RMR, *see* Resting metabolic rate
ROS, *see* Reactive oxygen species
Rosiglitazone, effects of rexinoids and, on obesity and uncoupling protein isoform mRNA, 1610-1615
RQ, *see* Respiratory quotient
RT1^u haplotype, metabolic syndrome in spontaneous HTG with, 1140-1144

S, *see* Sucrose
S447X polymorphism of LPL, postheparin lipase activity, plasma lipid and plasma Lp concentrations and, 432-439
S_G, *see* Glucose effectiveness
S_i, *see* Insulin sensitivity
Safety of high-dose simvastatin, 1236
Safflower oil in soy protein diet, 1189
SAT, *see* Subcutaneous adipose tissue
Satiety, central versus peripheral effects of GLP-1 receptor agonist on weight loss and, in NIDDM, 709-717
Saturated fatty acids (SFAs)
  and effects of dietary FA composition in pregnant and nonpregnant subjects on, 1183
  effects of restricted, on cell liver membrane PL, 977, 979, 980
  effects of short-term variation in CHOs and, on PP lipemia, 1151
  insulin resistance correlated with increased, in SM TGs, 220-224
  in LF diet, 68, 732
  in obesity-inducing diet, 1296
  RBC and SM membrane, 1165
  see also Saturated fatty acids, soy protein and
Saturated fatty acids (SFAs), soy protein and
  and arterial LDL delivery, 1189
  in hyperlipidemia, 538, 539
  in LF diet, 68, 732
  in soy-based breakfast cereal, 1497
SC, *see entries beginning with term*: Subcutaneous

Scavenging activity
of nicorandil and tilisolol hydrochloride on free radicals and LPO in STZ-DM, compared, 427-431
see also Gliclazide scavenging activity in NIDDM
Seasonal variation in insulin sensitivity and glucose effectiveness in men, 32-38
Secondary amenorrhea in Cushing's syndrome, testosterone production and, 230
Sedentary (untrained) men, AT metabolism in, 122-128
Semen, simvastatin and pravastatin effects on, in hypercholesterolemia, 118, 119
Sepsis, T_4 and TBG in, 753-754
Serine (Ser)
effects of, on system A transport of MeAIB in mammary gland, 875, 876
in glutamine-containing diet, 142
hyperammonemia effects on metabolism of, 1332
IV glutamine effects on synthesis of muscle, 1556, 1557
metformin effects on, 1623
plasma, glucagon dosage effects on concentrations of, 41
Serotonin, plasma, in obesity, exendin-4 effects on, 711, 712
SERP-1, metabolism and distribution of, 1449-1452
Serum advanced glycation end (AGE) products in diabetic nephropathy, 1030-1035
Serum albumin in cirrhosis, circulating CT and, 48
Serum alkaline phosphatase (ALP) in cirrhosis, circulating CT and, 48
Serum androstenedione (A; Δ_4-DIONE), rIGF-I and hCG effects on concentrations of, in ovaries, 316
Serum apolipoprotein(a) [apo(a)], fasting, and variation in CHD and NIDDM risk, 248
Serum apolipoprotein A-I (apo A-I), fasting, and variation in CHD and NIDDM risk, 248
Serum apolipoprotein A-II (apo A-II), fasting, and variation in CHD and NIDDM risk, 248
Serum apolipoprotein B (apo B), fasting, variation in CHD and NIDDM risk, 248
Serum arylesterase, activity of, in NIDDM, PON1 gene polymorphisms and, 1400-1405
Serum aspartate aminotransferase (AST) in cirrhosis, circulating CT and, 48
Serum bilirubin in cirrhosis, circulating CT and, 48
Serum Ca and Ca^{2+} (calcium)
and bone metabolism in HIV infection, 1136, 1137
in young women on OCs, 1079
Serum campesterol, stanol ester effects on, 474
Serum cholestanol, stanol ester effects on, 474
Serum Δ8 (delta8)-cholestenol, stanol ester effects on, 474
Serum Δ8 (delta8)-cholestenol/sitosterol, stanol ester effects on, 474
Serum cholesterol (C)
in diabetic nephropathy, 1031
in metabolic syndrome, 750
in NIDDM, *see* Serum cholesterol in NIDDM
paradoxically normal, in obese women, prevalence of, 600-606
and RBC FA composition, 1165
soy protein effects on, 540
stanol ester effects on, 474
Serum cholesterol (C) in NIDDM
CS-045 effects on, 1168-1170
fasting, variation in CHD and NIDDM risk and, 248
total, bezafibrate therapy effects on, 332
Serum cortisol (hydrocortisone), levels of, prior to FSIGTT, correlated with S_G, 305-307
Serum C-peptide in NIDDM subjects' relatives, 898
Serum creatinine (Cr)
in cirrhosis, circulating CT and, 48
Serum creatinine (Cr) (*Continued*)
CS-045 effects on, in DM with obesity, 1362
in LPI, 622
of older hypertensive subjects with LVH, 1357
see also Serum creatinine in diabetic nephropathy
Serum creatinine (Cr) in diabetic nephropathy
and progression of diabetic nephropathy, 1493
serum AGE products and, 1031
Serum dehydroepiandrosterone (DHEA), circadian rhythms of cortisol, cortisol/DHEA molar ratio and, after single DHEA administration in young and older subjects, compared, 548-551
Serum dehydroepiandrosterone sulfate (DHEAS), serum estradiol, soy protein intake and, in relation to psychological well-being of perimenopausal and postmenopausal women, 1561-1564
Serum desmosterol, stanol ester effects on, 474
Serum desmosterol/sitosterol, stanol ester effects on, 474
Serum diazoxonase, activity of, in NIDDM, PON1 gene polymorphisms and, 1400-1405
Serum estradiol (E_2)
rIGF-I and hCG effects on concentrations of, in ovaries, 316
serum DHEAS, soy protein intake and, in relation to psychological well-being in perimenopausal and postmenopausal women, 1561-1564
Serum estrone, rIGF-I and hCG effects on concentrations of, in ovaries, 316
Serum follicle-stimulating hormone (FSH), high-dose simvastatin effects on, in hypercholesterolemic men, 1236
Serum free fatty acids (FFAs; nonesterified fatty acids)
in NIDDM, CS-045 effects on, 1168-1170
in obesity, 1215
Serum glucose
CS-045 effects on, in DM with obesity, 1362
in LPI, lysine effects on, 624
masoprocol effects on, in F-induced HTG, 1107
preoperative feeding effects on, 489
Serum high-density lipoprotein (HDL), soy protein effects on, 540
Serum high-density lipoprotein-cholesterol (HDL-C)
in metabolic syndrome, 750
in NIDDM, *see* Serum high-density lipoprotein-cholesterol in NIDDM
Serum high-density lipoprotein-cholesterol (HDL-C) in NIDDM
bezafibrate therapy effects on, 332
fasting, variation in CHD and NIDDM risk and, 248
Serum high-density $lipoprotein_2$-cholesterol (HDL_2-C), fasting, variation in CHD and NIDDM risk and, 248
Serum high-density $lipoprotein_3$-cholesterol (HDL_3-C), fasting, variation in CHD and NIDDM risk and, 248
Serum homocysteine (HcY) in NIDDM, lack of association between carotid IMT with MTHFR gene polymorphism or, 718-723
Serum β-hydroxybutyrate, correlation between apo A-I mRNA and, 1574-1575
Serum insulin
CS-045 effects on, in DM with obesity, 1362
effects of seasonal S_G variation on, 34
fasting, *see* Fasting serum insulin
and glycemia after protein ingestion, 2
IRS-1 and PI 3K effects on, 956
leptin and, *see* Serum insulin, leptin and
in LPI, lysine effects on, 624
in metabolic syndrome, 750
in NIDDM, CS-045 effects on, 1170-1171
preoperative feeding effects on, 489
Serum insulin, leptin and
leptin relationship to S_I and, during and after preeclamptic or healthy pregnancy, 259-263

Serum insulin, leptin and (*Continued*)
in obese children, and relationship between PAI-1 antigen, leptin, and FM, 891, 892
Serum insulin-like growth factor-binding proteins (IGFBPs)
in IDDM, IGFBP-2 protease activity and, 626-633
in NIDDM subjects' relatives, 898
Serum intact parathyroid hormone (iPTH), effects of Mg supplementation on intestinal absorption of $^{45}CaCl$ in women with low erythrocyte Mg, 1092-1098
Δ7 (delta7)-Serum lathosterol, stanol ester effects on, 474
Δ7 (delta7)-Serum lathosterol/sitosterol, stanol ester effects on, 474
Serum leptin, 1278-1288
in children with severe PEM, 819-825
hyperthyroidism and, 1285-1288
relationship between sex steroid levels, body composition, insulin levels and, 1278-1284
Serum lipids
effects of low-fat diet with soluble fiber and soy and vegetable protein on, 67-72
in hypercholesterolemia, simvastatin effects on, 1235
in obesity, 1215
soy protein effects on, 67-72
see also specific lipids
Serum lipoproteins (Lps)
acute alcohol intake effects on, 64
see also specific lipoproteins
Serum low-density lipoprotein (LDL)
prevalence of paradoxically normal, in obese women, 608, 610
soy protein effects on, 540
Serum low-density lipoprotein-cholesterol (LDL-C), fasting, variation in CHD and NIDDM risk and, 248
Serum luteinizing hormone (LH), high-dose simvastatin effects on, in hypercholesterolemic men, 1236
Serum mevalonic acid, urinary excretion and concentration of, during acute alcohol intake, 62-66
Serum Na (sodium) in cirrhosis, circulating CT and, 48
Serum peptides, rIGF-I and hCG effects on concentrations of, in ovaries, 316
Serum sex hormone-binding globulin (SHBG), high-dose simvastatin effects on, in hypercholesterolemic men, 1236
Serum sitosterol, stanol ester effects on, 474
Serum testosterone (T), IGF-I and hCG effects on concentrations of, in ovaries, 316
Serum thyrotropin (TSH) in hyperthyroidism, 1286, 1287
Serum thyroxine (T_4), free, in hyperthyroidism, 1286, 1287
Serum triglycerides (TGs)
in fructose-induced hypertriglyceridemia, masoprocol effects on, 1106-1110
in metabolic syndrome, 750
and RBC FA composition, 1165
see also Serum triglycerides in NIDDM
Serum triglycerides (TGs) in NIDDM
bezafibrate therapy effects and, 332
CS-045 effects on, 1168-1170
fasting, variation in CHD and NIDDM risk and, 248
with fibrinolysis, troglitazone effects on, 663
Serum triiodothyronine (T_3), free, in hyperthyroidism, 1286
Serum uric acid
effects of D-tagatose on, 971
in obesity, 1215
Serum very-low-density lipoprotein-cholesterol (VLDL-C), fasting, variation in CHD and NIDDM risk and, 248
Serum vitamin D_3 ([1,25$(OH)_2D_3$]; 1,25-dihydroxycholecalciferol), and bone metabolism in HIV infection, 1136, 1137
Severity of disease
of cirrhosis, relationship of circulating CT to CGRP and, 47-52
see also specific conditions
Sex
of acromegalic subjects, 635
of alcoholics, HDLs and, 1408
of atherosclerotic subjects, 1272, 1275
and blood lipid response to exercise, 517
of cachexic cancer subjects, 932, 933
of CAH patients, 791
of cirrhotic subjects, *see* Sex of cirrhotic subjects
of depressed subjects, 1146
of diabetic nephropathy subjects, 1031
and effects of nutritional status on ethanol metabolism, 379-385
of ESRD subjects on HD, vitamin B_{12} effects on plasma HcY and, 217
fasting plasma leptin and plasma insulin and, 500
and HKII expression in SM, 815
and hypopituitarism, 564
of IGT subjects, 1319, 1323
and IMGU with relatively low Mg, 419
and insulin resistance, *see* Sex of insulin-resistant subjects
and insulin sensitivity 1502, 1503
of IUGR infants, 1468
and IV glutamine effects on muscle protein synthesis, 1558
and kinetics of TEF, 1342, 1344
of LPI subjects, 622
of metabolic syndrome subjects, 1023
of NIDDM subjects, *see* Sex of NIDDM subjects
of NIDDM subjects' relatives, 834, 897
of normolipidemic subjects, 1208
of older hypertensive subjects with LVH, 1357
and RBC FA composition, 1165
and relationship of PP RMR and TEF to body composition and AT distribution, 7, 8
and SNP effects on insulin-mediated SM blood flow and glucose uptake, 374
of TD patients, 771
Sex of cirrhotic subjects
circulating CT and, 48
GSH synthesis and, 1435
having undergone liver transplantation, 368
Sex hormone-binding globulin (SHBG)
genetic study of, before and after endurance exercise, 1014-1020
in postmenopausal and perimenopausal women, 1562, 1563
see also Sex hormone-binding globulin in hypercholesterolemic men
Sex hormone-binding globulin (SHBG) in hypercholesterolemic men
pravastatin effects on, 119
simvastatin effects on, 119, 1236
Sex hormone receptor, soy protein effects on LDL oxidation and activity of, in hyperlipidemia, 537-543
Sex of insulin-resistant subjects
CV risk factors and, 1251
insulin resistance correlation with increased SFAs in SM TGs, 221
plasma NO and, 960
TNF-α gene polymorphism and, 1507
Sex of NIDDM subjects
and acetyl-L-carnitine effects, 705
apo E polymorphism, leptin and, 728
bezafibrate therapy effects and, 332
and BK effects on exercise-induced glucose uptake and GT4 translocation in SM, 923
fibrinolytic NIDDM, 663
and indomethacin effects on insulin secretion, 840
and metabolic effects of $VOSO_4$, 400-410

Sex of NIDDM subjects (*Continued*)
and MTHFR gene, 719, 721
with nephropathy, TGF-β_1 activation and, 355
obese, glucose intolerance and, 187
with PPARγ2 Pro12Ala gene, 1268
Sex steroids
relationship between serum leptin, body composition, insulin levels, and levels of, 1278-1284
see also specific sex hormones
SF (skinfold thickness), determination of body composition in underweight chronic gastrointestinal disease subjects with DXA, BIA, TBW-^3H_2O and, compared, 360-366
SFAs, *see* Saturated fatty acids
SHBG, *see* Sex hormone-binding globulin
Short leptin receptor isoforms in PBMCs, effects of, on leptin, 1537-1541
Short-term exercise, effects of, on leptin and insulin, 858-861
Short-term variation in dietary fat and CHOs, PP lipemia after, 1150-1155
Simvastatin effects in hypercholesterolemic men
on gonadal function, 115-121
high-dose, on adrenal and gonadal steroidogenesis, 1234-1238
Sitosterol
serum, stanol ester effects on, 474
in soy protein diet, 539
Size-exclusion chromatography of agouti-related protein(83-132) BBB crossing, 1444-1449
Skeletal muscle (SM)
GLUT4, BK effects on exercise-induced translocation of, 920-930; *see also* mRNA, GLUT4, in SM
in STZ-DM, anthocyanoside effects on CFA of, 880-885
see also entries beginning with terms: Skeletal muscle
Skeletal muscle (SM), exercise and
exercise effects on aging-induced decrease in IRS-1 and PI 3K in SM, 954-958
in NIDDM, exercise-induced GLUT4 translocation in SM, 920-930
Skeletal muscle (SM), insulin and
HKII expression and, 814-818
insulin-mediated blood flow in, in the elderly, SNP effects on, 373-378
NA-induced changes in PC and PE FAs associated with insulin responsiveness in healthy subjects, 232-238
Skeletal muscle (SM) insulin resistance
induced by GS protein expression downregulation in SM cells, 962-968
postoperative, preoperative feeding effects on, 486-491
see also Skeletal muscle insulin resistance in obesity
Skeletal muscle (SM) insulin resistance in obesity
correlated with increased SFAs, SM TGs and, 220-224
GTG effects on insulin resistance but not on hyperinsulinemia in, SM GLUT4 overexpression effects on, 340-346
in NIDDM, thiazolidinedione effects on liver and SM fatty acid oxidation in, 521-525
Skeletal muscle (SM) membrane fatty acid (FA) composition, RBC FA composition as index of, 1164-1166
Skeletal muscle (SM) in NIDDM
and BK effects on exercise-induced GLUT4 translocation in SM, 920-930
glucose transport in, 686
with obesity, thiazolidinedione effects on FA oxidation in liver and, 521-525
Skin
rheological disorders and impaired vasoconstrictive response of, to sympathetic activation in obesity, 600-606
see also entries beginning with terms: Cutaneous, Subcutaneous
Skinfold thickness (SF), determination of body composition in underweight chronic gastrointestinal disease subjects with DXA, BIA, TBW-^3H_2O and, compared, 360-366
SM, *see* Skeletal muscle
Small dense low-density lipoprotein (LDL; β-lipoprotein) in NIDDM, oxidative stress and, S1:32-33
SMCs, *see* Smooth muscle cells, vascular
Smoking
and blood lipid response to cycle-ergometer exercise, 515
and bone metabolism in HIV infection, 1135, 1136
differential effects of, on myocardial infarction risk according to Gln/Arg 192 polymorphism of PON1 gene, 557-559
and influence of TG concentration on relationship between HDL-C and LDL-C and apo B and apo A-I, 55
insulin resistance, CV risk factors and, 1248, 1249, 1251
in NIDDM, *see* Smoking in NIDDM
by postmenopausal and perimenopausal women, 1562
Smoking in NIDDM
MTHFR gene and, 719, 721
variation in NIDDM and CHD risk and, 247
Smooth muscle cells (SMCs), vascular
aortic SMCs, OA and LA effects on ET-1 binding and action in, 1386-1389
EPA effects on oxidized LDLs and lysophosphatidylcholine-induced migration in, 560-562
long-term EPA-E effects on dysfunctional, 1588-1591
SNP (sodium nitroprusside), lack of effects of, on insulin-mediated blood flow and glucose disposal in older subjects, 373-378
SNS, *see* Sympathetic nervous system
SOD, *see* Superoxide dismutase
Sodium, *see* Na
Sodium nitroprusside (SNP), lack of effects of, on insulin-mediated blood flow and glucose disposal in older subjects, 373-378
Sodium/potassium (Na/K) adenosine triphosphatase (ATPase), RBC, in IDDM, insulin and C-peptide effects on, 868-872
Soluble fiber, soy protein and
effects of LF diet with soy and vegetable protein and soluble fiber on serum lipids and oxidized LDLs, 67-72
in hyperlipidemia, 538
in soy-based breakfast cereal, 1497
Somatotropic hormone (STH), fasting, in liver transplantation recipients, S_G and, 368
Sorbitol, intracellular mesangial cell, troglitazone effects on, 311
South Asian men, plasma lipid relationship to FFAs, AT, and insulin resistance in Afro-Caribbean, European and, variation in risk of NIDDM and CHD and, 245-252
South Indians, plasma glucose during OGTT correlated with FPG in, 455-457
Soy protein
effects of, on arterial LDL and LDL-C delivery to arteries of diabetic and nondiabetic male subjects, 1188-1196
serum DHEAS, serum estradiol, and intake of, in relation to psychological well-being in perimenopausal and postmenopausal women, 1561-1564
see also Soy protein effects on LDL oxidation and lipids
Soy protein effects on LDL oxidation and lipids
on serum lipids, 67-72
and on sex hormone receptor activity in hyperlipidemia, 537-543
soy-based breakfast cereal effects on blood lipids and oxidized LDLs, 1496-1500
Soybean oil in obesity-inducing diet, 1296
Spectrometry, GC/mass, of plasma galactose and galactitol concentrations in galactosemia due to GALT deficiency, 1460-1466
Splanchnic area, effects of long-term high-S diet with dexamethasone on AT depots, liver steatosis, and lipid fluxes in, 1289-1291

Splanchnic substrate supply, insulin regulation of, 676-683
Spleen
SERP-1 distribution to, 1452
TNF-α in, 1313, 1314
Splenocytes, diet effects on insulin and nutrient metabolism in MLN cells, pancreatic islets and, 1111-1117
Spontaneous hypertension, *see* Hypertension
Spontaneous hypertriglyceridemia (HTG) with $RT1^u$ haplotype, metabolic syndrome in, 1140-1144
Squalene, stanol ester effects on PP retinyl palmitate and, 473-478
SSPCP (steady-state plasma C-peptides), post-pancreas transplantation, effects of systemic and/or portal venous drainage site on insulin action and, 461
SSPG (steady-state plasma glucose) and SSPI (steady-state plasma insulin), post-pancreas transplantation, effects of systemic and/or portal venous drainage site on insulin action and, 461
Stanol ester, effects of, on PP squalene and retinyl palmitate, 473-478
Starchy foods
leptin regulation with chronic high-glycemic index starch diet, 764-769
in LF diet, effects of sucrose or, on blood lipids, FVIIc, and fibrinogen, 731-735
see also specific types of foods
Statins, *see* Atorvastatin; Cerivastatin; Pravastatin; Simvastatin effects in hypercholesterolemic men
Steady-state lipoprotein lipase (LDL) gene mRNA (messenger ribonucleic acid) in omental versus adipose tissue, 1224-1227
Steady-state plasma C-peptides (SSPCP), post-pancreas transplantation, effects of systemic and/or portal venous drainage site on insulin action and, 461
Steady-state plasma glucose (SSPG) and insulin (SSPI), post-pancreas transplantation, effects of systemic and/or portal venous drainage site on insulin action and, 461
Stearic acid
RBC and SM membrane, 1165
in SM TGs of insulin-resistant obese and lean subjects, 222
Steroidogenesis, high-dose simvastatin effects on gonadal and adrenal, in hypercholesterolemic men, 1234-1238
Stevioside, effects of, on beta cell insulin secretion independent of activity of cAMP and ATP-sensitive K^+ channels, 208-214
STH (somatotropic hormone), fasting, in liver transplantation recipients, S_G and, 368
Stigmasterol in soy protein diet, 539
Stomach, TNF-α in, 1313, 1314
Streptozotocin-induced diabetes mellitus (STZ-DM), 990-1000
AGE product inhibition and cross-link breakage effects on, 996-1000
anthocyanoside effects of SM CFA in, 880-885
diazoxide effects on beta cell function in transplanted pancreatic islets for, 657-661
with hypoglycemia, glucagon and glucose response to SC insulin in, 984-989
intraperitoneal insulin in, *see* Intraperitoneal insulin in STZ-DM
metformin and troglitazone effects on dietary fat in, 1390-1394
obesity with, hyperinsulinemia and LPL activity in, 134-140
preeclamptic pregnancy in, 853-857
scavenging effects of nicorandil and tilosolol hydrochloride on free radicals and LPO in, compared, 427-431
T-1095 effects on hyperglycemia of, 990-995
Stress, *see* Oxidative stress
Stress hormones, *see* Cortisol; Epinephrine; Glucagon; Norepinephrine in hypoglycemia; Plasma norepinephrine
Stromal osteoprogenitor cells, bone marrow, effects of hydrochlorothiazide and furosemide on, compared, 17-21
STZ-DM, *see* Streptozotocin-induced diabetes mellitus
Subcutaneous (SC) adipocytes, effects of TNF-α and TGF-β_1 on PAI-1 secretion by, 666-671
Subcutaneous adipose tissue (SAT)
central, associated with risk of CV disease in men independently of total AT and CV fitness, 1379-1385
lipogenic potential of, 596, 597
in NIDDM, apo E polymorphism, leptin and, 725, 726, 728
and relationship of PP RMR and TEF to body composition and distribution of, in lean and obese subjects, 7, 8
Subcutaneous (SC) insulin, glucagon and glucose response to, in hypoglycemic STZ-DM, 984-989
[2,3^{13}C]Succinate, hepatocyte, effects of glycerol-1,2,3-tris(methyl-[2,3^{13}C]succinate) on, 179
Sucrose (S)
in HF diet, *see* Sucrose in HF diet
in LF diet, effects of starchy foods or, on blood lipids, FVIIc, and fibrinogen, 731-735
in obesity-inducing diet, 1296
in restricted FA and energy diet, 978
in soy protein diet, 1189
see also Sucrose-rich diet
Sucrose (S) in HF diet
and diurnal variation in plasma leptin, 504
effects of, on MTHFR and CβS in HcY metabolism, 736-741
Sucrose (S)-rich diet
CS-045 effects on GIIS patterns and hypertriglyceridemia in subjects on, 1346-1351
long-term, effects of dexamethasone with, on AT depots, liver steatosis, and lipid fluxes through retroperitoneal and splanchnic areas, 1289-1291
Sulfonylureas, *see* Sulfonylureas, effects of, on oxidative stress; Sulfonylureas in NIDDM
Sulfonylureas, effects of, on oxidative stress
and CHD, S1:30-31
oxidative stress reduction, S1:33
see also Glibenclamide; Gliclazide scavenging activity in NIDDM
Sulfonylureas in NIDDM
and sensitivity of ATP-sensitive K^+ channels from beta cells and extrapancreatic tissues to, S2:3-6
see also Gliclazide in NIDDM
Superoxide dismutase (SOD)
nicorandil effects on, in STZ-DM, 428, 429
in NIDDM, gliclazide and glibenclamide effects on, S1:24, S1:33
Superoxide free radicals, gliclazide effects on, S1:14-16
Supplementation
Mg, effects of, on intestinal absorption of $^{45}CaCl_2$ in women with low RBC Mg, 1092-1098
vitamin B_{12}, effects of supplementation with, on plasma HcY in ESRD subjects on HD, 215-219
vitamin E, oxidative stress evaluation in IDDM and NIDDM before and after glycemic control and after, 160-162
Surgery
orchidectomy, aging effects on calcitonin release in, 252-258
parathyroid adenoma, in primary hyperparathyroidism on levels of IL-6 and IL-2 receptors, 192-194
TBG and TTR consumption during CABG, 270-274
vagotomy effects on HGP and liver glucose uptake, 11-18
see also Surgical trauma; Transplantation
Surgical trauma, and preoperative feeding effects on SM insulin resistance, 486-491
Sympathetic nervous system (SNS)
effects of rheological disorders on skin vasoconstrictive response to sympathetic activation in obesity, 600-606
role of, in effects of HTN and antihypertensive therapy on fasting FFAs, 81-87

Sympathoadrenal response to exercise at high altitude by women, 1036-1042
Syndrome X, *see* Metabolic syndrome
Synthase
  cystathionine-β-, *see* Cystathionine-β-synthase
  downregulation of glycogen, inducing insulin resistance in SM cells, 962-968
  FA, in SAT, 596, 597
  glycogen synthase protein, insulin resistance in SM cells induced by downregulated expression of, 962-968
  nitric oxide, of aortic endothelial cells, insulin effects on, 147-150
System A transport of MeAIB in mammary gland, 873-879
Systemic glucose, *see* Glucose
Systemic venous drainage site, effects of, on insulin action after pancreas transplantation, insulin resistance, risk of atherosclerosis and, 458-466
Systolic pressure, *see* Blood pressure

T, *see* Testosterone
T_3, *see* Triiodothyronine
T_4, *see* Thyroxine
T-1095, effects of, on hyperglycemia of STZ-DM, 990-995
TAG, *see* Triacylglycerol, diet effects on
D-Tagatose
  effects of, on blood uric acid, 969-976
  effects of, on liver metabolism, ^{31}P-MRS of, 1335-1339
Taiwanese subjects, NIDDM, PPARγ2 Pro12Ala gene and BMI in, 1267-1270
Tangier disease (TD) fibroblasts, C efflux from normal and, into normal, HDL-deficient, and apo E-deficient plasmas, 770-777
Taurine, hyperammonemia effects on metabolism of, 1332
TBARS, *see* Thiobarbituric acid-reactive substances
TBG (thyroxine-binding globulin), consumption of, during CABG, 270-274
TBK (total body potassium), determination of, with DXA, BIA, SF, and TBW-^3H_2O methods in underweight subjects with chronic gastrointestinal disease, compared, 360-366
TBW-^3H_2O method, determination of body composition in underweight chronic gastrointestinal disease subjects with DXA, BIA, SF and, compared, 360-366
TC, *see* Total cholesterol
T-cell lymphopenia in NIDDM with obesity, weight loss effects on, 1261-1266
TCF1 gene, HNF1α, in African Americans with familial NIDDM, molecular analysis of, 280-284
TD (Tangier disease) fibroblasts, C efflux from normal and, into normal, HDL-deficient, and apo E-deficient plasmas, 770-777
Teenagers, *see* Adolescents, obese
TEF, *see* Thermic effect of food
Temocapril, effects of, on LVH and circulating BNPs in hypertensive elderly subjects, 1356-1360
Testosterone (T)
  and bone metabolism in HIV infection, 1136
  in CAH, 791
  in older men, *see* Testosterone, decrease and/or deficiency of, in older men
  plasma, *see* Plasma testosterone
  production of, in Cushing's syndrome, 229-231
  race and effects of, on lipids, in boys, 1124-1129
  serum, rIGF-I and hCG effects on concentrations of, in ovaries, 316
  simvastatin and pravastatin effects on, in hypercholesterolemic men, 117-118
Testosterone (T), decrease and/or deficiency of, in older men
  in African American men, leptin and, 1085-1091
  questionnaire on, 1239-1242
12-*O*-Tetradecanoyl phorbol-13-acetate (TPA), effects of, on pancreatic islets, 266
TG(s), *see* Triglyceride(s)
TGF-β_1, *see* Transforming growth factor-β_1
Thermic effect of food (TEF)
  of caffeine in young and older women, compared, 101-107
  see also Thermic effect of food, body composition and
Thermic effect of food (TEF), body composition and
  kinetics of, 1340-1345
  relationship of PPRMR and, to body composition and AT distribution in lean and obese subjects and, 6-10
Thiazolidinediones, *see* PAT5A; Pioglitazone, CS-045 and; Rosiglitazone; Troglitazone
Thiobarbituric acid-reactive substances (TBARS)
  in IDDM and NIDDM before and after glycemia control and after vitamin E supplementation, oxidative stress and, 161, 162
  T_3 effects on, 801
Thioglucose, gold-, insulin resistance but not hyperinsulinemia improved with, in obesity with GLUT4 overexpression, 340-346
Threonine (Thr)
  effects of, on system A transport of MeAIB in mammary gland, 875, 876
  in glutamine-containing diet, 142
  hyperammonemia effects on metabolism of, 1332
  IV glutamine effects on synthesis of muscle, 1556, 1557
  metformin effects on, 1623
  myocardial plasma, in CHD, 1366
Thrombocyte count in NIDDM nephropathy, TGF-β_1 activation and, 355
Thyroid calcitonin (CT), aging effects on release of, 255, 256
Thyroid gland, *see* Hyperthyroidism; Hypothyroidism *and entries beginning with element*: Thyro-
Thyroid hormones
  and plasma CETP in hypothyroidic infants, 1176-1179
  therapeutic, kinetics of TEF and, 1342, 1344
  see also Thyroxine; Triiodothyronine
Thyrotropin (TSH)
  aging effects on, 1119, 1121
  consumption of, during CABG, 272
  in hypothyroidic infants, 1178
  and leukocyte generation of ROS, 800
  in sepsis, 754
  serum, in hyperthyroidism, 1286, 1287
Thyroxine (T_4)
  changes in adenylyl cyclase isoforms and modulation of cardiac β-adrenergic receptor responsiveness by, 275-279
  free, *see* Free thyroxine
  and leukocyte generation of ROS, 800
  TBG and, during CABG, 271-272
  thyroxine-binding protein and, in sepsis, 753-754
  in weight-losing cancer subjects, 934
L-Thyroxine (T_4) therapy of hypothyroidism in infants, 1176-1178
Thyroxine-binding globulin (TBG), consumption of, during CABG, 270-274
Thyroxine-binding protein, T_4 and, in sepsis, 753-754
Tilisolol hydrochloride, scavenging activity of nicorandil and, on free radicals and LPO in STZ-DM, compared, 427-431
Tissue damage, free radical-mediated, S1:3-5
  antioxidants against, S1:5; *see also* Scavenging activity
  consequences of, S1:3-5
Tissue distribution of TNF-α, 1309-1317
Tissue insulin sensitivity, contribution of beta cells and, to IGT, 1318-1325
Tissue oxidative stress in NIDDM, $VOSO_4$ effects on, 404-405

Tissue plasminogen activator (tPA), troglitazone effects on, in NIDDM with fibrinolysis, 665
Tissue plasminogen activator antigen (tPA-Ag), relationship between leptin, fat mass and, in obese children and adolescents, 890-895
Tissue specificity of sulfonylureas, S2:4-5
TNF-α, *see* Tumor necrosis factor-α; Tumor necrosis factor-α gene polymorphism
α (alpha)-Tocopherol (vitamin E)
  oxidative stress evaluation in IDDM and NIDDM before and after glycemic control and after supplementation with, 160-162
  T_3 effects on reserve of, 801
Tolerance and intolerance
  high-dose simvastatin, 1236
  lysinuric protein, lysine effects on urea cycle in, 621-625
  see also Glucose intolerance; Glucose tolerance
Total adipose tissue (AT), subcutaneous central AT associated with risk of CV disease independently of CV fitness and, 1379-1385
Total antioxidant capacity, plasma, peroxidation indices and, in methionine-induced hyperhomocysteinemia, 225-228
Total bilirubin in cirrhosis, 1435
Total body potassium (TBK), determination of, with DXA, BIA, SF, and TBW-^3H_2O methods in underweight chronic gastrointestinal disease subjects, compared, 360-366
Total body water (TBW), measurement of, in underweight chronic gastrointestinal disease subjects with TBW-^3H_2O, DXA, BIA, and SF methods, compared, 360-366
Total cholesterol (TC)
  apheresis of, 1432
  carotid IMT and, 719, 721
  diet effects on, *see* Total cholesterol, diet effects on
  exercise and, *see* Total cholesterol, exercise and
  in FHTG, 944-946
  in HHL, aging-associated changes in metabolism of, 553, 554
  in hypercholesterolemia, *see* Total cholesterol in hypercholesteremia
  in hyperlipidemia, 1628
  in hypopituitarism, GH therapy effects on, 565, 566
  in LT recipients, S_G and, 368
  in metabolic syndrome, 1023
  in methionine-induced hyperhomocysteinemia, 225
  in nephrotic syndrome, NO-1886 effects on, 589
  in NIDDM, *see* Total cholesterol in NIDDM
  in obesity, *see* Total cholesterol in obesity
  in postmenopausal women on estrogen alone or estrogen with progestin, 785, 787
  subcutaneous central AT, risk of CV disease and, 1380, 1383
  in 10-to-15-year-old boys, race and variation in, 1126, 1127
Total cholesterol (TC), diet effects on
  effects of short-term variation in CHOs and dietary fat on TC, 1152
  of soy protein, 1191, 1498
  of sucrose-starchy food diet, 733
Total cholesterol (TC), exercise and
  and exercise effects on plasma HDL CE, 829
  plasma, response of, to cycle-ergometer exercise, 516
Total cholesterol (TC) in hypercholesteremia
  in hypercholesterolemic men, simvastatin and pravastatin effects on, 117
  and plasma viscosity, 811
Total cholesterol (TC) in insulin resistance
  CV risk factors and, 1248, 1249, 1251
  depression and, 1256
  with TNF-α gene polymorphism, 1507, 1508
Total cholesterol (TC) in NIDDM
  effects of high-monounsaturated fat diet and olive oil diet on, 1513, 1514
  with fibrolysis, 663
Total cholesterol (TC) in NIDDM (*Continued*)
  HDL_3 binding to leukocytes and, 691
  JTT-501 effects on, 864
  leptin and apo E polymorphism and, 725, 726
  and MTHFR gene, 719, 721
  with PPARγ2 Pro12Ala gene, 1268, 1269
  serum, bezafibrate therapy effects on, 332
  TNF-α G308A gene polymorphism and, 1617
Total cholesterol (TC) in obesity
  α_2-, β_2-, and β_3-AR genes, obesity phenotype and, 1067, 1068
  effects of regular moderate wine consumption by moderately obese women on, 1475
  GH therapy, weight loss and, 907
  HTN and, 1525
  in Japanese men with polymorphism of β_2-AR gene, 1215
  skin vasoconstrictive response to sympathetic activation and, 601
Total fat mass (FM), and variation in CHD and NIDDM risk, 247, 249
Total glucose, vagotomy effects on, 14
Total monounsaturated fatty acids (MUFAs), RBC and SM membrane, 1165
Total parenteral nutrition (TPN), metabolic effects of insulin and IGF-I in endotoxemia during, 611-615
Total polyunsaturated fatty acids (PUFAs), RBC and SM membrane, 1165
Total protein
  CS-045 effects on, in DM with obesity, 1362
  plasma, in methionine-induced hyperhomocysteinemia, 225
  in soy protein diet, 538
Total saturated fatty acids (SFA), RBC and SM membrane, 1165
Total triglyceride(s) (TGs)
  in NIDDM, effects of high-monounsaturated fat diet and olive oil diet on, 1514
  and plasma viscosity in HCL or HTG, 811
  see also Total triglycerides in obesity
Total triglycerides (TG) in obesity
  effects of regular moderate wine consumption by moderately obese women on, 1475
  and obesity phenotype, α_2-, β_2-, and β_3-AR genes and, 1067, 1068
Toxicity of $VOSO_4$, 403
Toxin, effects of cholera, on GLP-1-induced insulin secretion in DM, 1581-1583
tPA (tissue plasminogen activator), troglitazone effects on, in NIDDM with fibrinolysis, 665
TPA (12-*O*-tetradecanoyl phorbol-13-acetate), effects on, on pancreatic islets, 266
tPA-Ag (tissue plasminogen activator antigen), relationship between leptin, fat mass and, in obese children and adolescents, 890-895
TPN (total parenteral nutrition), metabolic effects of insulin and IGF-I in endotoxemia during, 611-615
Training, *see* Exercise
Transamination, methionine, in homocystinuria due to CβS deficiency, 1071-1077
Transdermal 17β-estradiol with cyclical oral NETA, effects of, on insulin sensitivity, secretion, and elimination in postmenopausal women, 742-747
Transfer protein, *see* Cholesteryl ester transfer protein
Transferase, *see* Acyltransferase; Galactose-1-phosphate uridyltransferase deficiency; Galactosyltransferase
Transforming growth factor-β_1 (TGF-β_1)
  activation of, in NIDDM nephropathy, 353-359
  effects of TNF-α and, on subcutaneous and omental adipocyte PAI-1 secretion, 666-671

Transplantation
liver, for cirrhosis, S_G following, 367-372
pancreas, portal and/or systemic venous drainage site effects on insulin action after, insulin resistance, risk of atherosclerosis and, 458-466
pancreatic islet, in STZ-DM, diazoxide effects on beta cell function in, 657-661
Transport
system A, of MeAIB in mammary gland, 873-879
see also Transport, cholesterol
Transport, cholesterol
in NIDDM, weight loss and, 14
see also Reverse cholesterol transport, and alcohol consumption
Transporter protein(s)
ontogeny of G6Pase, and catalytic subunit p36 of microsomal hepatic G6Pase system, 1200-1203
see also entries beginning with acronym: GLUT
Transthyretin (TTR)
in CABG surgery, 270-274
in sepsis, 754
Trauma and injury
hypercatabolism in, and ubiquitin-proteasome pathway and muscle proteolysis, 689-691
surgical, and preoperative feeding effects on SM insulin resistance, 486-491
ventromedial hypothalamus lesions in obesity, effects of JTT-501 on, 574-578
see also Oxidative damage
Triacsin C, palmitate, 2-bromopalmitate, and FFAs downregulating adipocyte leptin, 326-330
Triacylglycerol (TAG), diet effects on
of long-term high-S diet with dexamethasone, 1291, 1292
of short-term variation in dietary fat and CHOs, 1152, 1153
Triglyceride(s) (TG)
apo A-I and, *see* Apolipoprotein A-I, TGs and
apo B and, *see* Apolipoprotein B, TGs and
in atherosclerosis, *see* Triglyceride(s), atherosclerosis and
beta cell, GIIS loss in dysfunctional beta cells and elevated, 755-759
diet effects on, *see* Triglyceride(s), diet effects on
FFAs and, *see* Triglyceride(s), FFAs and
in healthy subjects, *see* Healthy subjects, TGs in
hepatic, glucagon dose effects on, 41
of HF diet-induced insulin resistance on, 1519
in HHL, aging-associated changes in metabolism of, 553, 554
in HTN, glucose metabolism and, 1531
in hypercholesterolemic men, simvastatin and pravastatin effects on gonadal function and, 117
in hyperlipidemia, 1628
in hypopituitarism, GH therapy effects on, 565, 566
in IDDM, *see* Triglyceride(s) in IDDM
in insulin resistance, *see* Triglyceride(s) in insulin resistance
in liver transplantation recipients, S_G and, 368
in metabolic syndrome, *see* Triglyceride(s) in metabolic syndrome
in methionine-induced hyperhomocysteinemia, 225
in nephrotic syndrome, NO-1886 effects on, 589
in NIDDM, *see* Triglyceride(s) in NIDDM
in normolipidemia, 1208
in obesity, *see* Triglyceride(s) in obesity
in postmenopausal women on estrogen alone or estrogen with progestin, 785, 787
in premenopausal women, 1103
serum, *see* Serum triglycerides
subcutaneous central AT, risk of CV disease and, 1380, 1383
in TD, 771
in 10-to-15-year-old boys, race and variation in, 1126, 1127
Triglyceride(s) (TG) (*Continued*)
total, *see* Total triglycerides
see also Hypertriglyceridemia
Triglyceride(s) (TG), atherosclerosis and
and LDL oxidation, 1272
and risk of atherosclerosis after pancreas transplantation, 463
Triglyceride(s) (TG), diet effects on
effects of dietary FA composition in pregnant and nonpregnant subjects, 1182
of LF diet with sucrose and starchy foods, 733
of restricted diet effects, in NIDDM, 108-114
soy protein diet, *see* Triglyceride(s), soy protein diet and
with α-tocopherol supplementation, 161
Triglyceride(s) (TG), FFAs and
HTN and antihypertensive therapy effects on fasting FFAs and, 82
variation in CHD and NIDDM risk and, 248, 249
Triglyceride(s) (TG), soy protein diet and
effects of, on arterial LDLs, 540
LDL oxidation and, 1191, 1498
Triglyceride(s) (TG) in IDDM
exercise effects on, 643
following vitamin E supplementation and before and after glycemia control, oxidative stress and, 161
Triglyceride(s) (TG) in insulin resistance
CV risk factors and, 1248, 1249, 1251
insulin resistance correlated with increased SFAs in SM TGs, 220-224
in insulin-resistant lean nondiabetic women, 287
role of BMI and TGs in insulin-resistant healthy Japanese subjects, 1001-1005
with TNF-α gene polymorphism, 1507, 1508
Triglyceride(s) (TG) in metabolic syndrome
ET-1 concentrations and, 749, 750
TNF-α gene polymorphism and, 1023
Triglyceride(s) (TG) in NIDDM
cerivastatin effects on, 1049-1054
effects of high-monounsaturated fat diet and olive oil diet on, 1513
exercise effects on, 643
following vitamin E supplementation and before and after glycemia control, oxidative stress and, 161
HDL_3 binding to leukocytes and, 691
JTT-501 effects on, 864-865
leptin, apo E polymorphism and, 725, 726, 728
and MTHFR gene, 719, 721
with PPARγ2 Pro12Ala gene, 1268, 1269
restricted diet effects on NIDDM and TGs, 108-114
serum, *see* Serum triglycerides in NIDDM
TNF-α G308A gene polymorphism and, 1617
YM440, troglitazone, and pioglitazone effects on, compared, 413
Triglyceride(s) (TG) in obese women
in insulin-resistant obese nondiabetic women, 287
prevalence of paradoxically normal serum C and, 608, 610
Triglyceride(s) (TG) in obesity
GH therapy, weight loss and, 907
with insulin resistance, 1525
rheological disorders and skin vasoconstrictive response to sympathetic activation and, 601
see also Triglyceride(s) in obesity with NIDDM; Triglyceride(s) in obese women
Triglyceride(s) (TG) in obesity with NIDDM
thiazolidinedione effects on, 522
weight loss effects on, 1454
Triiodothyronine (T_3)
changes in adenylyl cyclase isoforms and modulation of cardiac β-adrenergic receptor responsiveness by, 275-279

Triiodothyronine (T_3) (*Continued*)
effects of, on ROS generation by leukocytes, oxidative damage indices, and antioxidant reserve, 799-803
free, *see* Free triiodothyronine in hypothyroidism
GH and, and leptin biosynthesis in AT, 240-242
in sepsis, 754
in weight-losing cancer subjects, 934
Triphosphatase, RBC Na/K adenosine, insulin and C-peptide effects on, in NIDDM, 868-872
Triphosphate, *see* K^+ channels, ATP-sensitive
Tritium dilution method, body composition measurement in underweight subjects with chronic gastrointestinal disease with DXA, BIA, SF and, compared, 360-366
Troglitazone (CS-045)
and dietary fat in STZ-DM, 1390-1394
effects of, on hypertriglyceridemia and GIIS patterns, 1346-1351
leptin release in AT regulated by, 1485-1490
mRNA and, *see* mRNA, troglitazone effects on
renal protective effects of, in DM with obesity, 1361-1364; *see also* Troglitazone, effects of, in NIDDM with obesity
see also Pioglitazone, CS-045 and; Troglitazone, effects of, in mesangial cells; Troglitazone, effects of, in NIDDM
Troglitazone (CS-045), effects of, in mesangial cells
on glycolysis and intracellular glucose metabolism, 308-313
on TNF-α-induced MCP-1 mRNA expression, 163-166
Troglitazone (CS-045), effects of, in NIDDM
glibenclamide effects and, on fibrinolysis, compared, 662-665
on hyperglycemia of NIDDM without AT weight change, YM440 and pioglitazone effects compared with, 411-417
see also Troglitazone, effects of, in NIDDM with obesity
Troglitazone (CS-045), effects of, in NIDDM with obesity
on FA oxidation in SM and liver, 521-525
prevention and reversal of dyslipidemia, defective insulin secretion, and histologic abnormalities as, 1167-1175
Tryptophan (Trp)
effects of, on system A transport of MeAIB in mammary gland, 875, 876
in glutamine-containing diet, 142
hyperammonemia effects on metabolism of, 1332
IV glutamine effects on synthesis of muscle, 1556, 1557
TSH, *see* Thyrotropin
TTR, *see* Transthyretin
Tumor necrosis factor-α (TNF-α)
effects of TGF-β_1 and, on subcutaneous and omental adipocyte PAI-1 secretion, 666-671
tissue distribution of, 1309-1317
troglitazone effects on MCP-1 mRNA expression induced by, in mesangial cells, 163-166
see also Tumor necrosis factor-α gene polymorphism
Tumor necrosis factor-α (TNF-α) G308A gene polymorphism
insulin resistance, fasting plasma glucose and, in young, old, and NIDDM Japanese men, 1616-1618
in metabolic syndrome, 1021-1024
Tumor necrosis factor-α (TNF-α) gene polymorphism
of *Nco*I gene, effects of, on insulin resistance in Japanese subjects, 1506-1509
see also Tumor necrosis factor-α G308A gene polymorphism
Two-compartment minimal model analysis of glucose metabolism in HTN, 1529-1536
Type 1 diabetes mellitus, *see* Insulin-dependent diabetes mellitus
Type 2 diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus
Tyrosine (Tyr)
effects of, on Phe hydroxylation in men, 444-449
in glutamine-containing diet, 142
hyperammonemia effects on metabolism of, 1332
Tyrosine (Tyr) (*Continued*)
IV glutamine effects on synthesis of muscle, 1556, 1557
myocardial plasma, in CHD, 1366
Tyrosine hydroxylase gene microsatellite (TH HUMTH01), polymorphism of, associated with insulin resistance in depressive disorder, 1145-1149

Ubiquitin-proteasome pathway in muscle proteolysis, hypercatabolism and, 689-691
Ultralente insulin, effects of, on postbreakfast and fasting beta cell function in healthy subjects, 1243-1246
Uncoupling protein isoform mRNA (messenger ribonucleic acid), effects of rosiglitazone and rexinoids on obesity and, 1610-1615
Underweight subjects with chronic gastrointestinal disease, DXA, BIA, SF, and TBW-^3H_2O methods in determination of body composition in, compared, 360-366
Unsaturated fatty acids (FAs)
in SM TGs in insulin-resistant obese and lean subjects, 222
see also Monounsaturated fatty acids; Polyunsaturated fatty acids
Untrained (sedentary) men, AT metabolism in, 122-128
Urate in obesity, HTN and, 1525
Urea
in ESRD subjects on HD, vitamin B_{12} effects on plasma HcY and, 217
lysine effects on urea cycle in LPI, 621-625
Urea nitrogen
fructose effects on, 1568
see also BUN
Uric acid
blood, effects of D-tagatose on, 969-976
in healthy and/or preeclamptic pregnancy, 260
and MTHFR gene, 719, 721
in NIDDM, TNF-α G308A gene polymorphism and, 1617
plasma, *see* Plasma uric acid
D-tagatose effects on, 1338
urinary excretion of, *see* Urinary excretion of uric acid
Uricemia in obesity, rheological disorders and skin vasoconstrictive response to sympathetic activation and, 601
Uridine, *see* Plasma uridine
Urinary excretion
adenosine, furosemide effects on, 886-889
amino acid and orotic acid, in LPI, lysine effects on, 623-624
Ca, *see* Urinary excretion of Ca and Ca^{2+}
cortisol, in Cushing's syndrome, 761
glucose, in IDDM and NIDDM before and after glycemic control and after vitamin E supplementation, 161
of isoflavonoids, soy protein diet and, 539
mevalonic acid, during acute alcohol intake, 62-66
Mg, IMGU and, 419
of β_2-microglobulin, effects of long-acting vessel dilators, natriuretic peptides, and kaliuretic peptides on, 1592-1597
of purine bases, *see* Urinary excretion of purine bases
D-tagatose, 1338
of TNF-α, 1314
see also entries ending with suffix: -uria; *for example*: Albuminuria
Urinary excretion of Ca and Ca^{2+}
Ca, bone turnover and, in young women on OCs, 1078-1084
Ca^{2+}, and bone metabolism in HIV infection, 1136, 1137
Urinary excretion of purine bases
BCAA effects on, not mediated by glucagon or insulin, 98-100
furosemide effects on, 886-889
see also Urinary excretion of uric acid
Urinary excretion of uric acid
BCAA effects on, not mediated by glucagon or insulin, 98-100
furosemide effects on, 886-889
D-tagatose effects on, 972

Urinary insulin-like growth factor-binding proteins (IGFBPs) in IDDM, IGFBP-2 protease activity and, 626-633

$\dot{V}O_2$ (aerobic capacity)
in women exercising at altitude, 1037, 1039
see also $\dot{V}O_2$ in exercising men
$\dot{V}O_2$ (aerobic capacity) in exercising men
α-adrenergic antagonist effects on, 387
AT metabolism during, 124
$\dot{V}O_2$max (maximal aerobic capacity)
of NIDDM subjects' relatives, 834, 836
of obese NIDDM subjects, 469
and seasonal variation in S_I and glucose effectiveness in men, 34
thermic response of young and older women to caffeine and, 103
see also $\dot{V}O_2$max, exercise and
$\dot{V}O_2$max (maximal aerobic capacity), exercise and
in cycle-ergometer exercise, 515
and exercise effects on leptin and insulin, 859
in IDDM and NIDDM subjects, 642
see also $\dot{V}O_2$max in exercising men
$\dot{V}O_2$max (maximal aerobic capacity) in exercising men
α-adrenergic antagonist effects on, 387
AT metabolism during, 123, 124
Vagotomy, effects of, on HGP and liver glucose uptake, 11-18
Vagus nerve, hepatic, role of, in HGP and liver glucose uptake, 11-18
Valine (Val)
effects of, on system A transport of MeAIB in mammary gland, 875, 876
in glutamine-containing diet, 142
hyperammonemia effects on metabolism of, 1332
IV glutamine effects on synthesis of muscle, 1556, 1557
in NIDDM, MTHFR gene and, 721
plasma, *see* Plasma valine
Vanadate, effects of, on hepatic G6Pase, hepatic G6PDH, and PEPCK in lean IDDM subjects, gluconeogenesis and, 321-325
Vanadyl sulfate ($VOSO_4$), metabolic effects of, in NIDDM, 400-410
Vascular benefits of gliclazide in NIDDM, S2:17-20
Vascular disease, microvascular disease in IDDM, effects of glycemic control on platelet function abnormalities and, 88-91
Vascular endothelial cells
FA activation of, 1006-1013
long-term EPA-E effects on dysfunctional, 1588-1591
Vascular smooth muscle cells (VSMCs), EPA effects of, on oxidized LDLs and lysophosphatidylcholine-induced migration in, 560-562
Vasoconstrictive response of skin to sympathetic activation in obesity, effects of rheological disorders on, 600-606
Vasodilation with hydralazine and/or furosemide, effects of, on ATBF in lean and obese exercising men, 583
VAT, *see* Visceral adipose tissue
Vegetable protein, *see* Soy protein
Venous drainage site, effects of systemic and/or portal, on insulin action after pancreas transplantation, insulin resistance, risk of atherosclerosis and, 458-466
Ventricular hypertrophy, left, temocapril effects on circulating BNPs and, in hypertensive elderly subjects, 1356-1360
Ventromedial hypothalamus (VMH) lesions in obesity, effects of JTT-501 on HTG in, 574-578
Very-low-density lipoprotein(s) (VLDL)
cerivastatin effects on, 1050
effects of insulin resistance on, in nondiabetic lean and obese women, compared, 285-292
effects of regular moderate wine consumption by moderately obese women on, 1475
hepatic, aging and, in HHL, 553
Very-low-density lipoprotein(s) (VLDL) (*Continued*)
and LPL gene, 434, 435
stanol ester effects on, 473-478
see also Very-low-density lipoprotein-apolipoprotein B; Very-low-density lipoprotein-apolipoprotein B-100; Very-low-density lipoprotein-apolipoprotein E; Very-low-density lipoprotein-cholesterol; Very-low-density lipoprotein receptor gene
Very-low-density lipoprotein (VLDL)-apolipoprotein B (apo B), kinetics of, in normolipidemia, 1204-1210
Very-low-density lipoprotein (VLDL)-apolipoprotein B-100 (apo B-100), GH therapy effects on turnover of, in hypopituitarism, 563-566
Very-low-density lipoprotein (VLDL)-apolipoprotein E (apo E), platelet function in FHTG and, 942-949
Very-low-density lipoprotein-cholesterol (VLDL-C)
effects of high-monounsaturated fat diet and olive oil diet on, 1514
exercise and, *see* Very-low-density lipoprotein-cholesterol, exercise and
in FHTG, 944-946
in hyperlipidemia, 1628
in hypopituitarism, GH therapy effects on, 565
in insulin resistance, *see* Very-low-density lipoprotein-cholesterol in insulin resistance
and plasma viscosity in HCL or HTG, 811
variation in NIDDM and CHD risk and, 248-250
Very-low-density lipoprotein-cholesterol (VLDL-C), exercise and
by IDDM and NIDDM subjects, exercise effects on, 643
response of plasma, to cycle-ergometer exercise, 516
Very-low-density lipoprotein-cholesterol (VLDL-C) in insulin resistance
CV risk factors and, 1248, 1249, 1251
in insulin-resistant lean and obese nondiabetic women, 287, 289
Very-low-density lipoprotein (VLDL) receptor gene, lack of linkage between fasting serum insulin, HOMA insulin resistance index or, 293-297
Vessel dilators, effects of long-acting kaliuretic peptides, natriuretic peptides and, on urinary excretion of β_2-microglobulin, 1592-1597
Visceral adipose tissue (VAT)
effects of obesity-inducing diet on, 1297
in NIDDM, apo E polymorphism, leptin and, 725, 726
and relationship of PP RMR and TEF to body composition and distribution of, in lean and obese subjects, 7, 8
Viscosity of plasma, fibrinogen and Lp contribution to, in HCL and HTG, 810-813
Vitamin(s)
in diet of hyperinsulinemic pregnant and nonpregnant subjects, 1181
in HF diet, 504
in soy protein diet, 1189
in starch diet, 765
see also specific vitamins
Vitamin A, T_3 effects on reserve of, 801
Vitamin B_{12}, effects of supplementation with, on plasma HcY in ESRD subjects on HD, 215-219
Vitamin D_3 ([1,25$(OH)_2D_3$]; 1,25-dihydroxycholecalciferol)
concentration of, in primary hyperthyroidism, 192-194
serum, and bone metabolism in HIV infection, 1136, 1137
Vitamin E, *see* α-Tocopherol
VLDL, *see* Very-low-density lipoprotein(s)
VLDL-C, *see* Very-low-density lipoprotein-cholesterol
VMH (ventromedial hypothalamus) lesions in HTG with obesity, effects of JTT-501 on, 574-578

Voglibose
beta cell mass in NIDDM reduced by, 347-352
effects of pre-evening meal administration of, on nocturnal hypoglycemia in IDDM subjects on intensive insulin therapy, 440-443
$VOSO_4$ (vanadyl sulfate), metabolic effects of, in NIDDM, 400-410
VSMCs (vascular smooth muscle cells), EPA effects on oxidized LDLs and lysophosphatidylcholine-induced migration in, 560-562

Waist-to-hip ratio (WHR)
and antihypertensive therapy effects on fasting FFAs, 82
in hyperlipidemia, 1628
of IDDM subjects, exercise effects on, 643
of IGT subjects, 1319, 1323
and IMGU with relatively low Mg, 419
and insulin resistance, *see* Waist-to-hip ratio, insulin resistance and
and insulin sensitivity, 1502
and kinetics of TEF, 1342, 1344
leptin and, *see* Waist-to-hip ratio, leptin and
of liver transplantation recipients, 368
morning cortisol levels, S_G and, 306, 307
of NIDDM subjects, *see* Waist-to-hip ratio of NIDDM subjects
of NIDDM subjects' relatives, beta cells and, 897
of obese subjects, *see* Waist-to-hip ratio of obese subjects
and rheological disorders and skin vasoconstrictive response to sympathetic activation, 601
Waist-to-hip ratio (WHR), insulin resistance and
in healthy subjects, 960
with TNF-α gene polymorphism, 1507-1508
see also Waist-to-hip ratio of metabolic syndrome subjects
Waist-to-hip ratio (WHR), leptin and
apo E polymorphism and, 725-726
see also Waist-to-hip ratio, plasma leptin and
Waist-to-hip ratio (WHR), plasma leptin and
and HF diet effects on diurnal variation in plasma leptin, 500
in hyperinsulinemic women, 1056
Waist-to-hip ratio (WHR) of metabolic syndrome subjects
ET-1 concentrations and, 749, 750
with TNF-α gene polymorphism, 1023
Waist-to-hip ratio (WHR) of NIDDM subjects
apo E polymorphism, leptin and, 725, 726
effects of high-monounsaturated fat diet and olive oil diet on, 1513
exercise effects on, 643
with nephropathy, TGF-β_1 activation and, 355
and troglitazone effects on fibrinolysis, 663
Waist-to-hip ratio (WHR) of obese subjects
with β_2-AR gene polymorphism in Japanese subjects, 1215
GH therapy, weight loss and, 907
HTN and, 1525
of obese children, relationship between PAI-1 antigen, leptin, and FM and, 891, 892
WAT (white adipose tissue), retroperitoneal, in obese STZ-DM subjects, 135
Water, total body, in underweight chronic gastrointestinal disease subjects, measurement of, with DXA, BIA, SF, and TBW-^3H_2O methods, compared, 360-366
Weaning, effects of insulin and dietary changes at, on intestinal galactosyltransferase activity during postnatal development, 526-531
Weight, *see* Body weight; Organ weight; Weight loss
Weight loss
by cachexic cancer patients, 931-936
effects of, on muscle, *see* Muscle, weight loss effects on
peripheral versus central GLP-1 receptor agonist effects on satiety and, 709-717
see also Weight loss in NIDDM

Weight loss in NIDDM
effects of, on apo A-I and HDL subfractions distribution in obese NIDDM subjects, 1453-1459
effects of, on T lymphopenia in depression, 1261-1266
GH therapy-induced, effects of, on muscle lipids, 467-472
GLP-1 receptor agonist effects on, 709-717
improved glycemic control and, 692-697
Well-being, psychological, in perimenopausal and postmenopausal women, serum DHEAS, serum estradiol, and soy protein intake in relation to, 1561-1564
Western blot assay
of p36 G6Pase protein changes, 1201
of PLC isozymes in pancreatic islets, 1159
Western diet
effects of, on NIDDM with dyslipidemia, 22-31
see also specific diets
White adipose tissue (WAT), retroperitoneal, in obese STZ-DM subjects, 135
White Americans, *see* Race and ethnicity
WHR, *see* Waist-to-hip ratio
Wine consumption, regular moderate, by moderately obese women, effects of, on insulin sensitivity, 1473-1478
Women
effects of acute cold exposure on, 421-423
exercising at high altitude, sympathoadrenal responses of, 1036-1042; *see also* Exercise
hyperinsulinemia and plasma leptin in, 1055-1062
with low erythrocyte Mg, effects of Mg supplementation on intestinal absorption of $^{45}CaCl$, 1092-1098
see also Healthy subjects; Older women; Postmenopausal women; Premenopausal women; Women, leptin in; Women, obese; Young women *specific conditions and studies*
Women, lean and obese
nondiabetic, effects of insulin resistance on HDLs, LDLs, and VLDLs in, compared, 285-292
premenopausal and postmenopausal, PP RMR and TEF relationship to body composition and AT distribution in, compared, 6-10
see also Lean subjects
Women, leptin in
leptin relationship to serum insulin and insulin sensitivity during and after preeclamptic or healthy pregnancy, 259-263
leptin release by AT in hyperglycemic and normoglycemic women, 807
Women, obese
effects of regular moderate wine consumption on insulin sensitivity in moderately, 1473-1478
normoglycemic and hyperglycemic, leptin release by AT in, 807
prevalence of paradoxically normal serum C in, 600-606
see also Obesity; Women, lean and obese
Wortmannnin, effects of, on ET-1 stimulated insulin secretion, 266

Xanthine, *see* Plasma xanthine
Xanthine oxidase (XOD), nicorandil effects of, in STZ-DM, 428
X-ray absorptiometry, *see* Dual-energy x-ray absorptiometry

YM440 ([Z]-1,4-bis{4-[3,5-dioxo-1,2,4-oxadiazolidin-2-yl]phenoxy}-but-2-ene), hyperglycemia of NIDDM normalized without AT weight change with, pioglitazone and troglitazone effects compared with, 411-417
Young men
IV glutamine effects on synthesis of mixed muscle proteins in, 1555-1560
Japanese, TNF-α G308A gene polymorphism, insulin resistance, and fasting plasma glucose in, 1616-1618
see also Young subjects

Young subjects
effects of single DHEA administration on circadian rhythms of serum DHEA, cortisol, and cortisol/DHEA molar ratio in, 548-551
hepatic expression of LDL receptor and LDL receptor-related protein in, delayed chylomicron clearance from circulation and, 492-498
insulin-mediated SM blood flow and glucose uptake in, SNP effects on, 373-378
see also Young men; Young women

Young women
IV glutamine effects on synthesis of mixed muscle proteins in, 1555-1560
on OCs, urinary Ca excretion and bone turnover in, 1078-1084
thermic effect of caffeine in older and, compared, 101-107
see also Young subjects

Zeaxanthin/lutein, T_3 effects on reserve of, 801
Zenarestat, effects of, on diabetic peripheral neuropathy, 1395-1399